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ABSTRACT
The Effect of Psilocybin on Personality
By
Ravital Segal LaBua
Chair: Paul Wachtel, Ph.D.
As classic psychedelics are increasingly legalized and reintroduced into the
psychotherapeutic frame, a deeper understanding of their effect on personality and overall
wellbeing - as well as their clinical contraindications and potential pitfalls - will prove essential.
As a result, this study represents a preliminary investigation into the effect of psilocybin
exposure on a range of personality constructs.
Methods: Data was collected through a collaboration with The Psychedelic Society, an
organization that legally administers psilocybin truffles in the Netherlands to self-selecting
retreat attendees who have been screened for mental health disorders in accordance with Johnson
et al.’s (2008) widely accepted safety guidelines. Participants completed the following measures
via online questionnaire the day before psilocybin exposure, two days after psilocybin exposure,
and at a one-month follow-up: Brief Symptom Inventory (BSI), Experiences in Close
Relationships-Revised (ECR-R), Mentalization Scale (MentS), Inventory of Personality
Organization (IPO), Pathological Narcissism Inventory (PNI), Pro-Environmental Behavior
(PEB) and the Ryff Scale of Psychological Well-Being (Ryff). As rigorous double-blind clinical
studies have linked psychedelic-occasioned mystical experiences to sustained improvement in
personality-related domains (Maclean et al., 2011; Griffiths et al., 2006; Griffiths et al., 2008,
Griffiths et al., 2011), the Mystical Experience Questionnaire (MEQ) was also administered.
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Lastly, participants provided self-report responses to open-ended questions regarding subjective
experiences following psilocybin exposure.
Results: Due to the Covid-19 pandemic, data collection was prematurely cut short, and only
preliminary conclusions can be drawn. Those provisional conclusions include significantly
improved overall symptomatology (BSI GSI), identity diffusion (IPO-ID) and reality testing
(IPO-RT) following psilocybin exposure. Significant interactions were also identified for
primitive defenses (IPO-PD) and narcissistic grandiosity (PNI-G), with the non-mystical
experience group trending toward improvement, and the mystical-experience group remaining
largely unchanged over time. Due to methodological constraints encountered, these findings
remain preliminary. Nevertheless, the presence of multiple significant findings (however
nascent) within the context of so few participants suggests the possibility of more robust findings
in the context of a larger sample size.
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CHAPTER ONE
Introduction
“The future may teach us to exercise a direct influence, by means of particular chemical
substances, on the amounts of energy and their distribution in the mental apparatus. It may be
that there are other still undreamt-of possibilities of therapy,” -Sigmund Freud, 1940
Classic (serotonergic) psychedelics 1 are a group of psychoactive drugs that alter
consciousness through agonism action at the cortical 5-HT2A (serotonin) receptor (Aixala, dos
Santos, Hallak, & Bouso, 2018; Bouso, dos Santos, Alcázar-Córcoles, & Hallak, 2018).
Throughout human history, indigenous peoples have ritually used these substances for medicinal,
spiritual and therapeutic purposes, including ayahuasca in the Amazonian basin, iboga root in
West Africa, psychedelic mushrooms in southwestern Mexico and peyote cactus in the western
United States (Aixala et al., 2018; Furst, 1976; Grinspoon & Doblin, 2001; Nichols, 2016; Sessa,
2012).
Industrialized society encountered its own psychedelic when, in 1938, Albert Hoffman
synthesized lysergic acid diethylamide (LSD) in a Swiss laboratory, inspiring a flurry of clinical
and scientific interest (Shroder, 2014). LSD was quickly enlisted as a psychotherapeutic aid for
patients suffering from a panoply of mental health difficulties, ranging from depression,
neuroticism and refractory psychoanalytic treatments, to schizophrenia, substance dependence
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The term ‘hallucinogen’ is considered a misnomer by many, as true hallucinations are not a common feature of the
substances in question (Carhart-Harris & Goodwin, 2017; Chandler & Hartman, 1960; Ditman & Bailey, 1967;
Domínguez-Clavé, Soler, Elices, Pascual, Álvarez, De La Fuente Revenga, Friedlander, Feilding & Riba, 2016).
This text therefore uses the more accurate term ‘psychedelic,’ which combines the Greek words psychē (ψ υ χ ή,
‘soul’) and dēloun (δ η λ ο ῦ ν, ‘to make visible, to reveal’) to denote ‘mind-revealing’ (Carhart-Harris & Goodwin,
2017). The origins of this term can be found in Osmond’s (1957) paper on the topic:
“I have tried to find an appropriate name for the agents under discussion: a name that will include the
concepts of enriching the mind and enlarging the vision. Some possibilities are: psychephoric, mindmoving; psychehormic, mind-rousing; and psycheplastic, mind-molding. Psychezymic, mind-fermenting,
is indeed appropriate. Psycherhexic, mind bursting forth, though difficult, is memorable. Psychelytic, mindreleasing, is satisfactory. My choice, because it is clear, euphonious, and uncontaminated by other
associations, is psychedelic, mind-manifesting. One of these terms should serve.” (p. 429)
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and end-of-life anxiety (Johnson, Richards, & Griffiths, 2008; Schmiege, 1963). By the mid
1960s, over 1000 peer-reviewed clinical papers had been published on the topic, tracking
approximately 40,000 patients (Shroder, 2014), detailing notably promising findings (Abramson,
1967; Ditman, 1968; Passie, 1997) and identifying very few, if any, negative side effects in the
context of controlled settings (Ditman & Bailey, 1967; Grinspoon & Bakalar, 1979; Grof, 1967;
Pahnke, Kurland, Unger, Savage & Grof, 1970; Schmiege, 1963).
Nevertheless, growing socio-political opposition was beginning to cloud this clinical and
scientific promise. According to psychedelic historian, Tom Shroder (2014),
“The release of LSD into the public consciousness coincided suggestively with widening
fault lines of a culture that would soon be at war with itself. Feminism,
environmentalism, antimilitarism, anticorporatism, secularism, and the civil rights
movement all underlined a growing discontent with the status quo, a status quo most
notably guarded by a white, male elite…It was hard to avoid seeing a connection.” (p. 48)
Indeed, society’s old guard was justified in fearing LSD’s influence on the counterculture, as
research has since suggested a relationship between the use of classic psychedelics and decreased
materialism (Grof, 1970; Savage, Fadiman, Mogar, & Allen, 1966), social status strivings
(Savage et al., 1966) and authoritarian political views (Grof, 1970; Lyons, Taylor, & CarhartHarris, 2018; Nour, Evans, & Carhart-Harris, 2017), as well as increased environmentalism
(Doblin, 1991; Forstmann & Sagioglou, 2017; Grof, 1970; Lyons et al., 2018; Nour et al., 2017;
Watts, Day, Krzanowski, Nutt, Carhart-Harris, Bossis, & Grob, 2017), progressive politics (Nour
et al., 2017) and political activism (Doblin, 1991).
Simultaneously serving as both a cause - as well as a reflection - of mounting social
anxiety, the mid-1960s saw an alarmist media campaign (Carhart-Harris & Goodwin, 2017;
Ditman, 1968) detailing sensational, anecdotal and often unsourced stories, with lurid headlines
linking LSD to a range of horrors, including gangrene, blindness, narcotic addiction, leukemia,
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birth defects, chromosomal damage, psychosis, suicide, crime and murder (Baumeister &
Placidi, 1983; Johnson et al., 2008; Shroder, 2014). In 1966, two clinical researchers, Walter
Pahnke and William Richards (1966), issued a prescient warning:
“We are confronted by the very real possibility that the known and unknown uses of
these drugs that could prove to be legitimate and beneficial for individual persons and
society may be suppressed until some future century when investigation will be permitted
to proceed unhampered by popular hysteria and over-restrictive legislation. In the United
States, interested and capable scientists are hesitating to investigate this field because of
the abundance of unfavorable publicity and the threat of condemnation…Paradoxically, a
significant danger confronting our society may lie in losing out on the values that the
responsible use of these drugs may offer.” (p. 176)
Strikingly, history has revealed Walter Pahnke to be both capable of prophecy as well as
hypocrisy. In 1991, Rick Doblin conducted a long-term follow-up of Pahnke’s famous 1962
Marsh Chapel Experiment (during which Harvard divinity students ingested psilocybin while
attending a Good Friday church service) and unexpectedly uncovered Pahnke’s own bias, as the
published findings “significantly underemphasized the difficult psychological struggles
experienced by most of the psilocybin subjects,” (p. 24). Doblin (1991) surmises:
“With some proponents of psychedelics exaggerating the benefits and minimizing the
risks, a backlash against these substances was predictable. With the intriguing connection
reported by several psilocybin subjects between mystical experiences and political action,
the backlash in retrospect may have been inevitable.” (p. 24)
Ultimately, following a moral outcry without scientific basis (Nutt, King & Nichols,
2013; Winkelman, Roberts & Thomas, 2007), Congress passed the United States Controlled
Substances Act of 1970, which classified serotonergic psychedelics as a Schedule 1 drug and
effectively halted academic research for over thirty years (Johnson et al., 2008; Shroder, 2014).
In order to receive a Schedule 1 classification, a drug must: 1) lack safety under medical
supervision, 2) carry high abuse potential, and 3) have no accepted medicinal value (Nutt et al.,
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2013). As Winkelman and colleagues (2007) point out, (and as the following discussion
explores), with regard to classic psychedelics, “none of these statements are defensible,” (p. 85).
The effects of classic psychedelics are directly linked to “set and setting,” (Grof, 1967;
Johnson et al., 2008; Mogar, Savage, Gendlin, & Eugene, 1964; Pahnke, 1969; Savage, Terrill,
& Jackson, 1962; Schmiege, 1963; Sherwood, Stolaroff & Harmon, 1968; Studerus, Gamma,
Kometer, & Vollenweider, 2012), a phrase first coined by the (in)famous psychedelic researcher,
Timothy Leary (Leary, Litwin & Metzner, 1963, p. 572). Instead of narrowly addressing a
specific symptom formation, classic psychedelics instead operate as “powerful catalysts,”
(Metzner, 1998, p. 340), “unspecific amplifiers,” (Grof, 1979, p. 52) and “microscopes” (Watts,
1962, p. 15) that “[strip] off the protective barriers of the ego,” (Savage et al., 1962, p. 430),
release unconscious material (Chandler & Hartman, 1960; Cutner, 1959; Grof, 1970; Majić,
Schmidt & Gallinat, 2015; Pahnke & Richards, 1966; Savage et al., 1962; Savage, Savage,
Fadiman & Hartman, 1964; Sherwood et al., 1968; Studerus, Kometer, Hasler & Vollenweider,
2011; Tenenbaum, 1961; Unger, 1963; Winkelman et al., 2007) and magnify both internal and
external inputs, regardless of valence (Savage et al., 1962). Thus, the psychedelic encounter
varies widely as a function ‘set’ (intrapsychic factors, such as personal expectations, mood, and
ability to surrender to the experience) and ‘setting’ (environmental context, such as experimenter
expectations, availability of support and cultural milieu) (Johnson et al., 2008; Leary et al., 1963;
Pahnke, 1969; Sherwood et al., 1968; Studerus et al., 2012). Put another way,
“[The psychedelic experience is] the result of a complex set of determinants, only one of
which is the ingestion of a particular chemical agent. The significance of contradictory
results obtained with LSD therapy have often been obscured by the persistent search for
‘drug specific’ reactions. Inconsistent findings become more understandable if the
response to LSD is viewed as the resultant of complex transactions between the patient,
the therapist, set or expectation, and the setting. In short, the administration of LSD is
inevitably embedded in a larger psycho-therapeutic process.” (Mogar et al., 1964, p. 159)
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With proper preparation and support, classic psychedelics may potentiate a therapeutic
encounter; absent such conditions, the very same substance may precipitate anxiety, depression,
and even acute or chronic psychosis (Ditman, 1968). As Doblin (1991) points out, “Some of the
backlash that swept psychedelics out of the research labs and out of the hands of physicians and
therapists can be traced in part to the thousands of cases of people who took psychedelics in nonresearch settings, were unprepared for the frightening aspects of their psychedelic experiences
and ended up in hospital emergency rooms,” (p. 24).
In a recreational context, where contraindications may be poorly understood, classic
psychedelics are not risk-free (Cohen, 1960; McGlothlin & Arnold, 1971; Strassman, 1984;
Winkelman et al., 2007). No matter how rare, these risks can prove serious and therefore
necessitate clear-eyed consideration. Most concerningly, classic psychedelics have precipitated
prolonged psychoses in individuals who are genetically loaded for psychotic disorders (Cohen,
1960; Johnson et al., 2008; Schmiege, 1963; Winkelman et al., 2007). As Johnson et al. (2008)
point out, it is unknown whether psychosis represents an inevitable reality for such individuals,
or whether a psychotic break could have been avoided in the absence of drug exposure. As a
result of these findings, current safety guidelines exclude individuals who either meet criteria (or
have first- or second-degree relatives who meet criteria) for bipolar or psychotic disorders
(Johnson et al., 2008). Research studies that exclude such participants consistently report no
evidence of psychotic sequelae in their subject pools (Gasser, 1996; Studerus et al., 2011).
Classic psychedelics have also been linked to flashback phenomena, whereby individuals
re-experience perceptual irregularities initially encountered while under the influence, such as
seeing flashes of color (Winkelman et al., 2007). Although these experiences are often
characterized as pleasurable, thought-provoking, benign and short-lived (Frecska & Luna, 2006;
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Lerner, Gelkopf, Skladman, Oyffe, Finkel, Sigal et al., 2002; Strassman, 1984; Winkelman et al.,
2007), they are occasionally (albeit rarely) associated with clinical distress and impaired
functioning (Baggott, Erowid, Erowd, Robertson, 2006; Cohen, 1960; Halpern & Pope, 2003;
Lerner et al., 2002; McGlothlin & Arnold, 1971). In such instances, a diagnosis of Hallucinogen
Persisting Perception Disorder (HPPD) may be warranted (American Psychiatric Association,
2013). Although the incidence of HPPD is currently unknown, it is considered “very
uncommon,” (Halpern, Lerner, & Passie, 2016; Johnson et al., 2008, p. 608; Linszen, Kleijer, &
Sommer, 2017). Notably, reports of HPPD are higher in uncontrolled settings (where polydrug
use2 and unscreened psychiatric disorders likely represent confounding variables) and lower in
clinical research settings with carefully screened subject pools (Cohen, 1960; Halpern & Pope,
2003; McGlothlin & Arnold, 1971; Strassman, 1984).
As classic psychedelics are known to activate unconscious material (Chandler &
Hartman, 1960; Cutner, 1959; Majić et al., 2015; Savage et al., 1962; Savage et al., 1964;
Studerus et al., 2011; Tenenbaum, 1961; Unger, 1963; Winkelman et al., 2007), individuals may
also encounter challenging emotions while under the influence, as well as in the days and weeks
that follow (Carhart-Harris, Kaelen, Bolstridge, Williams, Williams, Underwood, & Nutt, 2016;
Cohen & Eisner, 1958; Grof, 1967; Johnson et al., 2008). As Savage et al. (1962) point out,
“Once we open Pandora’s box, we cannot always control what flies out. The
[psychedelic] experience may strip the patient of his capacity for lies and rationalization;
he may see himself in all his psychological nakedness. To expose him so violently and
suddenly to his shortcomings may only increase his guilt to an intolerable degree…the
intervention of the therapist makes the difference between a helpful and a damaging
experience.” (p. 429)

2

Current safety guidelines exclude individuals who are taking tricyclic antidepressants, lithium, serotonin reuptake
inhibitors (SSRIs) and haloperidol, as these drugs potentiate psychedelic effects (Johnson et al., 2008).
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Thus, psychotherapeutic supports are at times necessary in order to help individuals successfully
process and integrate new psychological landscapes (Johnson et al., 2008; Pahnke et al., 1970;
Studerus et al., 2011). As Pahnke & Richards (1966) further clarify,
“[Challenging psychedelic] experiences may be useful in facilitating psychotherapy if a
competent therapist is available both at the time these experiences occur and in the
following weeks to help the patient integrate feelings and insights. Without competent
psychiatric supervision, such experiences may, at best, remain frightening memories and,
at worst, cause a person to decompensate under the stress.” (p. 187)
In particularly unsupportive, over-stimulating or stressful environments, classic
psychedelics may also precipitate overwhelming anxiety in the form of transient
psychotomimetic (psychotic-like) experiences (Carhart-Harris et al., 2016; Cohen & Eisner,
1958; Ditman, 1968; Savage et al., 1962). As a result, early investigators initially administered
classic psychedelics in a misguided attempt to create and then study model psychoses (Belleville,
1956; Savage et al, 1962). This practice quickly fell out of favor once the psychotomimetic
experience was understood to be a reflection of the disturbing context within which drug
administration occurred and not an inherent quality of the psychedelic experience itself (Savage
et al., 1962; Unger, 1963). As Pahnke & Richards (1966) contend,
“When subjects were given a psychedelic drug without knowing what to expect or how to
respond, often being left alone in a dark room or threatened by unfamiliar researchers
demanding cooperation in psychological testing, it is easy to understand why many
experiences quickly became psychotic. If nonpsychotic experiences are desired, subjects
must be prepared, must feel secure in a friendly environment, and above all must be
willing and able to trust reality greater than themselves.” (p. 188)
Although extremely rare, individuals under the influence of classic psychedelics have
also acted violently toward others, as well as toward themselves (Johnson et al., 2008; Keeler &
Reifler, 1967; O’Brien, 2006; Reitman & Vasilakis, 2004; Reynolds & Jindrich, 1985). These
incidents almost exclusively occur in the context of hazardous and unsupervised settings, carried
out by individuals with severe pre-existing psychopathology (Cohen, 1960; Winkelman et al.,
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2007). Cohen’s (1960) study, which synthesized data from 5,000 individuals (and approximately
25,000 psychedelic exposures), found 0 attempts or completed suicides by (healthier) research
participants following drug exposure, and 1.2 attempts and .4 completed suicides per 1000
patients (suffering from pre-existing psychopathology). According to Cohen, the majority of
these suicides could not be definitively and causally linked to the psychedelic experience. Of
note, other investigators have since reported similar findings (Gasser, 1996; Malleson, 1971).
Nevertheless, according to Johnson et al.’s (2008) widely accepted safety guidelines:3
“Even under unsupervised and unprepared conditions, reactions to hallucinogens
involving violence and self-destructive behavior are rare, and our intention is not to
create an unrealistic account of the dangers of hallucinogens. Nonetheless, even
infrequent reports of such dangers require that investigators take seriously such risks and
take steps to avoid their occurrence.” (p. 607)
Importantly, once researchers and clinicians recognized the profound impact of set and
setting on the psychedelic experience, the frequency of adverse reactions dropped precipitously
(Johnson et al., 2008). In the context of controlled and supportive settings, and with the
implementation of relevant exclusion criteria, classic psychedelics demonstrate safety and
tolerability in both the short- and long-term (Dos Santos, R., Osório, F., Crippa, J., Riba, J.,
Zuardi, A., & Hallak, J. 2016; Pahnke et al., 1970; Schmiege, 1963; Strassman, 1984; Studerus et
al., 2011; Winkelman et al., 2007). Within the discipline of psychopharmacology, acute drug
toxicity is traditionally measured with what’s called the therapeutic index: a ratio of the lethal
dose for 50% of subjects (LD50) to the effective dose for 50% of subjects (ED50) (Winkelman et
al., 2007). With higher numbers reflecting safer profiles, classic psychedelics have therapeutic
indices above 600, compared to aspirin’s index of 199 and nicotine’s of 21 (Winkelman et al.,
2007). Indeed, normal functioning is almost completely restored within 24 hours after drug

3

Johnson et al.’s (2008) safety guidelines are written for “high-dose hallucinogen research” (e.g. ≥ 25 mg psilocybin
or 200 mcg LSD) (p. 604)
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administration (Studerus et al., 2011) and complications are both rare and unimpressive (Aixalà,
et al., 2018; Ditman & Bailey, 1967; Grof, 1967; Studerus et al., 2011), most often including
headache, fatigue and mild somatic discomfort (Johnson et al., 2008; Studerus et al., 2011).
Additionally, classic psychedelics are not associated with increased psychopathology (Bouso,
Palhano-Fontes, Rodriguez-Fornells, Ribeiro, Sanches, Crippa, & Riba, 2015; Dos Santos,
Osório, Crippa, & Hallak, 2016; Johansen & Krebs, 2015; Krebs & Johansen, 2013),
neurocognitive decline (Barbosa, Strassman, Da Silveira, Areco, Hoy, Pommy, Thoma, &
Bogenschutz, 2016; Bouso et al., 2015; Dos Santos et al., 2016b; Halpern & Pope, 1999;
Halpern, Sherwood, Hudson, Yurgelun-Todd & Pope, 2005), organ impairment (Gable, 1993;
Gable, 2004; Nichols, 2004; Strassman, 1984) or chromosomal damage - as was falsely
contended by an anti-LSD, government-funded media campaign in the late 1960s (Johnson et al.,
2008). To the contrary, classic psychedelics carry a positive side-effect profile (Carhart-Harris
& Goodwin, 2017), as they are associated with lower rates of suicidality and psychopathology
(Hendricks, Johnson & Griffiths, 2015; Johansen & Krebs, 2015; Krebs & Johansen, 2013), and
preliminarily linked to strengthened neurocognitive capacity (Bouso et al., 2015).
Additionally, although classic psychedelics evidence a tolerance effect (and therefore
require increasingly higher doses to produce similar effects over time) (Winkelman et al., 2007),
they are not physiologically addictive and are therefore not associated with compulsive drug
seeking or withdrawal symptoms (Johnson et al., 2008; McGlothlin & Arnold, 1971; National
Institute on Drug Abuse [NIDA], 2001; NIDA, 2006; O’Brien, 2006; Pahnke et al., 1970;
Studerus et al., 2011; Winkelman et al., 2007). Quite the opposite, classic psychedelics may
have antiaddictive effects and have been successfully employed in the treatment of substance
dependence (Barbosa et al., 2016; Dos Santos et al., 2016b; Mascher, 1967).
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Overall, when viewed through the lens of the scientific literature, the Schedule 1
categorization of classic psychedelics is unjustified, as these substances are neither addictive,
lacking in medicinal value, nor unsafe in the context of controlled settings. Nevertheless, as a
function of socio-political pressure, the first wave of classic psychedelic research came to an end
in the early 1970s (Carhart-Harris & Goodwin, 2017; Johnson et al., 2008; Nutt et al., 2013;
Strassman, 1991). As Johnson et al. (2008) point out, “the decades-long virtual dormancy of
human hallucinogen research stands as a unique case in the history of modern clinical
pharmacology,” (p. 604). Importantly, we are currently in the midst of “an intriguing new
zeitgeist in modern psychiatry,” (Watts et al., 2017, p. 521), as classic psychedelics are
experiencing a renaissance (Carhart-Harris & Goodwin, 2017). Indeed, the second wave of
research into classic psychedelics, which tentatively began in the early 1990s, is currently
cresting, with a 2017 academic conference representing the largest to date, with over 3000
attendees from over 40 countries (Carhart-Harris, Erritzoe, Haijen Kaelen, & Watts, 2018).
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CHAPTER TWO
Literature Review
Personality change constitutes an important area of investigation within both the first and
second wave of classic psychedelic research. Although clinicians and researchers have long
viewed personality as a potent predictor of physical, emotional and relational health (Borghans,
Duckworth, Heckman & Ter Weel, 2008; Ozer & Benet-Martínez, 2006; Roberts, 2006; Roberts,
Kuncel, Shiner, Caspi & Goldberg, 2007), a widespread and discouraging consensus also casts
personality as an entity that changes only incrementally and over a time horizon of many years
(Erritzoe, Roseman, Nour, Maclean, Kaelen, Nutt & Carhart-Harris, 2018; Roberts, 2006). It’s
therefore striking to note that preliminary research links psychedelic exposure to accelerated
rates of personality change (Aixalà et al., 2018; Chandler & Hartman, 1960; Erritzoe et al., 2018;
Savage et al., 1966; Tenenbaum, 1961).
In order to map the territory already traversed by psychedelic researchers on the topic of
personality, a literature review was conducted with the following search strategy. First, an
electronic search was performed in the Academic Search Complete database (1887-2019) using
the following search terms: (psychedelic OR hallucinogen OR mescaline OR psilocybin OR
lysergic acid diethylamide OR dimethyltryptamine OR ayahuasca) AND (personality*). Next, in
light of the fact that first-wave publications from the mid-twentieth century are not widely
accessible online, all reference lists were then manually reviewed for additional studies and
downloaded from the Multidisciplinary Association for Psychedelics Studies (1931-1995)
Psychedelic Bibliography (MAPS, 2018).
In keeping with convention, this literature review only included classic (serotonergic)
psychedelics and excluded similar substances with a different mechanism of action, such as
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empathogens (e.g., MDMA) and dissociative anesthetics (e.g., ketamine) (Bouso et al., 2018;
Johnson et al., 2008). Classic psychedelics are distinguished by their agonism action at the
cortical 5-HT2A serotonin receptor and include substances such as mescaline, psilocybin,
dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) (Aixalà et al., 2018). In
addition to a shared biochemical interaction, serotonergic psychedelics also create a similar
profile of subjective effects (Unger, 1963), as well as a unique constellation of therapeutic
benefits. According to Carhart-Harris & Goodwin (2017), with proper preparation and support,
classic psychedelics encourage individuals to “address rather than suppress or side-step aversive
memories and emotions,” which may distinguish this class of drugs from “alternative, largely
‘palliative’ [pharmacological] treatment options,” (p. 2107). Additionally, classic psychedelics
are notable for their physiological non-addictiveness (Johnson et al., 2008; McGlothlin &
Arnold, 1971; NIDA, 2001; NIDA, 2006; O’Brien, 2006; Pahnke et al., 1970; Studerus et al.,
2011; Winkelman et al., 2007).
This literature review yielded 27 articles on the topic of personality from the first wave of
psychedelic research (published between 1956 and 1980) and 27 articles from the second wave
(published between 1991 and 2018). In order to cast a wide net and avoid a priori assumptions
regarding the definitional parameters of personality, articles were included that discuss mood,
behavior, attitudes, values, neurocognitive capacity and self/ego structure.
First-wave articles almost exclusively share a psychoanalytic orientation and include 17
research studies (Belleville, 1956; Bottrill, 1969; Cohen & Eisner, 1958; Cohen, 1969; Chandler
& Hartman, 1960; Cwynar & Rydyznski, 1966; Ditman & Bailey, 1967; Hartung, Jurgen &
Skorka, 1980; Keeler & Reifler, 1967; McGlothlin & Arnold, 1971; Mogar et al., 1964; Rinkel,
DiMascio, Robey & Atwell, 1961; Savage et al., 1964; Savage et al., 1966; Savage, Hughes &
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Mogar, 1968; Tenenbaum, 1961; Von Felsinger, Lasagna & Beecher, 1956), 6 theoretical pieces
(Cutner, 1959; Grof, 1967; Grof, 1970; Osmond, 1957; Savage et al., 1962; Unger, 1963), 2 case
reports (Schoen, 1964; Sherwood, Stolaroff & Harman, 1962) and 1 systematic review (Mascher,
1967). With regard to first-wave research, the most studied psychedelic is LSD (14 studies),
followed by psilocybin (3 studies), and the most common outcome measure is the Minnesota
Multiphasic Personality Inventory (MMPI) (9 out of 17 studies), followed by therapist
assessment of diagnostic change (3 studies). Additionally, first-wave investigators most
frequently studied classic psychedelics through the lens of psycholytic psychotherapy, where
psychedelic exposure was repeated over the course of months to years, embedded within the
context of long-term psychotherapeutic treatment (Ditman, 1968; Grof, 1970; Majic et al., 2015;
Pahnke, 1969; Pahnke et al., 1970). As a result, first-wave subject pools span the diagnostic
spectrum, skew toward severe pathology, and include mood disturbances, substance addiction,
personality pathology and psychosis.
Second-wave articles include 24 research studies (Barbosa, Ribeiro, Cazorla, Giglio &
Strassman, 2009; Barbosa et al., 2016; Barrett, Johnson & Griffiths, 2017; Borg, Andrée,
Soderstrom & Farde, 2003; Bouso, González, Fondevila, Cutchet & Fernández, Barbosa,
Alcazar-Córcoles, Araújo, Barbanoj, Fábregas & Riba, 2012; Bouso et al., 2015; Carhart-Harris
et al., 2016; Doblin, 1991; Erritzoe et al., 2018; Forstmann & Sagioglou, 2017; Griffiths,
Richards, McCann & Jesse, 2006; Griffiths, Richards, Johnson, McCann & Jesse, 2008;
Griffiths, Johnson, Richards, Richards, McCann & Jesse, 2011; Kavenská, Simonová, Kavenská
& Simonová, 2015; Lebedev, Kaelen, Lövdén, Nilsson, Feilding, Nutt & Carhart‐Harris, 2016;
Lerner & Lyvers, 2006; Lyons & Carhart-Harris, 2018; Maclean, Johnson & Griffiths, 2011;
Nour et al., 2017; Schmid & Liechti, 2018; Studerus et al., 2011; Studerus et al., 2012;
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Tagliazucchi, Roseman, Kaelen, Orban, Muthukumaraswamy, Murphy, Laufs, Leech,
Mcgonigle, Crossley, Bullmore, Williams, Bolstridge, Feilding, Nutt & Carhart-Harris, 2016;
Watts et al., 2017), 3 systematic reviews (Bouso et al., 2018; Rucker, Jelen, Flynn, Frowde &
Young, 2016; Dos Santos, Osório, Crippa & Hallak, 2016) and 1 literature review (DomínguezClavé et al., 2016). Among second-wave research, the most studied psychedelic is psilocybin
(11 studies), followed by ayahuasca (5 studies) and LSD (4 studies). Additionally, second-wave
research most commonly utilizes trait-based (e.g., Five-Factor Model) outcome measures from
the discipline of personality psychology, such as the NEO Personality Inventory-Revised (NEO
PI-R) (5 out of 24 studies), the Temperament and Character Inventory (TCI) (4 studies), the Big
Five Inventory (BFI) (2 studies), Freiburg Personality Inventory (FPI) (2 studies) and the Ten
Item Personality Inventory (TIPI) (2 studies). On the whole, and in contrast to first-wave
research, second-wave methodologies do not investigate classic psychedelics in the context of
long-term psychotherapeutic treatment but, instead, administer 1-2 psychedelic doses in a
supportive setting, with the possibility of follow-up psychotherapeutic supports when necessary.
Drawing an additional comparison to first-wave subject pools, second-wave research participants
skew in a diagnostically healthier direction, as contemporary safety guidelines exclude psychotic
and bipolar disorders (Johnson et al., 2008), with a subset of investigators also excluding
personality disorders, substance dependence and neuroticism (Bouso et al., 2018; Winkelman et
al., 2007).
First-wave studies are often critiqued for failing to meet modern-day methodological
standards (Studerus et al., 2012). This scrutiny is undeniably warranted, as early findings often
rely on anecdotal clinical accounts (Johnson et al., 2008) and research designs that lack adequate
sample sizes (Bouso et al., 2018; Mogar et al., 1964; Winkelman et al., 2007), standardized
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clinical interventions (Winkelman et al., 2007), control groups with random assignment (CarhartHarris & Goodwin, 2017; Mogar et al., 1964; Winkelman et al., 2007), psychometrically reliable
outcome measures (Bouso et al., 2018; Mogar et al., 1964) and blind raters (Winkelman et al.,
2007). Even still, the first-wave research included in this literature review collectively details
psychedelic-assisted psychotherapeutic work with thousands of patients. It would therefore
prove intellectually imprudent to disregard the (albeit preliminary) clinical insights on offer.
Although second-wave research has adopted notably more stringent standards with regard
to experimental design and outcome measures (Carhart-Harris & Goodwin, 2017), psychedelic
research nevertheless continues to face methodological challenges. Promising drug liberalization
efforts notwithstanding, the illegal status of classic psychedelics continues to compromise
research, as investigators are not infrequently obliged to implement observational and
correlational designs, which, in turn, undermine causal claims (Bouso et al., 2018; Kavenská et
al., 2015; McGlothlin & Arnold, 1971; Nour et al., 2017). Of course, this arrangement supports
a circular logic, whereby classic psychedelics are frequently disregarded by the mainstream due
to a lack of sound data. Even for those few institutions that successfully clear the formidable
regulatory, legal and financial hurdles, the double-blind standard remains difficult to achieve, as
it’s often obvious when a psychedelic has been administered (Doblin, 1991; Grinspoon &
Doblin, 2001).
Most relevant to the topic of this literature review, what the second wave gained in
methodological rigor, it also lost in clinical nuance. Though psychometrically sound, secondwave outcome measures reflect the Five-Factor Model’s trait-based taxonomy of personality,
which reduces personality to five constructs (also known as the Big Five personality traits):
extraversion, neuroticism, conscientiousness, agreeableness and openness. As Funder (2001)
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points out, “this lack of comprehensiveness becomes a problem when researchers, seduced by
convenience and seeming consensus, act as if they can obtain a complete portrait of personality
by grabbing five quick ratings,” (p. 201). Conversely, while first-wave research is
methodologically messy, its psychoanalytic paradigm renders a much more nuanced and
phenomenological exploration of personality. As a result, this literature review integrates firstand second-wave data in order to present a complete picture of what is currently known
regarding the relationship between classic psychedelics and personality.
Overall, this literature review preliminarily links psychedelic exposure (in the context of
supportive and supervised settings) to shifts in the following (interdependent and overlapping)
personality-related domains: 1) Personality Traits, 2) Neurocognitive Capacity, 3) Mood and
Emotional Repertoire, 4) Personality Pathology and Psychosis, 5) Relationship to Self and the
Interpersonal Other, 6) Relationship to the Collective Other, and 7) Spirituality and Relationship
to the Universal Whole.
Personality Traits
Representing one of the most widely documented findings of second wave (personality-related)
research, increased openness constitutes a reliable mid- to long-term effect of psychedelic
exposure (Barbosa et al., 2016; Carhart-Harris et al., 2016; Erritzoe et al., 2018; Maclean et al.,
2011; Nour et al., 2017). Within the Five-Factor taxonomy of personality, this trait encompasses
openness to ideas, actions, feelings, values, fantasy and aesthetics (McCrae & Costa, 2010).
Though identified far less frequently, psychedelic exposure is also preliminarily linked to
decreased neuroticism (anxiety, insecurity, emotionality) (Erritzoe et al., 2018), increased
extraversion (sociability, optimism, loquaciousness) (Erritzoe, 2018; Kavenská et al., 2015), and
increased agreeableness (pro-social tendencies and altruism) (Barbosa et al., 2016). It is perhaps
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relevant to note that no Five-Factor data yet exists linking psychedelic exposure to increased
conscientiousness (self-discipline, efficiency, impulse control). Although first-wave research
does not assess personality through the Five-Factor lens, it nevertheless provides support for
similar trait-based change, with evidence linking psychedelic exposure to increased openmindedness (Savage et al., 1966), aesthetic appreciation (Ditman & Bailey, 1967; Savage et al.,
1962), creativity (Hartung et al., 1980), imaginative fantasy (Hartung et al., 1980), optimism
(Grof, 1970), and empathy (Ditman & Bailey, 1967; Grof, 1970; Hartung et al., 1980).
Neurocognitive Capacity
This literature review identifies a nascent connection between classic psychedelics and
improved neurocognitive capacity. According to Bouso et al.’s (2012) study, when compared to
controls, 127 ritual ayahuasca users (with a minimum of two ayahuasca ceremonies per month
for at least 15 years) performed better on neurocognitive tasks, such as the Stroop test (which
measures processing speed, selective attention and automaticity), the Wisconsin Card Sorting
Test (attention, working memory and visual processing) and the Letter-Number Sequencing task
from the Wechsler Adult Intelligence Scale III (working memory). Preliminary research also
links acute and long-term ayahuasca exposure to improved planning and inhibitory control (Dos
Santos et al., 2016c). Perhaps most strikingly, classic psychedelics anecdotally generate
“creative insights into complex problems” (Friedman, 2013, p. 354), with two Nobel Prize
winners, Francis Crick and Kary Mullis, partially crediting experiences with LSD for their
respective prize-winning discoveries of DNA’s double helical structure and molecular biology’s
Polymerase Chain Reaction (PCR) technique (Friedman, 2013).
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Mood and Emotional Repertoire
Both first- and second-wave research link psychedelic exposure to decreased guilt (Grof,
1970), anxiety (Dos Santos et al., 2016a; Grof, 1970; Mascher, 1967; Savage et al., 1962; Savage
et al., 1964; Savage et al., 1968), and depression (Barbosa et al., 2016; Dos Santos et al., 2016 a;
Grof, 1970; Lyons et al., 2018; Mascher, 1967; Rucker et al., 2016). According to Rucker et
al.’s (2016) meta-analysis, which synthesizes data from 19 first-wave studies examining the
therapeutic use of psychedelics in the treatment of unipolar mood disorders (and which includes
diagnoses such as contemporary depressive disorder with co-morbid anxiety, as well as more
antiquated classifications, such as ‘neurotic’ and ‘psychoneurotic’ disorders), 79.2% of patients
(335 out of 423) evidenced “clinician-judged improvement” (p. 1220) following psychedelicassisted treatment. Correspondingly, classic psychedelics are also associated with improved
mood (Dos Santos et al., 2016a; Griffiths et al., 2011; Schmid & Liechti, 2018), increased
equanimity (Doblin, 1991; Griffiths et al., 2008; Grof, 1970; Kavenská et al., 2015; Watts et al.,
2017), a more positive outlook on life (Carhart-Harris et al., 2016; Griffiths et al., 2011; Grof,
1970; Kavenská et al., 2015; Schmid & Liechti, 2018), and an expanded emotional repertoire
(Savage et al., 1962; Watts et al., 2017). According to 6-month follow-up interviews with three
separate subjects who had participated in Watts et al.’s (2017) open-label trial of psilocybin for
treatment-resistant depression: “I used to get angry about having anxiety, now I think I can have
the anxiety, I can just feel it and it will go, I don’t have to have the fear or run away,” (p. 541).
“I used to just put [bad things in the back of my mind]. After [the psilocybin experience], I
[allow] myself to experience everything – even if it is sadness. Now I know how to deal with my
feelings rather than repress them,” (p. 541). “I have a felt sense of acceptance; more acceptance
of agony, boredom, loneliness, and also appreciation of the wonderful times. [A] willingness to
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try to accept the negative times,” (p. 541). Perhaps due to a lessened need for maladaptive
coping strategies, psychedelic exposure is also associated with reduced substance use (Barbosa et
al., 2016; Dos Santos et al., 2016a; Krebs & Johansen, 2013; Mascher, 1967).
Personality Pathology and Psychosis
Although second-wave investigators have failed to pick up this thread, first-wave
research explores psychedelic-assisted psychotherapy as a potential treatment modality for
personality pathology (Belleville, 1956; Bottrill, 1969; Chandler & Hartman, 1960; Cohen &
Eisner, 1958; Cutner, 1959; Cwynar & Rydzynski, 1966; Grof, 1967; Grof, 1970; Mascher,
1967; Mogar et al., 1964; Pahnke & Richards, 1966; Savage et al., 1962; Savage, Stolaroff,
Harman, & Fadiman, 1963; Savage et al., 1964; Savage et al., 1966; Savage et al., 1968;
Schmiege, 1963; Schoen, 1964; Sherwood et al., 1968; Tenenbaum, 1961; Unger, 1963).
According to Chandler & Hartman (1960):
“With LSD as an aid, it has been possible to ‘reach’ and work with patients who are
otherwise unresponsive to psychotherapy. This includes…severe characterological
defense systems of the obsessive compulsive and acting-out types, as well as several of
the overly inhibited schizoid types.” (p. 74)
The following success rates are identified by Mascher’s (1967) systematic review, which
analyzes data from 42 papers (1953-1965) and includes psychedelic-assisted treatment with 1603
patients, grouped by the following anachronistic diagnostic categories (many of which overlap
with contemporary personality disorder classifications): anxiety neuroses (9 papers, 70%
success), depressive reactions (4 papers, 62% success), character neuroses and sociopaths (10
papers, 61% success), borderline cases (4 papers, 53% success), obsessive-compulsive neuroses
(10 papers, 42% success), and hysteria and conversion symptoms (2 papers, 31.5% success) 4.

4

Mascher’s (1967) systematic review also reports “good results” for 50% of all “sexual perverts and prevailing
homosexuals” detailed in 7 papers. This troubling finding may understandably complicate this report’s
trustworthiness.
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By way of example, Savage et al.’s (1966) study administered the Minnesota Multiphasic
Personality Inventory (MMPI) to assess personality in 77 long-term psychotherapy patients
before and after one high-dose of LSD, as well as at two-, six-, and twelve-month follow-ups.
According to their findings, borderline psychotic personalities significantly improved at two
months, but lost ground by six months:
“Their dystonic defensive structure has been restored, but they have less depression,
anxiety, and guilt. It would appear that they have insufficient ego resources to capitalize
on the significant characterological changes noted at two months. One would conclude
that additional therapy is required to supplement personal resources which are inadequate
to instrument newly-acquired insights.” (p. 245)
Hysterical personalities followed a similar trajectory, with improvement at two months, followed
by a regression at six months:
“This group is characterized clinically by passive-dependency, lack of a sense of personal
responsibility, and poor reality testing which contribute to their inability to integrate the
LSD experience into their self-system and life circumstances. This group tends to retain
some degree of magical or unrealistic expectations with regard to outcome. They sit back
passively and wait for the drug to transform them. They bask in the greatly expanded
sense of well-being and take no steps to translate their insights into living reality…A
longer period of preparation might lead to more realistic expectations. Another alternative
might be to repeat the psychedelic experience after six months.” (p. 245)
All other diagnostic categories, which include subjects characterized by “cyclothymic impulsive
trends, anxiety and tension states, obsessive compulsive symptoms, reactive depressions and
passive-aggressive tendencies,” demonstrated,
“Stable, positive changes throughout the follow-up period…[Although] these groups
tended to display less spectacular shifts in mood shortly after LSD, [they] continued to
show positive changes in character structure at the six-month follow-up… [At one year]
these groups not only sustain improvement but continue to realize potentialities
discovered under LSD.” (p. 245-6)
With regard to characterologically “normal” individuals, who tend to suffer from “philosophical
neuroses” due to difficulty finding “identity and meaning” in the context of “modern man’s deep
sense of alienation,” Savage et al. (1966) argue that “these subjects benefit considerably from the
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psychedelic experience along the lines of self-actualization, richer creative experience, and
enhancement of special abilities and aptitudes,” (p. 250). Savage et al. (1966) conclude:
“With regard to the nature of changes characterizing different personality types, shifts
tend to occur consistent with the symptoms and defense patterns of a given group. Thus
anxiety neurotics are less anxious, compulsive and withdrawn, while close object
relations are more gratifying. In contrast, impulsive, hyperactive subjects lead a more
orderly, less hectic existence and display greater impulse control.” (p. 246)
Although not mentioned in this particular study, first-wave investigators also warn that classic
psychedelics may exacerbate grandiose tendencies if proper therapeutic supports are not in place
(Chandler & Hartman, 1960; Cohen & Eisner, 1958; Savage et al., 1962). According to
Chandler & Hartman (1960),
“[Psychedelic exposure may cause an individual] to feel that he has discovered the
answer to everything, that he has acquired philosophical insights into the meaning of life,
the nature of the universe, etc. If utilized in the proper manner during regular
psychotherapy…these philosophical understandings can be a valuable part of the person’s
growth, but they will prove harmful to him if he…uses them as a defensive means of
supporting neurotic delusions of superiority.” (p. 75)
With regard to psychosis, contemporary safety guidelines prohibit the use of classic
psychedelics with individuals who meet criteria (or have first- or second-degree relatives who
meet criteria) for bipolar or psychotic disorders (Cohen, 1960; Johnson et al., 2008; Schmiege,
1963; Winkelman et al., 2007). It’s nevertheless worth noting that Stanislav Grof M.D. Ph.D., a
preeminent psychedelic psychiatrist and researcher, holds a divergent (albeit minority) view. In
Beyond Psychoanalysis: Implications of LSD Research for Understanding Dimensions of Human
Personality, Grof (1970) details psycholytic psychotherapy with 50 patients at the Psychiatric
Research Institute of Prague over the course of seven years (1960-1967). With regard to
psychosis, Grof details a case report of a woman who initially presented with psychosis but who,
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after 90 LSD dosing sessions, no longer suffered from psychotic symptomatology and instead
presented with a “completely restructured personality,” (p. 72). According to Grof (1970),
“She had a new zest for life, appreciation for nature and art, a purified attitude to her
children and could completely give up her unrealistic ambitions and fantasies. She was
able to resume her job, accomplish divorce from her husband and care for her children in
a very independent way. Three years after discontinuation of treatment, and at the time of
the last follow-up feedback session, the condition was even more stabilized.” (p. 72)
Relationship to Self and the Interpersonal Other
Research preliminarily suggests that classic psychedelics may support the healing of
one’s relationship to self and other. More specifically, psychedelic exposure is associated with
improved introspection (Savage et al., 1966; Savage et al., 1968), self-compassion (Grof, 1970;
Watts et al., 2017), physical and psychological self-care (Griffiths et al., 2011), self-esteem
(Griffiths et al., 2011; Savage et al., 1964; Savage et al., 1968), self-acceptance (Kavenská et al.,
2015) and self-actualization (Doblin, 1991; Savage et al., 1964). Psychedelic exposure is also
associated with healthier interpersonal relationships (Griffiths et al., 2011; Kavenská et al., 2015;
Savage et al., 1964), characterized by stronger communication (Savage et al., 1966; Savage et
al., 1968), fewer arguments (Savage et al., 1966; Watts et al., 2017), and deeper emotional bonds
(Ditman & Bailey, 1967; Watts et al., 2017). Notably, individuals also report feeling increased
compassion in the wake of psychedelic experiences, even toward those individuals who have
abused and wronged them (Ditman & Bailey, 1967; Watts et al., 2017). According to one
research subject, who had participated in an open-label psilocybin trial, and who had been
severely abused by his mother during childhood,
“When I was being toilet trained, my mother lost it with me and drowned me in my own
human waste and throughout my life, I tend to replay that. [During the dosing session], I
realized that my mother was out on a ledge, we were two people out on a ledge, she too
was completely unconnected, disconnected. I felt some compassion for her…a different
perspective, that it wasn’t an all-powerful world and universe against me, my mother too
was out on a ledge.” (Watts et al., 2017, p. 533)
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Relationship to the Collective Other
This literature review suggests a link between classic psychedelics and an individual’s
relationship to the collective other. With regard to values, psychedelic exposure is associated
with decreased materialism (Savage et al., 1966), social status strivings (Grof, 1970; Savage et
al., 1966), and authoritarian political views (Grof, 1970; Lyons & Carhart-Harris, 2018; Nour et
al., 2017). Additionally, psychedelic exposure is also associated with increased liberal politics
(Nour et al., 2017), nature relatedness (defined as self-identification with nature) (Doblin, 1991;
Forstmann & Sagioglou, 2017; Grof, 1970; Lyons & Carhart-Harris, 2018; Nour et al., 2017) and
vegan/vegetarianism, with anecdotal reports of research participants receiving “lessons”
regarding the importance of eating plants instead of animals during dosing sessions (Watts et al.,
2017, p. 532).
Preliminary evidence also suggests that classic psychedelics may influence an
individual’s behavior toward the collective other. For example, psychedelic exposure may be
associated with pro-environmental behavior (Forstmann & Sagioglou, 2017), increased altruism
(Griffiths et al., 2011; Grof, 1970; Schmid & Liechti, 2018) and political activism (Doblin,
1991). During a follow-up interview approximately twenty years after psilocybin administration,
a research participant reflected on how psychedelic-assisted insights regarding the nature of
death ultimately influenced his political activism:
“When you get a clear vision of what [death] is and have sort of been there, and have left
the self, left the body, you know, self leaving the body, or soul leaving the body, or
whatever you want to call it, you would also know that marching in the Civil Rights
Movement or against the Vietnam War in Washington [is less scary]…In a sense [it takes
away the fear of dying]…because you've already been there. You know what it's about.
When people approaching death have an out-of-body experience…[you] say, ‘I know
what you're talking about. I've been there. Been there and come back. And it's not
terrifying, it doesn't hurt.’” (Doblin, 1991, p. 15)
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Spirituality and Relationship to the Universal Whole
As Chandler & Hartman (1960) point out, reports of psychedelic-assisted spiritual
insights are “just as frequent among scientifically and intellectually sophisticated patients with
strictly materialistic orientations,” (p. 72). Indeed, classic psychedelics are associated with selfreported mystical experiences (Ditman & Bailey, 1967; Doblin, 1991; Griffiths et al., 2008;
Grof, 1970; Kurland, Unger, Savage, Olsson, & Pahnke, 1968; Lerner & Lyvers, 2006; Maclean
et al., 2011; Pahnke et al., 1970; Unger, 1963), euphoria (Ditman & Bailey, 1967; Doblin, 1991;
Savage et al., 1962; Watts et al., 2017), reduced fear of death (Doblin, 1991; Grob, Danforth,
Chopra, et al., 2011; Ross, Bossis, Guss, Agin-Liebes, Malone, Cohen, et al., 2016), greater
purpose and meaning in life (Ditman & Bailey, 1967; Savage et al., 1966), increased
commitment to spiritual lifestyles (Dos Santos et al., 2016c; Griffiths et al., 2011; Winkelman et
al., 2007), and a changed relationship to time (Grof, 1970; Savage et al., 1962). Grof (1970)
explains, “the obsessive dwelling in the past alternating with indulgence in unrealistic
daydreaming and building of wind castles in the future [is] considerably reduced [following the
psychedelic experience] and replaced by an enhanced emotional emphasis on the here and now,”
(p. 68). Additionally, psychedelic exposure is preliminarily associated with increased selftranscendence (Bouso et al., 2012; Bouso et al., 2015; Doblin, 1991). According to the
Temperament and Character Inventory (TCI), self-transcendence refers to,
“Identification with everything conceived as essential and consequential parts of a unified
whole. This involves a state of ‘unitive consciousness’ in which everything is part of one
totality. In unitive consciousness, there is no individual self because there is no
meaningful distinction between self and other—the person is simply aware of being an
integral part of the evolution of the cosmos. This unitive perspective may be described as
acceptance, identification, or spiritual union with nature and its source.” (Cloninger,
Svrakic & Przybeck, 1993, p. 981)

24

Importantly, a number of researchers have not only identified personality change directly
following one (or a few) psychedelic doses (Aixalà et al., 2018; Bouso et al., 2018; CarhartHarris & Goodwin, 2017; Erritzoe et al., 2018; Savage et al., 1966), but have also successfully
tracked the stability of personality change in longitudinal studies of up to one year (Bouso et al.,
2018; Griffiths et al., 2011; Lyons et al., 2018; Maclean et al., 2011; Savage et al., 1966; Savage
et al., 1968; Schmid & Liechti, 2018). Perhaps most notably, at a 14-month follow-up, 67% of
Griffiths et al.’s (2006) research participants rated their encounter with psilocybin as among the
five most personally meaningful and spiritually significant experiences of their lives, similar to
the birth of a child or the death of a parent (Griffiths et al., 2008).
Proposed Mechanisms
Classic psychedelics may inspire a paradigm shift with regard to both
psychopharmacology and psychotherapy, as this drug class does not narrowly address a specific
set of symptoms (Grof, 1970), but is instead thought to promote a nonordinary state of
consciousness that may transform personality through the accelerated emergence of unconscious
material (Chandler & Hartman, 1960; Cutner, 1959; Majić et al., 2015; Savage et al., 1962;
Savage et al., 1964; Studerus et al., 2011; Tenenbaum, 1961; Unger, 1963; Winkelman et al.,
2007). According to the literature, to describe this “therapeutically useful state of
consciousness” (Majić et al., 2015, p. 241) is to “communicate a quality of experience [that]
borders on the incommunicable,” (Sherwood et al., 1968, p. 108). Ineffability notwithstanding,
the psychedelic encounter has been described as a “catalyzer” (Grof, 1970, p. 73) that “enlarges
the psychic horizon” (Savage et al., 1964, p. 119), “broadens perception” (Winkelman et al.,
2007, p. 55), “expands consciousness” (Sherwood et al., 1968, p. 96), and creates a “four
dimensional” sensory experience (Watts et al., 2017, p. 530). According to Unger (1963), “the
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personality is touched to its core and is led into provinces of psychic life otherwise unexplored;
light is shed on boundaries otherwise dark and unrevealed,” (p. 115). It’s certainly intriguing
that observer and participant alike have invoked similar language to characterize the psychedelic
experience. According to one team of clinical researchers, classic psychedelics provide “a
dramatic freeing…from [the self’s] habitual ways of viewing the world, an opportunity to see
clearly without distortion, without a defensive structure [that] limits and filters perception,”
(Savage et al., 1964, p. 119). Likewise, a research participant from an open-label psilocybin trial
reflected on his experience in related terms: “[During the dosing session], I could see [my
relationships] clearly, almost as if for the first time. I had fresh insight…It was as if suddenly the
scales dropped from my eyes, I could see things as they really are,” (Watts et al., 2017, p. 532).
The literature suggests that individuals may need to psychologically surrender to the
psychedelic experience and “work cooperatively with the drug” (Chandler & Hartman, 1960, p.
67) in order to maximize therapeutic benefit (Savage et al., 1962; Sherwood et al., 1968; Watts et
al., 2017). As Savage et al. (1962) warn, “[if a subject is unwilling or unable] to give himself up
to the effects of the drug…[or] if [he] is very concerned about maintaining control…the
experience can [become] frightening, sometimes terrifying,” (p. 427). Indeed, in Watts et al.’s
(2017) open-label psilocybin trial for treatment-resistant depression, “the two patients who
showed less marked improvement in symptoms posttreatment described not being able to ‘let
go,’ implying that ‘letting-go’ may be a key factor in lasting responses,” (p. 538).
For individuals who are able to surrender to the experience, the literature suggests that
classic psychedelics may foster greater acceptance and non-defensiveness in the face of
potentially painful insights (Cohen & Eisner, 1958; Savage et al., 1962; Tenenbaum, 1961; Watts
et al., 2017; Winkelman et al., 2007). According to Tenenbaum (1961), “ego-alien unconscious
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material is able to come forth without decompensation,” (p. 460-1). In this context, it is perhaps
relevant to note that classic psychedelics are associated with decreased activation in the brain’s
anxiety and fear networks (Dos Santos et al., 2016b; Soler, Elices, Franquesa, Barker,
Friedlander, Feilding, Pascual, Riba, 2016; Winkelman et al., 2007). Additionally, in the context
of proper set and setting, the literature also preliminarily suggests that individuals may maintain
a capacity for intact reality testing while under the influence, as well as an ability to recall the
psychedelic experience after the fact (Chandler & Hartman, 1960; Studerus et al., 2011).
Chandler & Hartman (1960) define this capacity for reality testing in the following way:
“The drug does not appear to produce any serious or marked impairment in the major ego
functions when used in proper dosage and in an active therapeutic relationship. The
patient remains oriented [to] person, place and time. He does not appear to lose contact
with everyday reality but, rather, seems to gain contact with other levels of his own
psyche and to be freer to direct his attention to the emotions and projections of his
unconscious.” (p. 68)
In sum, with proper preparation and support, and for those individuals who are able to
release into the experience, the literature preliminarily suggests that classic psychedelics may
facilitate a nonordinary state of consciousness that expands awareness to include previously
unconscious material and nurtures non-defensiveness in the face of potentially painful insights,
all while maintaining ego function integrity. In the context of this potent psychological state, the
literature links shifts in personality to the following mechanisms: 1) Free Association, 2) Defense
Mechanisms Revealed, 3) Emotional Insight, 4) Psychosomatic Healing, 5) Traumatic Reliving,
6) Symbolic Insight, 7) Integration, 8) Neurobiology, 9) Mystical Encounters, and 10) Therapist
Intervention. At this juncture, a caveat may prove prudent, as this list of proposed mechanisms
likely reflects the theoretical orientation of this literature - as well as that of this writer - in ways
as yet not fully understood. As Savage et al. (1962) warn:
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Galileo’s contemporaries refused to look at the moons of Jupiter through his new
telescope. And some of our contemporaries refuse to contemplate the intricacies of the
LSD experience, or having contemplated them are unable to process the new
data…Instead of marveling: ‘My God, I’ve never been in this land before,’ they explain,
interpret and deny all in terms of their conventional framework…they cling desperately
to the old familiar terminology; they maintain a death grip on their ‘cathexes’ and
‘repressions’; and clinging to the old, they cannot let go and be intrigued by the new.
Acute discomfort is their lot, if they cannot hammer their data onto the cross (chi-square)
of their old methodology.” (p. 433)
Free Association
The psychedelic encounter is thought to strengthen cognitive dexterity, along with a
concomitant capacity for free association (Cohen & Eisner, 1958; Pahnke & Richards, 1966;
Savage et al., 1962). According to Pahnke & Richards (1966), “[While under the influence], one
[may feel] capable of thinking unusually sharply, quickly, and clearly…Further, one [may
become] conscious of the presuppositions underlying one's thoughts and of the interrelations
between different ideas. Chain reactions of associations and inferences may occur, and one may
feel as though one is able to think on several different levels of discourse all at once,” (p. 188-9).
From a psychotherapeutic perspective, and with regard to mechanisms that may undergird
personality change, “the [heightened] ability of the patient to follow his own
associations…permits a dramatic opportunity to trace [an intrapsychic] problem to its origin,”
(Cohen & Eisner, 1958, p. 537).
Defense Mechanisms Revealed
The psychedelic experience is also linked to increased awareness of previously
unconscious defense mechanisms (Chandler & Hartman, 1960; Grinspoon & Doblin, 2001;
Savage et al., 1962; Savage et al., 1966; Schmiege, 1963; Watts et al., 2017). While under the
influence, one “[may] literally ‘see’ [themselves] resisting, rationalizing, denying, [and]
isolating,” (Chandler, 1960, p. 74) or “[catch] [themselves] in the act of using [an ego defense,
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such as projection, denial or displacement],” (Grinspoon & Doblin, 2001, p. 680). According to
Savage et al. (1966), “the maladaptive defenses, found by the subjects to be anachronistic, often
[crumble] away over a short period of time. Thus, rapid personality changes do occur,” (p. 253).
Emotional Insight
Classic psychedelics are also associated with a deepened felt sense (Cutner, 1959; Pahnke
et al., 1969; Sherwood et al., 1968; Watts et al., 2017) and, in turn, reduced intellectualization
(Cutner, 1959; Schmiege, 1963; Sherwood et al., 1968; Tenenbaum, 1961), increased feelings of
connection (to self, other and the world) and a shift from avoidance to acceptance (Watts et al.,
2017). According to Watts et al.’s (2017) phenomenological analysis of psilocybin exposure:
“People described that during the dosing session, unlike in their daily lives, they
[couldn’t just] avoid or hide from negative [emotions]. [They were] too overwhelming.
And they found that when they finally surrendered after years of trying to avoid or fight
these feelings, the feelings would swell and then diminish.” (p. 538)
According to one study participant,
“There was a lot of sadness, really really deep sadness: the loss, the grief, it was love and
sadness together, and letting go, I could feel the grief and then let it go because holding
onto it was hurting me, holding me back. It was a process of unblocking.” (p. 538)
Another study participant described her experience in the following terms, “Once I went into the
anger, it went ‘pouf’ and evaporated. I got the lesson that you need to go into the scary
basement, once you get into it, there is no scary basement to go into [anymore],” (p. 538).
Similarly, according to Pahnke & Richards (1966), “the unexpected confrontation [with]
guilt…may be strongly therapeutic,” (p. 187). Indeed, one research participant “who had been
seriously neglecting his wife and children,” described his LSD dosing session in the following
way:
“There seemed to be in front of [me]…many veils…I pushed each veil aside one by
one…And finally the last veil was pulled aside and there were my three children crying
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for their father…Before me was all of the selfish feelings – all of the selfish attitudes that
I had had throughout my entire married life.” (p. 187)
Often, study participants describe the experience of catharsis following emotional insight:
“[Before the dosing session] I had lost my ability to grieve and cry. [During the dosing session] I
cried and that was a cathartic experience for me, a very welcoming sweet experience,” (Watts et
al., 2017, p. 540). “I was weeping, tears were flowing out of me, it wasn’t a painful crying, it
was like turning on the taps, like a washing, a washing out,” (Watts et al., 2017, p. 540).
Psychosomatic Healing
The literature also includes references to psychedelic-assisted psychosomatic healing
(Chandler & Hartman, 1960; Cohen & Eisner, 1958; Schmiege, 1963; Watts et al., 2017).
According to Chandler & Hartman (1960),
“Pain is of frequent occurrence…It is an expression of a repressed affect, at times
associated with the memory of some trauma…The patient is always encouraged to go
along with the pain and let it become more intense, until the fantasy with which it is
associated breaks through into awareness. When this occurs, the pain usually disappears
immediately.” (p. 70)
According to Cohen & Eisner (1958), “With the uncovering of critical problems varying degrees
of somatic discomfort…are felt…The word most commonly used by the patient after an
experience of this sort is that he feels ‘purged,’” (p. 533). Watts et al.’s (2017) examination of
psilocybin exposure supports this conclusion: “Some [research participants] also reported
specific physical sensations, [which] they interpreted as emotions that had manifested as somatic
symptoms because they had not been expressed,” (p. 540). In the words of one such participant:
“The dose helped me realize why I felt the pain in my chest, I saw it visually and felt it
emotionally, then I felt so much lighter, like something had been released. It was an
emotional purging, the weight and anxiety and depression had been lifted.” (p. 540)
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Traumatic Reliving
Representing a controversial contention in the context of what we know regarding the
malleability of memory (Gonsalves & Paller, 2002; Loftus, 2004; Loftus, 2005; Roediger &
McDermott, 1995), the literature links psychedelic exposure to the reappearance of allegedly
repressed, traumatic memory (Chandler & Hartman, 1960; Cohen & Eisner, 1958; Cutner, 1959;
Grof, 1967; Schmiege, 1963; Tenenbaum, 1961; Watts et al., 2017; Winkelman et al., 2007),
dating back as early as infancy (Cutner, 1959; Pahnke, 1969; Watts et al., 2017) and possibly
including genuine prenatal and birth traumata (Cutner, 1959; Grof, 1979). According to
Chandler & Hartman (1960), “Several patients who had almost complete amnesia for childhood
events before 10 or 11 years of age uncovered a great wealth of material which proved of
tremendous therapeutic benefit,” (p. 74). The literature suggests that these memories are not just
recalled, but in fact “relived,” (Chandler & Hartman, 1960, p. 71; Cohen & Eisner, 1958, p. 530;
Grof, 1967, p. 165; Pahnke, 1969, p. 150; Tenenbaum, 1961, p. 460; Watts et al., p. 539).
Chandler & Hartman (1960) describe the phenomenon of reliving in the following way:
“The term ‘reliving’ describes the more intense experiences better than the term ‘recall.’
Scenes may be pictured with great vividness of color and other detail, and the patient
feels himself to be back in the situation and experiences the affects in all the original
intensity. Some patients describe it by saying that it is as though a 3-D film tape [is]
being run off in the visual field.” (p. 71)
Put another way, “Unconscious memories [are not only] recovered easily, but…relived [with
extreme realism] …frequently accompanied by changes in the body image, so that the patient
[feels as if] he [is] the physical size and age [as] when the traumatic experience occurred,”
(Pahnke, 1969, p. 186-7). According to Watts et al. (2017), one research participant reported
reliving, “from the perspective of himself as an infant, a pillow held over his face by a caregiver,
and felt a deep fear of annihilation,” (p. 539). In the words of another participant,
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“[I] became myself at age 7, after my [grandparent] had died. I totally was back there, so
vivid, so real, I had the emotions that I would have felt at the time: fearful, why did this
happen, the naivety, the shock and confusion. I was getting overly upset and my parents
were saying ‘boys don’t cry.’” (p. 539)
It may prove consequential that memories are said to be relived through the child’s experience,
while simultaneously reexamined through the adult’s eyes:
“The recalled and relived experiences are reformulated on a grown-up level and
rationally integrated into the ego…The patient can oscillate between…experiencing the
present grown-up level and a deeply regressive infantile one. A very important factor
seems to be the patient’s ability to relive fully and with an intense emotional charge the
infantile traumatic material and at the same time to evaluate its relevancy from the point
of view of a grown person. This means an opportunity for rational mastering and for
mature and adequate judging of the significance of these experiences.” (Grof, 1967, p.
179)
As a function of traumatic reliving, clinical researchers have theorized that deep shifts occur on
the object relational plane (Savage et al., 1964): “A reorientation of object relationships can take
place on a level more archaic than that of language,” (Cutner, 1959, p. 723), as “the infantile
core, fully recalled and relived, loses its dominant position in the experiential field, and is
replaced by a new one,” (Grof, 1967, p. 177). Intriguingly, the literature anecdotally reports
incidents whereby patients later corroborate memories first uncovered during the psychedelic
encounter (Ditman, 1968; Frederking, 1955; Grof, 1967; Newland, 1962; Sandison & Whitelam,
1957). For example,
“A woman under LSD felt herself to become tiny. [In her words], ‘a helpless
baby…feeling very cold and hungry…seeing nothing but white, white tile…’ Several
weeks after this LSD experience, the woman learned from her mother, to her complete
amazement, that she had been placed in an incubator for several days directly after her
birth – a fact which she had not consciously known for all of her life.” (Ditman, 1968, p.
49)
As Ditman (1968) points out,
“It has been debated whether these early, repressed incidents which are recovered in the
LSD experience are in fact truly, realities relived; or whether they are fantasies evoked
for the sake of the therapist through the disinhibiting effects of the LSD
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experience…Whether such vivid upsurges of psychic material are based on actual events
or, rather, are symbolic representations of conflict-laden areas does not seem of much
relevance when, as a result of such LSD-induced fantasies, the patient achieves greater
insight and ability to resolve the problems which have been crippling his day-to-day
living.” (p. 48-50)
Symbolic Insight
The literature also suggests that psychological insight may be conveyed symbolically
(Ditman, 1968; Schmiege, 1963; Sherwood et al., 1962; Watts et al., 2017). According to
Pahnke & Richards (1966),
“Visions of objects not present may suddenly appear. At times, in a dreamlike state, one
may enter one’s visions and seem to be walking through gardens, art museums, medieval
castles, futuristic cities…Archetypal imagery may appear, and one [may find] oneself
encountering mythological characters such as angels, demons, dragons, and Grecian
gods.” (p. 185)
Sherwood (1962) further explains,
“The unconscious mind employs visual and other symbolic representations with
seemingly endless variety to convey insights to the conscious mind. They may represent
to the individual some aspect of his own picture of himself, or some characteristic of his
approach to life…Through [these] processes, the subject constantly works off repressed
material and unreality structures, false concepts, ideas, and attitudes, which have been
accumulated through his life experiences. Thus a form of psychological cleansing seems
to accompany the subjective imagery. This results in considerable ventilation and release
almost independent of intellectual clarification.” (p. 98)
As self-consciousness is thought to remain intact, this state may be compared to a lucid dream,
whereby an individual is empowered to interact with psychological conflicts symbolically. As
one research participant recounted, “There was this huge terrifying creature with a rifle, and
instead of running away, I looked at it, and it wasn’t as scary as it had seemed. [My] fear
subsided, it suddenly seemed ridiculous, I started laughing. If I had avoided it, it would have got
more terrifying,” (Watts et al., 2017, p. 538).
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Integration
In what Cohen & Eisner (1958) term the “integrative effect,” (p. 537), classic
psychedelics may also meld fissures in the personality structure (Cohen & Eisner, 1958; Grof,
1967; Grof, 1970). According to Grof (1967), “A very typical occurrence is the resolution of
ambivalent attitudes with a successive narrowing of the oscillation spectrum of contradictory
tendencies and a sort of mutual neutralization…the boundaries between controversial
components of various ambivalent attitudes melt,” (p. 177-9). According to Cohen & Eisner
(1958), “In our sample this integrative aspect appeared to occur in conjunction with resolution of
conflicts,” (p. 537). It may be theorized that an expansion of consciousness allows for an
encounter between previously split off parts of the self. With such a bridging in place,
psychological conflicts underlying personality chasms may resolve and, in turn, facilitate a more
integrated personality structure.
Neurobiology
Dos Santos et al. (2016b) conducted a systematic review of neuroimaging research and
identified 25 studies that met their four-pronged inclusion criteria: 1) investigation of acute and
non-acute effects of classic psychedelics on the human brain, 2) via observational or
interventional study design, 3) and the application of structural, functional or neurochemical
neuroimaging techniques, 4) with findings published in a peer-reviewed journal. When
considered in aggregate, the results of this systematic review preliminarily link classic
psychedelics to increased neuroplasticity, neurogenesis and integration of disparate cortical
regions, as well as increased activation of brain structures implicated in cognitive processes,
memory, interoception and mood regulation. Simultaneously, these findings also preliminarily
link psychedelic exposure to decreased activation of brain structures required for anxiety and
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fear processing, as well as rumination. Dos Santos et al.’s (2016b) systematic review also
identifies neural correlates for the psychedelic-assisted experience of ego dissolution, which
intriguingly resembles the brain’s state during deep meditation.
In this context, it is relevant to note that all neuroscientific literature, including the
aforementioned, may rest on “unquestioned but highly questionable foundations,” (Noë, 2010, p.
3). This critique is explored in The Manifesto for a Post-Materialist Science (2014), a mission
statement co-authored by an internationally diverse group of scientists (spanning the fields of
biology, neuroscience, medicine, psychiatry and psychology) at a 2014 summit co-organized by
the University of Arizona’s Gary E. Schwartz, Ph.D. and Mario Beauregard, Ph.D. and Columbia
University’s Lisa Miller, Ph.D. Of note, this summit was not specific to psychedelic research,
but instead a more universal meeting of the minds regarding the state of contemporary science:
“The modern scientific worldview is predominantly predicated on assumptions that are
closely associated with classical physics. Materialism—the idea that matter is the only
reality—is one of these assumptions. A related assumption is reductionism, the notion
that complex things can be understood by reducing them to the interactions of their parts,
or to simpler or more fundamental things such as tiny material particles. During the 19th
century, these assumptions narrowed, turned into dogmas, and coalesced into an
ideological belief system that came to be known as ‘scientific materialism.’ This belief
system implies that the mind is nothing but the physical activity of the brain, and that our
thoughts cannot have any effect upon our brains and bodies, our actions, and the physical
world.” (p. 1)
Similarly, as renowned neuroscientist Alva Noë, Ph.D. (2010) contends,
“The idea that the only genuinely scientific study of consciousness would be one that
identifies consciousness with events in the nervous system is a bit of outdated
reductionism…To move forward in our understanding of consciousness, we need to give
up the internal, neural microfocus…It is striking that the majority of scientists working
on consciousness don’t even notice there is an overlooked theoretical possibility here.
They tend to think that consciousness, whatever its ultimate explanation, must be
something that happens somewhere and sometime in the human brain, just as digestion
must take place in the stomach,” (p. 1-3).
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With regard to the mechanistic underpinnings of personality change, the assumption that
neurobiological events cause revelatory psychological events is just that – an assumption. It’s
just as plausible to conjecture that experiences of consciousness occur – and are then reflected on
the neurobiological plane.
Mystical Encounters
According to Pahnke & Richards (1966), classic psychedelics facilitate two qualitatively
different types of nonordinary states: the mystical and the non-mystical. In the context of nonmystical states, which have been discussed up until this point, “the empirical ego generally exists
as the subject viewing objects of a visionary nature, or pondering objects of a cognitive nature,”
(p. 183). In mystical (and some psychotic) 5 states, however, “the subject-object dichotomy is
transcended and the empirical ego extinguished,” (p. 184).
Mystical consciousness fits less neatly into the traditional psychotherapeutic paradigm
and therefore occasions more skepticism:
“Of all the varieties of psychedelic experiences, the type that has elicited the most
enthusiastic interest as well as the most indignant rebuttal from both psychiatric and
theological spokesmen is the mystical experience. The claim that spontaneous mystical
experiences are similar to, if not identical with…drug-facilitated mystical consciousness
has caused considerable apprehension and dismay among some religious professionals,
and the possible therapeutic potential…has been somewhat embarrassing to those
therapists who pride themselves on their scientific objectivity and lack of religious
involvement.” (Pahnke & Richards, 1966, p. 190)

5

Although a full reckoning of the psychotic versus mystical states is outside the scope of this paper, Ken Wilber’s
theory of the pre/trans fallacy may prove relevant. According to Wilber’s theoretical model, there are three broad
developmental stages of consciousness: the pre-personal (pre-egoic, such as the infantile or psychotic), the personal
(egoic, such as that of the healthy adult) and the trans-personal (trans-egoic, such as that of the mystic). According
to the pre/trans fallacy, non-rational stages of consciousness (which include the pre and trans stages) share certain
similarities (such as egolessness) and are therefore often confused for one another. For example, trans-rational
states (e.g. mystical experiences) are often conflated with pre-rational states (e.g. psychotic breaks), and vice versa.
According to Wilber, both Freud and Jung committed versions of the pre/trans fallacy: Freud erroneously reduced
the mystical experience to a regressed and infantile oceanic state, whereas Jung erroneously elevated pre-rational
myth to divine realization. For more on this, see: Wilber, 2000.
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Taboo notwithstanding, mystical experiences (also known as peak, cosmic and transcendental)
are one of the most potent predictors of post-psychedelic personality change (Doblin, 1991;
Griffiths et al., 2008; Grof, 1970; Kurland et al., 1968; Lebedev et al., 2016; Maclean et al.,
2011; Maslow, 1959; Pahnke, 1969; Pahnke et al., 1970; Savage et al., 1962; Unger, 1963).
Indeed, rigorous double-blind clinical studies have linked psilocybin-occasioned mystical
experiences to sustained improvement in the domains of openness (Maclean et al., 2011),
personal well-being, life satisfaction, and positive behavioral change (Griffiths et al., 2006;
Griffiths et al., 2008, Griffiths et al., 2011). Of note, not all individuals who ingest a psychedelic
will encounter a mystical experience: “a relatively high dosage is a necessary, but not sufficient,
condition,” (Pahnke & Richards, 1966, p. 199).
In an effort to experimentally operationalize mystical consciousness, Pahnke (1963)
content analyzed historical reports of spontaneous mysticism and identified the following nine
interrelated criteria (with subsequent investigators having since identified similar definitional
parameters, see reviews in: Hood, 2003; Hood, Hill & Spilka, 2009): 6 1) Unity, 2)
Transcendence of Time and Space, 3) Deeply Felt Positive Mood, 4) Sense of Sacredness, 5)
Noetic Quality, 6) Paradoxicality, 7) Ineffability, 8) Transiency, and 9) Persisting Positive
Changes in Attitude and Behavior. In an attempt to illuminate this opaque construct, each
criterion will be defined in turn.
Unity: According to Pahnke & Richards (1966), the hallmark of mystical consciousness
is “undifferentiated unity,” (p. 177), which may be experienced either internally (ego dissolution)

6

Studies included in this literature review administered the following measures in order to experimentally capture
mystical phenomena: Mystical Experience Questionnaire (created by Pahnke), States of Consciousness
Questionnaire (SOCQ), the Mysticism Scale, the Altered States of Consciousness questionnaire (ASC), and the EgoDissolution Inventory.
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or externally (transcendence of the subject-object dichotomy). By way of clarification, Pahnke
& Richards describe internal unity in the following terms:
“Awareness of all normal sense impressions (visual, auditory, cutaneous, olfactory,
gustatory, and kinesthetic) ceases, and the empirical ego (i.e., the usual sense of
individuality) seems to die or fade away while pure consciousness of what is being
experienced paradoxically remains and seems to expand as a vast inner world is
encountered…Internal unity occurs when consciousness merges with [the ground of
being] beyond all empirical distinctions. Although awareness of one’s empirical ego has
ceased, one does not become unconscious.” (Pahnke & Richards, 1966, p. 177)
Notably, neuroimaging studies have identified neurobiological correlates for this phenomenon
(Carhart-Harris et al., 2012; Lebedev et al., 2015; Tagliazucchi et al., 2016). For example,
Lebedev et al. (2016) acquired functional MRI scans of 15 healthy subjects during active
psilocybin exposure (as well as during a placebo condition) and identified an association
between psilocybin-induced ego-dissolution and decreased functional connectivity between the
medial temporal lobe and high-level cortical regions, as well as reduced interhemispheric
communication and a disintegration of the salience network (Lebedev et al., 2016, p. 3137). The
authors of this study conclude, “[These findings] suggest that the maintenance of ‘self’ or ‘ego,’
as a perceptual phenomenon, may rest on the normal functioning of these systems,” (Lebedev et
al., 2016, p. 3137). Of course, it’s just as reasonable to conjecture that such neurobiological
shifts are a reflection – and not a cause – of ego dissolution.
With regard to external unity, Pahnke & Richards (1966) describe the experience as
follows:
“Awareness of one or more particular sense impressions grows in intensity until suddenly
the object of perception and the empirical ego simultaneously seem to cease to exist as
separate entities, while consciousness seems to transcend subject and object and become
impregnated by a profound sense of unity, accompanied by the insight that ultimately ‘all
is One.’” (p. 178)
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One may reasonably conjecture that the unitive experience with nature and humanity at least
partially accounts for psychedelic-assisted increases in compassion, nature-relatedness and
political activism.
Importantly, the internal and external unitive experiences are thought to be two sides of
the same coin: “Although each form of unity occurs in a different manner, the states of
consciousness ultimately experienced may be identical,” (Pahnke & Richards, 1966, p. 177).
Notably, in experimental settings, scores of psychedelic-induced unitive experiences correlate
highly with scores of ego dissolution (Nour et al., 2016). Carhart-Harris et al. (2018) therefore
surmise, “One [may] consider the ego [to be] a counterforce to connectedness,” (p. 549).
Transcendence of Time and Space: Intrinsic to the mystical encounter is a perceived shift
in the space-time continuum, also described as “a radical change in perspective in which [one]
suddenly feels…outside of time, in eternity or infinity, beyond both past and future,” (Pahnke &
Richards, 1966, p. 179). As Sherwood et al. (1962) further elaborate, “He perceives what he
may attempt to describe as ‘levels’ of consciousness, as ‘other dimensions’ of space, as
‘traveling in time’; and yet as he tries to describe these he recognizes the effort to be as doomed
to partial failure as the effort to describe being in love to someone who has not experienced it,”
(p. 99).
Deeply Felt Positive Mood: The mystical encounter also encompasses overwhelming
feelings of joy, love, blessedness and peace, which may range from “nonsensual feelings of
ultimate concern for other persons to a state resembling prolonged intense sexual orgasm. The
latter degree of intensity is generally dissociated from any excitation of the sexual organs, being
‘spiritual’ rather than ‘erotic’ in nature,” (Pahnke & Richards, 1966, p. 180). Additionally,
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feelings of peace “entail not only deep relaxation, but a conviction that ultimately there is no
ground for anxiety,” (Pahnke & Richards, 1966, p. 180).
Sense of Sacredness: Deeply felt awe, humility, reverence and “perceived smallness in
the presence of vastness” also constitute essential components of the mystical encounter (Pahnke
& Richards, 1966, p. 549). According to Nour (2017),
“Awe occurs in response to stimuli that are vast…transcend current frames of reference,
and… require new schemata to accommodate what is being perceived…[Such]
experiences…[may] catalyze psychological change within an individual…by shifting
attention away from one’s individual concerns, and towards the larger entities of which
an individual is a part.” (p. 22)
Indeed, Carhart-Harris et al. (2018) conjecture that the mystical encounter may prove analogous
to ‘the overview effect’ experienced by some astronauts when gazing back at earth, whereby
one’s very self is altered through a transient shift in perspective.
Noetic Quality: William James assigned the term ‘noetic quality’ to this facet of mystical
consciousness, whereby the encounter is “intuitively felt to be of a more fundamental form of
reality than either the phenomena of everyday consciousness or the most vivid of dreams or
hallucinations,” (Pahnke & Richards, 1966, p. 178-9). According to Sherwood et al. (1962), “He
is convinced that, somehow or other, this other realm (which he feels he apprehends directly, in
contrast to the usual space-time world of practical experience of physics which he perceives with
physical senses) is ‘really’ there,” (p. 99). In the words of one research participant, “[The
mystical experience] left me with a completely unquestioned certainty that there is an
environment bigger than the one I’m conscious of…[This] went from a theoretical proposition to
an experiential one,” (Doblin, 1991, p. 14). As Pahnke & Richards (1966) point out, “Theories
that dismiss mystical consciousness as ‘mere regression’ or ‘an oceanic feeling of primary
process’…fail to wrestle with the noetic quality [of the experience],” (p. 201).
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Paradoxicality: This category reflects “the manner in which significant aspects of
mystical consciousness are felt by the experiencer to be true in spite of the fact that they violate
the laws of Aristotelian logic,” (Pahnke & Richards, 1966, p. 181). For example, an individual
may report that he “[ceases] to exist, yet obviously continues to exist…[Or] he may [report
being] ‘out of the body’ while…still [being] ‘in the body,’” (Pahnke & Richards, 1966, p. 181).
As one participant exclaimed, “I doubt if [any] statement can possibly be made to seem
meaningful at the ordinary level of consciousness. No wonder the mystics of all faiths teach that
understanding comes only when logic and intellect are transcended!” (Pahnke & Richards, 1966,
p. 181).
Ineffability: According to Pahnke & Richards (1966), “When a subject attempts to
communicate mystical consciousness verbally to another person, he usually claims that the
available linguistic symbols – if not the structure of language itself – are inadequate to contain or
even accurately reflect such experiences,” (p. 181). In the words of two separate research
participants: “To seek to condense any of my experiences into words is to distort them,” (Pahnke
& Richards, 1966, p. 182).
Transiency: In contrast to everyday consciousness, this category reflects the temporary
nature of the mystical encounter: “The characteristic of transiency indicates that the mystical
state of consciousness is not sustained indefinitely and marks one of the important differences
between it and psychosis,” (Pahnke & Richards, 1966, p. 182).
Persisting Positive Changes in Attitude and Behavior: According to Pahnke & Richards
(1966), individuals who experience mystical consciousness also evidence long-term changes in
attitudes and behaviors toward themselves, others, life, and mystical consciousness itself.
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Sherwood et al. (1962) summarize the relationship between the mystical encounter and
personality change in the following way:
“The subject [discovers] the vast extent of his own being, that he has understanding and
abilities far greater than he previously imagined…He mentions mystic or oceanic
experiences so profound as to remove neurotic symptoms forever after. The individual’s
conviction that he is, in essence, an imperishable self rather than a destructible ego brings
about the most profound reorientation at the deeper levels of the personality. He
perceives illimitable worth in this essential self, and it becomes easier to accept the
previously known self as an imperfect reflection of this. The many conflicts which are
rooted in lack of self-acceptance are cut off at the source, and the associated neurotic
behavior patterns begin to die away. Consequently the individual experiences less anxiety
in connection with situations previously painful. Incapacitating feelings of inadequacy
and guilt, re-examined in the light of this new self-discovery, seem inappropriate and are
relinquished.” (p. 107)
Therapist Intervention
First- and second-wave investigators agree that proper preparation is essential to the
success of a psychedelic encounter (Chandler & Hartman, 1960; Johnson et al., 2008; Savage et
al., 1963). According to the literature, such preparation should include building patient-therapist
rapport, explaining the range of experiences one might encounter and encouraging the patient to
mentally surrender during the dosing session, particularly in the face of challenging material
(Johnson et al., 2008). According to Chandler & Hartman (1960),
“Such discussions help to allay the anxiety which the patient might otherwise have when
confronted with the projections of the unconscious under LSD. The discussion helps to
support the conscious ego in its reaction to the previously unconscious material now
elicited under LSD and to encourage tolerance and acceptance of previously unacceptable
aspects of the unconscious. We have found that the more the patient understands about
the procedures, the experience, and the rationale of the process the better is his
therapeutic response.” (Chandler & Hartman, 1960, p. 65)
There is also widespread agreement that therapists must be available to provide support
during dosing sessions, particularly in moments of heightened anxiety (Cutner, 1959; Johnson et
al., 2008; Sherwood et al., 1968). According to Cutner (1959):
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“The ego-threshold is rather suddenly lowered and the patient’s defenses against the
impact of emotional and instinctual or archetypal contents are suddenly weakened, a
greater amount of anxiety may be engendered than is usual in general analysis. Due to
this, there is a much greater need for assurance…sometimes by physical touch.” (p. 722)
Beyond the provision of support, there’s disagreement within the literature regarding the
appropriateness of further therapeutic intervention during a dosing session. According to
contemporary research guidelines, study participants should be encouraged to “collect
experiences [while under the influence] to discuss after the drug effects have abated and [are
discouraged from analyzing] material or [communicating] excessively while the atypical states
of consciousness are still occurring,” (Johnson et al., 2008, p. 615). In contrast, first-wave
investigators are divided over the matter. Certainly, it’s possible to trace today’s safety
guidelines to first-wave thinkers, such as Sherwood et al. (1962):
“It will be noted that an outstanding characteristic of this method of therapy is that it
places major responsibility clearly on the patient and tends to discourage any sort of longterm dependency or transference relationship with the therapist. The therapist is not
called upon to analyze or to interpret except in a most minimal sense. The subject is
encouraged to discover that his own resources are more than adequate to his needs, and
the therapist's function is to provide support and guide him toward discovery.” (p. 99)
Nevertheless, first-wave clinicians were more inclined to view psychedelics as an “enhancer of
skilled psychotherapy,” (Pahnke et al., 1970, p. 1862) and therefore an agent to be incorporated
into an ongoing traditional psychoanalysis:
“The ability to make deep interpretations [is] important; the silent or reflective method
does not take the patient as rapidly as possible to the core of his problems. A fear of
premature or too penetrating interpretation is minimized by the patient’s ability to view
himself with detachment. Incorrect or unacceptable interpretations tend to be brushed
aside.” (Cohen & Eisner, 1958, p. 532)
According to this line of thinking, classic psychedelics potentiate the therapeutic encounter by
deepening a patient’s access to unconscious material and ability to tolerate challenging
interpretations. Additionally, numerous first-wave clinicians link psychedelic exposure to an
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enhanced capacity to work in the transference (Chandler & Hartman, 1960; Cohen & Eisner,
1958; Grof, 1967; Schmiege, 1963; Unger, 1963):
“Transference is more easily analyzed with LSD because of the intensification of affect
which occurs, so that the patient finds it harder than usual to conceal his feelings toward
the therapist…Greater availability of early memories and childhood emotions toward the
parents which so frequently parallel the transference reactions also facilitate analysis of
the transference. The material produced lends itself to the therapist’s interpretations of
the nature and operation of the less adaptive defenses. Patients more readily grasp
interpretations because of their greater capacity for insight.” (Carhart & Hartman, 1960,
p. 68)
The literature also highlights the relationship between an analyst’s own psychedelic
psychotherapy and the ability to work ethically with psychedelic-assisted transference:
“The emotional as well as the technical demands upon the therapist are greater than in
other forms of therapy because of the greater prominence of the ‘primary process’ type of
material with which he must deal. The intensification of affect and the fact that the
impulse life presents itself in much thinner disguise, or as none at all, may touch off
unconscious problems in the therapist if his own analysis and his exploration of his
unconscious under LSD had been inadequate. A therapist working with LSD should have
had extensive personal analysis himself, as well as a series of at least 20 to 40 sessions
with the drug, to explore all aspects of his unconscious and to become familiar with all
the typical symbols, identifications, projections, and transference reactions.” (Chandler &
Hartman, 1960, p. 68)
First- and second-wave investigators are also divided over the importance of long-term
psychotherapy. Likely a reflection of methodological considerations, second-wave investigators
do not study classic psychedelics in the context of long-term treatment but, instead, commonly
administer 1-2 psychedelic doses in a supportive setting, with the availability of follow-up
therapeutic supports when necessary. In contrast, a majority of first-wave investigators
resoundingly assert the importance of the long-term psychotherapeutic frame (Cohen, 1960;
Chandler & Hartman, 1960; Pahnke, 1969; Pahnke et al., 1970; Savage et al., 1962; Savage et
al., 1964; Savage et al., 1966; Schmiege, 1963). In their words: “The delusion that the drug in
itself can produce a cure may be a temptation to the immature therapist,” (Schmiege, 1963, p.
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205). “The psychedelic experience serves as an opening wedge. It is not nor has it been reported
to be the entire process,” (Savage et al., 1966, p. 252). Absent long-term psychotherapeutic
supports, “the social matrix will remold the patient and the LSD experience will become a
memory rather than an integral part of the personality,” (Savage et al., 1962, p. 435). First-wave
investigators also highlight the phenomenon of “psychedelic afterglow” (Pahnke et al., 1970, p.
1858), whereby the potency of psychotherapeutic interventions is heightened in the days and
weeks following a dosing session (Pahnke, 1969; Sherwood et al., 1962). Importantly, while
there’s second-wave evidence to support the long-term impact of even a single psychedelic dose
absent long-term psychotherapy (Bouso et al., 2018; Erritzoe et al., 2018; Griffiths et al., 2011;
Lyons et al., 2018; Maclean et al., 2011; Schmid & Liechti, 2018), there’s also sound first-wave
evidence suggesting psychedelic gains may be lost over time if proper psychotherapeutic
supports are not in place (Mogar et al., 1964; Savage et al., 1966; Savage et al., 1968). Although
impossible to conclusively adjudicate as the literature currently stands, first-wave subject pools
include more severe pathology and psychotherapy may therefore prove more integral to
psychedelic gains when working with clinical populations.
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CHAPTER THREE
Methods
To date, no investigator has yet probed the effect of classic psychedelics on personality
through a contemporary psychodynamic lens. As these substances are increasingly legalized and
reintroduced into the psychotherapeutic frame, a deeper understanding of their effect on
personality and overall wellbeing - as well as their clinical contraindications and potential pitfalls
- will prove essential. As a result, this study represents a preliminary investigation into the effect
of classic psychedelics on psychodynamic constructs that are thought to undergird personality:
psychiatric symptomatology, attachment style, mentalization, personality organization, prosocial
behavior and a capacity for flourishing.
Participants
Data will be collected through a collaboration with The Psychedelic Society, a non-profit
organization based in the United Kingdom. According to the organization’s mission statement:
“The Psychedelic Society believes the conscious use of psychedelics can help create a
more compassionate and joyful world through an appreciation of the unity and
interconnectedness of all things. Psychedelics have been used by humans for thousands
of years for healing and spiritual development. After decades of misinformation, and
outlawing on political as opposed to scientific grounds, the potential of these substances
is starting to be recognized again. We exist to reinstate the public understanding of and
access to psychedelics in the UK and beyond.”
As part of their work, The Psychedelic Society facilitates what they call Experience Retreats in
the Netherlands, where participants ingest psilocybin truffles in a safe, legal and ceremonial
context, under the guidance of experienced facilitators. Their rotating team of twelve facilitators
are trained in a variety of modalities, including psychotherapy, counseling, festival welfare,
bodywork, Dharma meditation, shamanic practices, sound healing and psychopharmacology.
According to the Psychedelic Society’s website, “retreats are aimed at people in good mental and
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physical health wanting to explore the nature of reality and the mind. They are not intended as a
substitute for medical or psychotherapeutic care.”
In order to attend a retreat, interested individuals must first apply to the Psychedelic
Society through an online application, where information is requested regarding personal and
familial history of mental health difficulty, medication management and exposure to
psychoactive substances. Exclusion criteria includes clinically diagnosed and treatment-resistant
depression and/or anxiety, psychosis (or a first-degree relative with schizophrenia), active PTSD,
or the following medications: SSRI or SNRI, lithium and benzodiazepines. Once individuals are
cleared to participate, they are invited to enroll in Experience Retreats via an online portal.
These 4-day retreats 7 accommodate 10-20 participants at a time, with at least one facilitator per
every five attendees. Retreats are offered on a sliding scale basis, ranging from 650 to 2000
euros per person. Due to the Schedule 1 classification of psilocybin in the United States and the
methodological obstacles that ensue, participants of an upcoming Experience Retreat will serve
as a self-selected convenience sample for this study.
Set and Setting
As set and setting strongly affect the psychedelic experience, a detailed description of the
Experience Retreat program is provided here.
Day 1: Participants meet in Amsterdam to purchase psilocybin together (two 22-gram
packs per person). They then travel approximately two hours by bus to the retreat center.
Accommodations are simple dormitories located in the woods, with approximately 1-2
participants per room. Upon arrival, participants are served dinner (all retreat meals are vegan).
Evening activities begin with an opening circle, where participants introduce themselves and
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Effective January, 2020, retreats will be 5-6 days in duration, which will slightly shift the schedule of events.
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ethical guidelines are discussed. As psilocybin exposure is thought to intensify projections and
emotional vulnerability, attendees are asked to refrain from sexual activity with one another
throughout the duration of the retreat and up to one month following. (These guidelines do not
apply to preexisting couples who attend the retreat together). Additionally, participants are also
asked to turn off electronics in order to support psychological presence and intentionality
throughout the retreat. The first evening concludes with a group exercise, which may include
bodywork, yoga or meditation.
Day 2: The day begins with a morning practice (bodywork, yoga or meditation), followed
by breakfast. Each participant then meets one-on-one with a designated retreat facilitator to
discuss the upcoming psilocybin ceremony. During these freeform conversations, participants
are invited to explore any lingering questions and concerns. Additionally, facilitators ask
participants whether they feel comfortable receiving physical comfort during the psilocybin
ceremony if necessary and whether they would rather receive such support from a male or
female facilitator. Participants are also encouraged to request help during the ceremony when
needed. Lastly, psilocybin dose is discussed. Most participants choose to ingest approximately
33 grams of psilocybin (1.5 packs), although up to 44 grams (2 packs) are offered depending on
individual preference. After one-on-one check-ins, and in advance of the ceremony, participants
gather together to press the psilocybin truffles into a paste.
The five-hour ceremony begins late morning (approximately 11:30 AM) and is held
indoors in an open room with natural light. An alter is placed at the center of the room with
objects that participants handpick from surrounding nature, such as pinecones and flowers. Each
participant is provided a mattress (arranged in a circle around the alter), as well as a pillow,
blanket and eyeshade. In order to initiate the ceremony, each participant is invited to share his or
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her intention for the psilocybin experience. The psilocybin paste is then mixed with hot water
and ingested as a tea, with most participants drinking two infusions. (A third infusion is offered
approximately one hour into the ceremony). Participants are then invited to lie down, wear their
eyeshades and psychologically surrender to the experience. A music playlist accompanies the
ceremony, curated by Dr. Mendel Kaelen, an ethnomusicologist who arranges soundtracks to
specifically support the trajectory of psychedelic exposure (for example, music intensifies as
drug impact peaks). Although participants are encouraged to quietly tune into themselves and
limit interaction with others, facilitators are available to escort participants to the bathroom when
necessary and provide emotional support if needed. Additionally, approximately four hours into
the ceremony, light snacks are offered, including sandwiches, dark chocolate and fruit.
Following the ceremony’s completion, gentle activities are facilitated (such as walking in
nature or making art). Dinner is then served, followed by a brief check-in circle before bed,
where participants are invited to share initial impressions and feelings.
Day 3: Day three of the retreat provides an opportunity for integration - the intentional
process of incorporating new insights into one’s emotional life and models of the world. Such
activities include bodywork, yoga, meditation, journaling, time in nature, the creation of art, song
and group discussion. Each participant also attends one-on-one check-ins with his or her
designated facilitator in order to reflect on the experience and enlist further support.
Day 4 and beyond: Following a morning practice (such as bodywork, yoga or
meditation), as well as breakfast, attendees participate in one final integration circle. Here,
participants are given another opportunity to verbally process their experience and share
reflections with the group. Additionally, facilitators offer best practices for post-psychedelic
reintegration into everyday life. For example, although participants are encouraged to make
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space and time for deep reflection, they are also discouraged from making any radical life
changes in the first few weeks following psychedelic exposure. Participants are also encouraged
to stay in touch and support one another as the integration process unfolds.
At approximately 1:30 PM, all participants board a bus back to Amsterdam. Following
the retreat, contact information is provided via follow-up email for further psychotherapeutic
supports in the event that such resources prove necessary. Additionally, a conference call is held
three weeks post-retreat, where participants are invited to reconnect and reflect on integration
experiences together.
When compared to first- and second-wave research methodologies, this study most
closely resembles the contemporary approach. In contrast to the first wave (where drug
administration predominantly occurred in the context of long-term psychotherapy with subject
pools that included severe psychopathology), this study’s participants will skew in a healthier
direction (due to the implementation of second-wave safety guidelines, such as the exclusion of
bipolar and psychotic disorders) and the administration of psilocybin will occur in the absence of
long-term psychotherapy. Of note, and representing a contrast to the most prevalent first- and
second-wave approaches, this study will administer psilocybin in a group (as opposed to an
individual) and ceremonial (as opposed to a clinical) context.
Measures
Participants will complete the following measures the day before drug exposure (via
hardcopy questionnaire during the bus ride to the retreat center), two days after drug exposure
(via hardcopy questionnaire during the bus ride back to Amsterdam) and at a one-month followup (via online questionnaire). Qualitative observations will also be collected and recorded
throughout the retreat. All participants will provide informed consent prior to data collection.
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Brief Symptom Inventory (BSI): The BSI (Derogatis & Melisaratos, 1983) is a 53-item
self-report inventory covering nine symptom dimensions: somatization (SOM), obsessioncompulsion (O-C), interpersonal sensitivity (I-S), depression (DEP), anxiety (ANX), hostility
(HOS), phobic anxiety (PHOB), paranoid ideation (PAR) and psychoticism (PSY). Each item is
ranked on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely), with rankings
intended to characterize distress intensity over the prior seven days. Three global indices of
distress are also captured: global severity (GSI), positive symptom total (PST) and positive
symptom distress severity (PSDI). Several studies have demonstrated the BSI’s adequate
internal consistency and construct validity, with a nine-factor structure (Derogatis, 1975; Boulet
& Boss, 1991).
Experiences in Close Relationships-Revised (ECR-R): The ECR-R (Fraley, Waller &
Brennan, 2000) is a self-report measure designed to capture adult attachment, with 36 items
ranked on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). The
ECR-R yields two subscale scores: attachment-related anxiety (Ax) (the extent to which
individuals fear rejection and abandonment) and attachment-related avoidance (Av) (the extent
to which individuals resist closeness and dependency). The ECR-R demonstrates adequate
psychometric properties, with a reliable and replicable dual factor structure and stable test-retest
reliability estimates of trait attachment (Sibley & Liu, 2004).
Mentalization Scale (MentS): The MentS (Dimitrijević, Hanak, Dimitrijević &
Marjanović, 2018) is a 28-item self-report measure of mentalization, defined as “the mental
process by which an individual implicitly and explicitly interprets the actions of himself and
others as meaningful on the basis of intentional mental states such as personal desires, needs,
feelings, beliefs, and reasons,” (Bateman & Fonagy, 2004, p. 21). Responses are provided on a
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5-point Likert scale, ranging from 1 (completely disagree) to 5 (completely agree). Three subscale scores are calculated: self-related mentalization (MentS-S), other-related mentalization
(MentS-O) and motivation to mentalize (MentS-M) (one’s need to understand the psychic world
of self and others). The MentS is a new measure (2018) and preliminarily demonstrates adequate
psychometric properties (Dimitrijević et al., 2018).
Inventory of Personality Organization (IPO): The IPO (Lenzenweger, Clarkin, Kernberg
& Felsch, 2001) is a psychometrically sound, 57-item, self-report measure of personality
organization. Responses are ranked on a 5-point Likert-scale ranging from 1 (never true) to 5
(always true). Three subscale scores are calculated: identity diffusion (21 items, self-other
differentiation), primitive defenses (16 items, includes defenses such as projective identification,
denial, omnipotence and devaluation) and impaired reality testing (20 items, an individual’s
ability to distinguish the subjective from the objective).
Pathological Narcissism Inventory (PNI): The PNI (Pincus, Pimentel, Cain, Wright,
Levy & Ansell, 2009) is a 52-item, self-report inventory, with each item ranked on a 6-point
scale, ranging from 0 (not at all like me) to 5 (very much like me). The PNI reliably measures
seven symptom dimensions of pathological narcissism: contingent self-esteem (CSE)
(dysregulation in the absence of admiration), exploitativeness (EXP) (manipulative interpersonal
approach), self-sacrificing self-enhancement (SSSE) (the use of purportedly altruistic acts to
inflate self-image), hiding the self (HS) (refusal to reveal faults or needs), grandiose fantasy (GF)
(fantasies of success, admiration, and recognition), devaluing (DEV) (disinterest in those who do
not provide admiration and feelings of shame when yearning for recognition from rejecting
others), and entitlement rage (ER) (angry affect following unmet and entitled expectations).
These subscales also yield three global indices: narcissistic grandiosity (PNI-G) (average of
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EXP, SSSE, and GF), narcissistic vulnerability (PNI-V) (average of CSE, SSSE, HS, and ER)
and pathological narcissism (average of PNI-G and PNI-V) (Wright, Lukowitsky, Pincus &
Conroy, 2010). Of note, the PNI demonstrates clinical utility and adequate psychometric
properties (Edershile, Simms, & Wright, 2019; Thomas, Wright, Lukowitsky, Donnellan, &
Hopwood, 2012).
Pro-Environmental Behavior (PEB): According to the United Kingdom’s Department for
Environment, Food and Rural Affairs (DEFRA, 2008), PEB reflects four behavioral domains:
domestic energy and water use, waste behavior, transport, and eco-friendly shopping. PEB is
reliably measured by a 17-item self-report questionnaire (Whitmarsh & O’Neill, 2010;
Forstmann & Sagioglou, 2017), which asks individuals to indicate how frequently they perform
certain environmentally considerate actions on a Likert scale ranging from 1 (never) to 4
(always).
The Ryff Scale of Psychological Well-Being (Ryff): The Ryff (Ryff, 1989) is a
psychometrically sound inventory (Ryff, 2014), consisting of 54 self-report items, rated on a 6point Likert scale, ranging from 1 (strongly disagree) to 6 (strongly agree). The Ryff yields
subscale scores on six dimensions of well-being: autonomy (self-determination and
independence, ability to resist social pressure), environmental mastery (competence managing
external environment and surrounding opportunities, ability to create contexts that reflect
personal needs and values), personal growth (ongoing expansion, movement toward realizing
potential and self-knowledge over time), positive relations with others (warm, satisfying and
trusting relationships, capacity for empathy, affection, and intimacy), purpose in life (sense of
meaning and direction) and self-acceptance (positive attitudes toward self, with an ability to
accept positive and negative qualities of past and present self).
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Mystical Experience Questionnaire (MEQ): The MEQ (MacLean, Leoutsakos, Johnson
& Griffiths, 2012) is a 30-item measure of self-reported mystical experience. Rankings are
provided on a six-point Likert scale, ranging from 0 (none, not at all) to 5 (extreme, more than
ever before in my life). The MEQ demonstrates adequate validity and reliability, as well as a
four-factor structure: 1) unity, noetic quality, sacredness, 2) positive mood, 3) transcendence of
space and time, and 4) ineffability (MacLean et al., 2012).
Hypotheses
This study predicts improvement across all personality-related measures directly
following drug exposure, as well as maintenance of improvement at a one-month follow-up.
More specifically, gains will be reflected in the following domains: psychiatric symptomatology
(measured by the Brief Symptom Inventory, BSI), attachment style (measured by the
Experiences in Close Relationships-Revised, ECR-R), mentalization (measured by the
Mentalization Scale, MentS), personality organization (measured by the Inventory of Personality
Organization, IPO, and the Pathological Narcissism Inventory, PNI), pro-social behavior
(measured by Pro-Environmental Behavior, PEB), and a capacity for flourishing (measured by
the Ryff Scale of Psychological Well-Being, Ryff). It is also hypothesized that mystical
experience during psilocybin exposure (measured by the Mystical Experience Questionnaire,
MEQ) will moderate improvement on the aforementioned measures.
The subject pool of approximately 60 subjects will likely skew in a psychologically
healthy direction due to the implementation of relevant exclusion criteria. As a result of the
relatively healthy makeup of this subject pool, findings will reflect the effect of classic
psychedelics on healthy populations and will likely preclude the direct exploration of classic
psychedelics and their effect on individuals suffering from personality disturbances.
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Nevertheless, if possible, post-hoc tests will preliminarily explore whether individuals high in
narcissism experience an exacerbation of narcissistic tendencies following psychedelic exposure
in the absence of long-term psychotherapy (as indicated by Savage et al., 1962; Chandler &
Hartman, 1960; Cohen & Eisner, 1958). If possible, post-hoc tests will also preliminarily
explore whether individuals organized at the borderline level evidence improvement directly
following drug exposure, but lose gains at a one-month follow-up in the absence of long-term
psychotherapy (an arc implied by Chandler & Hartman’s 1960 MMPI research).
Data Analysis
Hierarchical Linear Models (HLMs) are the preferred statistical method when estimating
growth models (estimates of between-person differences in within-person change over time), as
this approach provides numerous advantages, including an ability to estimate polynomial trends,
as well as a capacity to handle partially missing data and unequally spaced time points (Kwok,
Underhill, Berry, Luo, Elliott, & Yoon, 2008; Curran, Obeidat, & Losardo, 2010). As a result,
an HLM will be used to analyze the growth curves of within-person change on all measures
(BSI, ECR-R, MentS, IPO, PNI, PEB, and Ryff) and across three time points (day before drug
exposure, two days after drug exposure, and at a one-month follow-up). Additionally,
psychedelic-assisted mystical experiences (as measured by the MEQ) will be introduced as a
predictor into a conditional growth model. Serving as a Time-Invariant Covariate (TIC) (a
predictor variable that does not change in value as a function of time), it is hypothesized that the
mystical experience will determine the degree and rate of post-psychedelic change over time.
As this study’s sample is anticipated to be relatively psychologically healthy, post-hoc
tests will only preliminarily explore the effect of personality pathology on the aforementioned
outcome measures. If numbers allow, descriptive statistics will explore whether trajectories over
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time trend in the direction of aforementioned hypotheses (individuals high in narcissistic
pathology will evidence an exacerbation of narcissistic traits and/or individuals organized at the
borderline level will evidence initial improvement, followed by a regression at two months).
Alternatively, analysis may need to occur on an individual basis, whereby the trajectory of one
participant with high levels of personality pathology is analyzed to see whether he or she trends
in the hypothesized direction.
Statistical Power and Sample Size
Power analyses were conducted for linear growth models using a hierarchical mixed
model approach to repeated measures data (Kreidler, Muller, Grunwald, Ringham, CokerDukowitz, Sakhadeo, Baron, & Glueck, 2013). The design specified used a baseline assessment,
post-experience assessment, and follow-up assessment with various measures outlined above.
The hypotheses predict an improvement from baseline to post-experience assessment,
maintained at follow-up, and this was the pattern of means used for the power analysis. A
change of ½ SD was evaluated, as was a change of ¼ SD.
There is no available pilot data for the current design, so test-retest correlations were used
to approximate the intraclass correlation (ICC), which was required by the program. Test-retest
correlations were generally high, ranging from .72 (IPO Primitive Defenses) to .90 (BSI Global
Symptom Index), but reliability information was not available for all measures. Therefore, an
ICC value of .8 was assumed for all tests.
Other assumptions included power of .80, alpha = .05, and mean and variability scale
factors of 1. It was also assumed that the correlation between measurements over time
monotonically decreases with distance or time between repeated measurements. The model has
two correlation parameters, the base correlation and the decay rate. The base correlation
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describes the correlation between measurements taken 1 unit apart and this was assumed to be
.80 as per the test-retest correlations. The decay rate describes the rate of decrease in the base
correlation as the distance or time between repeated measurements increases, and this was also
assumed to be .50. Kreidler et al. (2013) recommend a decay rate of between .05 and .50 for
behavioral science data and the larger was chosen due to the presumed stability of these
characteristics and the high test-retest correlations found.
The results found that to achieve power of .80 to detect a ½ SD change in mean scores
would require a sample of approximately 19 subjects. For the sample power to detect a smaller,
¼ SD, change would require approximately 60 subjects.
Covid-19 Methodology Amendment
Due to the Covid-19 global pandemic, the Psychedelic Society unexpectedly and
indefinitely paused all Experience Retreats in March of 2020, which, in turn, prematurely halted
data collection. Although the sample size was initially projected to include 60 participants in
order to achieve statistical power, the sample in its current form includes a total of 21
participants, many of whom did not complete the entire protocol. Specifically, there were 8
participants with completed measures at all three time points, 3 participants with completed
measures at two time points, 3 participants with completed measures at one time point, and 7
participants with a partially completed dataset at the first time point.
In order to allow for the most robust analysis possible in the context of these unexpected
constraints on sample size, a qualitative and exploratory study design was proposed, with an
amended methodology detailed below:
1. Mixed Model Analyses: Though constrained by low power across the board, mixed
model analyses will assess the data’s preliminary statistical trends. In this context,
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mixed models remain preferable to ANOVAs, as they optimize data through the
inclusion of subjects with missing time points. Specifically, two Hierarchical Linear
Models (Model 1 and Model 2) with restricted maximum likelihood estimations will
be conducted for each measure in order to predict outcome scores over time, while
controlling for Social Desirability (SD). A random intercept will be included in each
model to account for varying baselines, with all other effects included as fixed
effects. Model 1 will use a Hierarchical Linear Model to test the degree and shape
(linear vs. curvilinear) of change over time (before psychedelic exposure, after
psychedelic exposure, and at a one-month follow-up) by including time as both a
linear effect (Time) and a quadratic effect (Time2). Additionally, in order to estimate
effect sizes for this model, a calculation of R2 from Hoffman (2015) will be used. In
this method, the model’s predicted values of the outcome variable will be correlated
with the actual values and then the correlation will be squared to obtain the
percentage of variance explained (small effect size = .02, medium = .09, large = .25).
Model 2 will examine whether Mystical Experiences (ME) affect trajectory over time
by conducting a Hierarchical Linear Model with all variables: Time, Time2, SD, ME
(1=yes, 2=no) and the interaction of ME x Time. In turn, the difference between the
effect sizes for Model 1 and Model 2 will indicate the amount of variance explained
by having had a mystical experience (ME), as well as the interaction of ME and
Time.
2. Reliable Change Scores: As stand-ins for historical controls, test-retest reliability
correlations will determine whether within-person change is sizable enough (reliable
change scores > ±1.96) to indicate clinical and statistical significance, or whether
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measurement error provides a more reasonable explanatory framework for
understanding variations between time points (reliable change scores < ±1.96)
(Jacobson & Truax, 1991).
3. Clinical Case Studies: In order to qualitatively explore the effect of psychedelic
exposure on personality, individual subjects will be selected and their trajectories
analyzed through a clinical lens in an effort to identify emerging patterns.
4. Qualitative Data Analysis: All qualitative data collected in response to open-ended
queries will be thematically analyzed in order to provide an additional framework for
understanding potential outcomes and mechanisms of change.
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CHAPTER FOUR
Results
Sample Characteristics
Sample characteristics are based on the 11 subjects with at least 2 complete datasets (see
Table 1). The majority of the sample identified as White (n = 8) and female (n = 7) between the
ages of 25 and 39 years old (n = 6). Participants were highly educated, with 100% of subjects
holding a bachelor’s degree or higher. The majority of the sample had no prior experience with
classic psychedelics (n = 7).
Table 1.
Demographic characteristics of the sample.
______________________________________________________________________________
Factor

n (%)

Age
18-24

1 (9%)

25-39

6 (55%)

40-60

3 (27%)

60+

1 (9%)

Female

7 (64%)

Male

4 (36%)

Other

0 (0%)

White

8 (73%)

Black or African American

1 (9%)

American Indian or Alaska Native

0 (0%)

Asian

1 (9%)

Native Hawaiian or Pacific Islander

0 (0%)

Hispanic or Latino

2 (18%)

Other

1 (9%)

No Formal Education

0 (0%)

Sex

Race/Ethnicity

Highest Education
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Highschool degree

0 (0%)

Bachelor’s Degree

4 (36%)

Master’s Degree

4 (36%)

Doctoral Degree

2 (18%)

Other

1 (9%)

Single

5 (46%)

Partnered for under 6 months

1 (9%)

Partnered 1-3 years

1 (9%)

Partnered 3-10 years

3 (27%)

Partnered 10+ years

1 (9%)

Under $20,000

4 (36%)

$20,001 to $40,000

2 (18%)

$40,0001 to $60,000

1 (9%)

$60,001 to $80,000

3 (27%)

$80,001 to $100,000

0 (0%)

$100,001 or more

1 (9%)

No therapy past or present

5 (46%)

Prior therapy, but not currently

2 (18%)

Currently in therapy

4 (36%)

None

7 (64%)

Mescaline / Peyote

0 (0%)

Psilocybin / Magic Mushrooms

3 (27%)

LSD / Acid

2 (18%)

Ayahuasca

0 (0%)

DMT

0 (0%)

Ibogaine

0 (0%)

Other

0 (0%)

0 experiences

7 (64%)

1 experience

1 (9%)

Romantic Partnership

Total Household Income

Psychotherapy

Prior Psychedelic Experience

Frequency of Experiences
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2-5 experiences

2 (18%)

6-10 experiences

1 (9%)

11-20 experiences

0 (0%)

More than 20 experiences

0 (0%)

______________________________________________________________________________
Of note, t-test analyses comparing the study sample with the 7 participants who dropped
out midway through baseline revealed no meaningful differences with regard to performance on
measures (see Table 2) or demographic characteristics (see Table 3).
Table 2.
Difference between baseline dropouts and study sample on self-report measures.

Variable
Brief Symptom Inventory
Global Severity Index

Dropout
Sample
________________________________
M (SD)
M (SD)
t

df

p

.440

.584

-1.014 19

1.39

2.343

2.659

-1.544 19

.342

Inventory of Personality Organization
Identity Diffusion

45.800

49.000

-.574 18

.251

Inventory of Personality Organization
Impaired Reality Testing

35.600

35.800

-.051 18

.990

Inventory of Personality Organization
Primitive Defenses

26.600

30.667

-1.159 18

.844

Pro-Environmental Behavior

*p < .05. **p <.01
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Table 3.
Demographic differences between baseline dropouts and dataset sample.
____________________________________________________________
Variable

x2

df

p

____________________________________________________________
Gender

0.175

1

.67

Age

1.330

3

.72

Race/Ethnicity

2.217

4

.70

Romantic Partnership

0.311

1

.58

Highest Level of Education

1.994

3

.57

Psychotherapeutic Treatment

0.543

2

.76

____________________________________________________________
*p < .05. **p < .01

Due to this sample’s small size and, in turn, limited capacity to discern meaningful
differences among subscales, global indices were chosen to represent each measure where
possible (see Table 4). Of note, the rationale for choosing each scale’s summary measure can be
found in Appendix A. All relevant scales show acceptable to excellent reliability, with the
exception of the Inventory of Personality Organization’s Impaired Reality Testing scale at one
time point (follow-up), which neared the .7 acceptability cut-off, with a .641 alpha coefficient.
With regard to the Ryff Scale of Psychological Wellbeing, five of eighteen sub-scales
showed questionable to unacceptable reliability. As a result, the item-total correlations and alpha
if item deleted statistics were examined to determine whether particular items were problematic.
These statistics were both low, indicating an overall problem with the Ryff subscales, rather than
a problem with one single item. As a result, all Ryff sub-scales were combined to create one
summary score.
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Table 4.
Alpha coefficients.

Scale

N items

Pre-test

Post-test

Follow-up

Brief Symptom Inventory
Global Severity

53

.891

.886

.948

Experiences in Close Relationships
Attachment-Related Anxiety

18

.923

.923

.932

Experiences in Close Relationships
Avoidance-Related Anxiety

18

.850

.951

.941

Mentalization Scale
Global

28

.871

.886

.735

Pathological Narcissism Inventory
Grandiosity

18

.812

.897

.904

Pathological Narcissism Inventory
Vulnerability

34

.947

.966

.958

Pathological Narcissism Inventory
Pathological Narcissism

52

.947

.967

.960

Pro-Environmental Behavior

17

.750

n/a

.822

Ryff Scale of Psychological Wellbeing
Autonomy

9

.767

.882

.773

Ryff Scale of Psychological Wellbeing
Environmental Mastery

9

.780

.777

.671

Ryff Scale of Psychological Wellbeing
Personal Growth

9

-.144

.177

.210

Ryff Scale of Psychological Wellbeing
Positive Relations with Others

9

.771

.845

.905

Ryff Scale of Psychological Wellbeing
Purpose in Life

9

.452

.677

.834

Ryff Scale of Psychological Wellbeing
Self-acceptance

9

.916

.941

.890

Ryff Scale of Psychological Wellbeing 54
Overall Wellbeing

.897

.942

.934
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Inventory of Personality Organization
Identity Diffusion

21

.885

.931

.952

Inventory of Personality Organization
Impaired Reality Testing

20

.809

.756

.641

Inventory of Personality Organization
Primitive Defenses

16

.769

.746

.891

Mystical Experience Questionnaire

30

.962

n/a

n/a

______________________________________________________________________________
Correlations between the Marlowe-Crowne Social Desirability (SD) scale and all other
measures were run in order to assess the potential relationship between self-report items and
social desirability biases (see Table 5). Although none of the correlations were statistically
significant, approximately one-quarter (25.7%) of all effect sizes were in the medium (r ≈.3) to
large (r ≈.5) range. As a result, all mixed model analyses (except where noted) controlled for
social desirability across measures.
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Table 5.
Self-report scales correlated with Marlowe-Crowne Social Desirability scale at each time point.
______________________________________________________________________________
Scale

r (Pre-test)

r (Post-test)

r (Follow-up)

______________________________________________________________________________
Brief Symptom Inventory
Global Index

-.510°°

-.038°

-.258

Experiences in Close Relationships
Attachment-Related Anxiety

-.264

.013

.227

Experiences in Close Relationships
Avoidance-Related Anxiety

-.073

.172

.019

Mentalization Scale
Global Index

.265

.453°

.081

Pathological Narcissism Inventory

-.057

.039

.040

Pathological Narcissism Inventory
Vulnerability

-.369°

-.081

.057

Pathological Narcissism Inventory
Grandiosity

-.057

.039

.040

Pro-Environmental Behavior

.027

n/a

Ryff Scale of Psychological Wellbeing
Overall Wellbeing

.397°

.078

.120

Inventory of Personality Organization
Identity Diffusion

-.449°

-.304°

-.140

Inventory of Personality Organization
Impaired Reality Testing

-.224

-.352°

-.111

Inventory of Personality Organization
Primitive Defenses

-.196

-.259

.139

-.640°°

______________________________________________________________________________
°medium effect size (r ≈ .3)
°°large effect size (r ≈ .5)
Overall, analyses for each measure were based on sample sizes ranging from 9 to 13
participants. Additionally, and across measures, this study’s sample was highly normative, with
the majority of participants falling within the normative range at all three time points. See
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Appendix B for a closer examination of sample characteristics by measure (including graphs of
scores over time by subject).
Hierarchical Linear Models
Though constrained by low power across the board, mixed model analyses assessed the
data’s preliminary statistical trends. Specifically, a Hierarchical Linear Model analysis was
conducted for each measure in order to predict the degree and shape of change over time, while
controlling for SD. Additionally, a second Hierarchical Linear Model was conducted for each
measure with two additional variables: ME (0 = No, 1 = Yes) and the interaction of ME x Time.
See Table 6 and Table 7 for a summary of all HLM analyses (with significant findings in bold)
and Appendix C for a more in-depth exploration of all HLM analyses by measure (including
fixed effects models and graphs of ME interactions over time).
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Table 6.
Summary of HLM findings for Model 1 by Summary Measure.
_____________________________________________________
Measure (n)

Model 1:
Effect of
Linear
Time2
Significant Significant
(p = .009)
(p = .020)

Effect
Size

Inventory of
Personality
Organization,
Identity
Diffusion (n =
12)

Not
Significant
(p = .128)

Significant
(p = .015)

Large Limited
(R2 = change at T2,
.636) followed by
improvement
at T3

Inventory of
Personality
Organization,
Reality
Testing (n =
12)

Not
Significant
(p = .071)

Significant
(p = .032)

Large Slight
(R2 = downward
.770) curve, with
improvement
by T3

Inventory of
Personality
Organization,
Primitive
Defenses (n =
12)

Not
Significant
(p = .394)

Not
Significant
(p = .973)

Large
(R2 =
.919)

Limited
change over
time, with one
significantly
improved RC
score by T3
with no ME

Pathological
Narcissism
Inventory,
Grandiosity (n
= 11)

Not
Significant
(p = .910)

Not
Significant
(p = .454)

Large
(R2 =
.883)

Limited
change over
time, with two
significantly
improved RC
scores by T3,
both non-ME

Pathological
Narcissism
Inventory,
Vulnerability
(n = 11)

Not
Significant
(p = .197)

Not
Significant
(p = .794)

Large
(R2 =
.857)

Limited
change over
time, with
three
significant RC
scores (two
improved and

Brief
Symptom
Inventory,
Global Index
(n = 13)

Model 1:
Effect of
Time

Nature of
Effect / Trend

Large Improvement
(R2 = at T2, return
.648) to baseline at
T3
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one
deteriorated
by T3)
Mentalization
Scale, Global
Index (n = 11)

Not
Significant
(p = .931)

Not
Significant
(p = .765)

Large
(R2 =
.836)

Limited
change over
time

Ryff Scale of
Psychological
Wellbeing,
Global Index
(n = 11)

Not
Significant
(p = .114)

Not
Significant
(p = .332)

Large
(R2 =
.859)

Limited
change over
time

Experiences in Not
Close
Significant
Relationships, (p = .256)
AttachmentRelated
Anxiety (n =
11)

Not
Significant
(p = .282)

Large
(R2 =
.811)

RC indicates
significant
improvement
and
deterioration,
but not a
uniform
trajectory

Experiences in Not
Close
Significant
Relationships, (p = .994)
AttachmentRelated
Avoidance (n
= 11)

Not
Significant
(p = .891)

Large
(R2 =
.865)

RC indicates
significant
improvement
and
deterioration,
but not a
uniform
trajectory

ProNot
Environmental Significant
Behavior (n = (p = .821)
9)

N/A (only
Large
administered (R2 =
at T1 and
.954)
T3)

Limited
change over
time

Note: T2 = Timepoint 2, T3 = Timepoint 3, RC = Reliable Change
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Table 7.
Summary of HLM findings for Model 2 by Summary Measure.
____________________________________________________________
Measure (n)

Model 2:
Effect of ME

Additional
Effect Size

Not
Significant (p
= .697)

Model 2:
Effect of ME
x Time
Not
Significant (p
= .357)

Brief
Symptom
Inventory,
Global Index
(n = 13)
Inventory of
Personality
Organization,
Identity
Diffusion (n
= 12)

Not
Significant (p
= .824)

Not
Significant (p
= .274)

Large
(additional
24.5%, R2 =
.881)

Non-ME
greater
improvement
than ME over
time

Inventory of
Personality
Organization,
Reality
Testing (n =
12)

Not
Significant (p
= .957)

Not
Significant (p
= .347)

Nearing
Small
(additional
1.5%, R2 =
.785)

Non-ME
greater
improvement
than ME over
time

Inventory of
Personality
Organization,
Primitive
Defenses (n
= 12)

Not
Significant (p
= .802)

Significant
(p = .049)

Small
(additional
2.4%, R2 =
.943)

Non-ME
improved;
ME stayed
consistent
over time

Pathological
Narcissism
Inventory,
Grandiosity
(n = 11)

Not
Significant (p
= .653)

Significant
(p = .008)

Small to
Medium
(additional
7%, R2 =
.953)

Non-ME
improved;
ME stayed
consistent
over time

Pathological
Narcissism
Inventory,
Vulnerability
(n = 11)
Mentalization
Scale, Global
Index (n = 11)

Small to
Medium
(additional
7.7%, R2 =
.724)

Nature of
Effect /
Trend
Non-ME
greater
improvement
than ME over
time

Not
Significant (p
= .840)

Not
Significant (p
= .397)

Negligible
(additional
.4%, R2 =
.868)

None

Not
Significant (p
= .392)

Not
Significant (p
= .116)

Small
(additional
2.8%, R2 =
.864)

Regression to
the mean
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Ryff Scale of
Psychological
Wellbeing,
Global Index
(n = 11)

Not
Significant (p
= .902)

Not
Significant (p
= .273)

Small to
Medium
(additional
4.2%, R2 =
.901)

Non-ME
greater
improvement
than ME over
time

Experiences in Not
Close
Significant (p
Relationships, = .481)
AttachmentRelated
Anxiety (n =
11)

Not
Significant (p
= .269)

Small
(additional
2.9%, R2 =
.840)

ME
deteriorated
slightly; nonME improved
slightly over
time

Experiences in Not
Close
Significant (p
Relationships, = .274)
AttachmentRelated
Avoidance (n
= 11)

Not
Significant (p
= .692)

Predicted
7.1% less
variance (R2
= .785)

None

ProNot
Environmental Significant (p
Behavior (n = = .504)
9)

Not
Significant (p
= .624)

Predicted
.7% less
variance (R2
= .947)

None

Note: ME = Mystical Experience group, Non-ME = Non-Mystical Experience group

In sum, twenty-two Hierarchical Linear Models were conducted (two for each of the
eleven summary measures) and only five models were significant. With such small sample sizes,
even statistically significant findings should be interpreted with prudence and viewed as
provisional. Within this cautionary context, it’s nevertheless relevant to note the following five
significant findings: 1) BSI GSI scores evidenced a significant curvilinear pattern over time, with
scores significantly decreasing (reflecting reduced symptomatology) directly following
psilocybin exposure and increasing at follow-up (reflecting a return toward baseline after one
month). 2) IPO-ID scores evidenced a significant curvilinear pattern over time, with a slight
downward curve (and improved identity diffusion) by the one-month follow-up. 3) IPO-RT
scores evidenced a significant and curvilinear pattern over time, with a slight downward curve
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(and improved reality testing) by the one-month follow-up. 4) With regard to IPO-PD scores, the
interaction for ME x Time was significant, indicating that the non-mystical experience group
trended toward improved (lower) levels of primitive defenses over time, whereas the mysticalexperience group maintained similar levels of primitive defenses across time points. 5) With
regard to PNI-G scores, the interaction of ME x Time was significant, indicating that the nonmystical experience group trended toward improved (lower) levels of grandiosity over time,
whereas the mystical-experience group maintained similar levels of grandiosity across time
points. While attempts to draw specific conclusions from any one particular finding would likely
prove imprudent, the presence of multiple significant findings that reflect personality-related
improvement (however nascent) within the context of so few participants suggest the importance
of future research in this domain.
Taking a wider view, and while the vast majority of HLMs yielded insignificant findings,
it’s perhaps still notable that every HLM also yielded large effect sizes when predicting the
impact of psilocybin exposure on the degree and shape of personality-related change over time
(while controlling for SD). While erratic outliers may explain this phenomenon, it’s also
possible that large effect sizes paradoxically occurring alongside predominantly insignificant
findings suggest the presence of relationships that would emerge in the context of larger sample
sizes. Additionally, and while perhaps less common in clinical research more globally, large
effect sizes are common in psilocybin research (Bogenschutz, 2015; Carhart-Harris, 2017; Davis,
Barrett & May, 2020; Griffiths, 2016), which may speak to the watershed experience of
psychedelic exposure.
With regard to HLMs analyzing the predictive power of ME and ME x Time, another
trend emerged. While only significant for two of the eleven relevant HLMs, seven of the eleven
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HLMs reveal a consistent trend, whereby the non-mystical experience group averaged greater
improvement relative to the mystical-experience group. This preliminary trend is contrary to the
literature (Doblin, 1991; Griffiths et al., 2008; Grof, 1970; Kurland et al., 1968; Lebedev et al.,
2016; Maclean et al., 2011; Maslow, 1959; Pahnke, 1969; Pahnke et al., 1970; Savage et al.,
1962; Unger, 1963) and also stands in contrast to study predictions, which projected the
mystical-experience group to demonstrate greater improvement than the non-mystical experience
group over time. While this phenomenon may reflect erratic outliers, it may also reflect a novel
finding that requires future investigation to further clarify.
Reliable Change Scores
Reliable change scores allow for the analysis of clinically and statistically significant
change on the individual level. With test-retest reliability correlations serving as stand-ins for
historical controls, reliable change indices were calculated for each subject in order to assess
within-person change over time. Specifically, and for every measure, two reliable change scores
were calculated for each participant: one reliable change score assessed within-person change
between Timepoints 1 and 2 (directly before and after psilocybin exposure) and one reliable
change score assessed within-person change between Timepoints 1 and 3 (directly before
psilocybin exposure and at the one-month follow-up). (Reliable change scores between
Timepoints 2 and 3 can be found in Appendix D). Of note, only one reliable change score was
calculated for PEB (between Timepoints 1 and 3), as this measure was not administered at
Timepoint 2. Taken together, a total of 21 reliable change indices were calculated for each
participant (two for each measure, except for PEB, where only one was calculated). Of note,
reliable change scores greater than ±1.96 indicate statistically significant within-person change
and reliable change scores less than ±1.96 point to measurement error as a more reasonable
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explanatory framework for variations between time points (Jacobson & Truax, 1991). See
Tables 8, 9 and 10 for reliable change scores for each subject by measure and timepoint (with
significant scores in bold) and Appendix D for a more in-depth analysis of all reliable change
score trends by measure.
Reliable change scores indicate that more significant change may have occurred than
HLMs were able to detect with such a small sample size. Although the majority of reliable
change scores were insignificant, it’s nevertheless notable that, for 12 of 21 measures, 2, 3 or 4
participants earned significant reliable change scores (20% to 44.4% of subjects with known
reliable change scores for that measure), indicating either significant improvement, or significant
deterioration. Measures with at least two participants with significant reliable change scores
include the Brief Symptom Inventory’s Global Index (between Timepoints 1 and 2, as well as
between Timepoints 1 and 3), the Inventory of Personality Organization’s Identity Diffusion
subscale (between Timepoints 1 and 3) and Reality Testing subscale (between Timepoints 1 and
3), the Pathological Narcissism Inventory’s Grandiosity subscale (between Timepoints 1 and 3)
and Vulnerability subscale (between Timepoints 1 and 2, as well as between Timepoints 1 and
3), the Mentalization Scale’s summary score (between Timepoints 1 and 2), the Experiences in
Close Relationships-Revised attachment-related Anxiety subscale (between Timepoints 1 and 2,
as well as Timepoints 1 and 3) and attachment-related Avoidance subscale (between Timepoints
1 and 2, as well as Timepoints 1 and 3).
In some cases, it’s possible that HLMs didn’t yield significant findings, as significant
effects in opposite directions may have canceled each other out, with some individuals
significantly improving, and others significantly deteriorating. These findings suggest that
psychedelic exposure may engender a potent psychological experience capable of catalyzing
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improvement and deterioration, with an as yet unidentified variable explaining the interaction.
Overall, and following an intervention that lasted only a few hours, it’s notable that even a few
participants evidenced significant within-person change (at times sustained at a one-month
follow-up), as psychological constructs (such as personality organization and attachment style,
for example) are thought to be deeply entrenched and, in turn, challenging to alter, even under
the best of psychotherapeutic circumstances. Future research is warranted to confirm these
preliminary conjectures and, perhaps most importantly, identify mechanisms that explain for
whom and when psychedelic exposure yields improvement versus deterioration.
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Table 8.
Reliable Change Scores by Subject for BSI GSI and IPO.
Subject

ME or
NonME

BSI GSI
T1 to T2

BSI GSI
T1 to T3

IPO-ID
T1 to
T2

IPO-ID
T1 to T3

IPORT T1
to T2

IPORT T1
to T3

IPOPD T1
to T2

IPOPD T1
to T3

1

ME

1.51

n/a

-0.89

n/a

** 2.96

n/a

-0.42

n/a

2

*6.29

*5.53

-0.18

*2.67

0.21

1.27

1.27

*2.12

3
4

NonME
ME
ME

*3.77
*4.03

1.38
n/a

-1.60
0.71

1.60
n/a

-0.63
0.21

0.42
n/a

0.64
-0.64

0.64
n/a

5

ME

-0.88

0.50

0.53

*2.32

0.85

0.00

-0.21

0.42

6

NonME
n/a

1.64

0.88

1.07

*3.03

0.42

1.69

1.49

1.91

n/a

**-2.01

n/a

1.96

n/a

1.48

n/a

0.42

1.38

0.00

-0.71

0.89

-0.63

0.21

-0.42

0.42

-1.26

n/a

n/a

n/a

n/a

n/a

n/a

n/a

10

NonME
NonME
ME

*3.65

n/a

1.96

n/a

-0.63

n/a

0.42

n/a

11

ME

-0.01

**-3.90

0.00

-0.36

-0.85

*2.33

1.27

0.64

12

ME

0.88

0.25

-1.07

-0.71

-1.06

-1.27

-0.42

0.00

13

ME

0.63

0.75

-0.71

-1.43

-1.90

**
-2.11

0.00

-0.85

33.3%
(n=4)

33.3%
(n=3)

0%
(n=0)

33.3%
(n=3)

9%
(n=1)

22.2%
(n=2)

0%
(n=0)

11.1%
(n=1)

7
8
9

% of
Significant
RC Scores

*Significant improvement (reliable change score >1.96)
**Significant deterioration (reliable change score <-1.96)
Note: T1 = Timepoint 1, T2 = Timepoint 2, T3 = Timepoint 3. ME = Mystical Experience group, Non-ME
= Non-Mystical Experience group. BSI GSI = Brief Symptom Inventory Global Scale Index. IPO-ID =
Inventory of Personality Organization, Identity Diffusion. IPO-RT = Inventory of Personality
Organization, Reality Testing. IPO-PD = Inventory of Personality Organization, Primitive Defenses.
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Table 9.

Reliable Change Scores by Subject for PNI, MENT-S, and the Ryff.
Subject

ME or
NonME

PNI-G
T1 to T2

PNI-G
T1 to T3

RyffOW
T1 to
T2

RyffOW
T1 to
T3

1

ME

-1.95

n/a

-0.47

n/a

1.36

n/a

0.36

n/a

2

1.27

*2.32

0.19

1.08

3

NonME
ME

0.34

-0.51

0.29

0.76

0.34

-0.35

*3.70

*3.33

-1.19

1.36

0.80

-0.18

4

ME

0.16

n/a

1.41

n/a

-0.17

n/a

0.65

n/a

5

ME

0.37

0.88

-1.64

-0.91

0.04

*5.33

*6.44

**
-3.40
*2.72

1.87

*3.62

**
-2.54
*7.83

6

NonME
n/a

0.51

1.45

-0.40

n/a

-0.94

n/a

1.71

n/a

n/a

n/a

n/a

-0.73

0.40

-0.60

1.57

-0.34

0.85

-0.36

0.80

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

10

NonME
NonME
ME

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

11

ME

-0.66

-0.01

-1.34

1.32

-0.34

-0.85

-0.15

-0.33

12

ME

-0.73

-0.12

-0.73

0.70

0.00

-1.36

0.54

-0.58

13

ME

-0.28

-0.36

1.16

0.91

-0.34

-0.68

0.84

-0.11

10%
(n=1)

22.2%
(n=2)

20%
(n=2)

33.3%
(n=3)

20%
(n=2)

0%
(n=0)

0%
(n=0)

0%
(n=0)

7
8
9

% of
Significant
RC Scores

PNI-V
PNI-V
T1 to T1 to T3
T2

MentS- MentST
T
T1 to
T1 to
T2
T3

*Significant improvement (reliable change score >1.96)
**Significant deterioration (reliable change score <-1.96)
Note: T1 = Timepoint 1, T2 = Timepoint 2, T3 = Timepoint 3. ME = Mystical Experience group, Non-ME
= Non-Mystical Experience group. PNI-G = Pathological Narcissism Inventory, Grandiosity. PNI-V =
Pathological Narcissism Inventory, Vulnerability. MentS-T = Mentalization Scale Total. Ryff-OW = Ryff
Scales of Psychological Wellbeing.
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Table 10.

Reliable Change Scores by Subject for ECR-R & PEB.
Subject
1

ME

ECR-R,
Ax
T1 to T2
0.85

2

Non-ME

1.09

*2.54

-0.26

0.64

1.13

3

ME

0.61

-0.24

0.67

-0.52

0.23

4

ME

*2.54

n/a

1.86

n/a

n/a

5

ME

**
-2.43

-1.35

-1.57

-1.31

0.23

6

Non-ME

*4.96

*3.50

*3.71

*3.98

-0.68

7

n/a

n/a

0.72

n/a

0.29

0.45

8

Non-ME

**
-2.54

**
-2.43

**
-3.31

**
-2.24

-0.45

9

Non-ME

n/a

n/a

n/a

n/a

n/a

10

ME

n/a

n/a

n/a

n/a

n/a

11

ME

0.48

**
-3.74

**
-2.79

0.00

-0.90

12

ME

0.24

-1.46

0.52

-0.26

0.23

13

ME

-0.61

0.37

0.52

0.26

-0.23

44.4% 30% (n=3)
(n=4)

22.2%
(n=2)

0% (n=0)

% of
Significant
RC Scores

ME or
Non-ME

40% (n=4)

ECR-R,
Ax
T1 to T3
n/a

ECR-R,
Av
T1 to T2
0.52

ECR-R, PEB
Av
T1 to T3
T1 to T3
n/a
0.45

*Significant improvement (reliable change score >1.96)
**Significant deterioration (reliable change score <-1.96)
Note: T1 = Timepoint 1, T2 = Timepoint 2, T3 = Timepoint 3. ME = Mystical Experience group, Non-ME
= Non-Mystical Experience group. ECR-R Ax = Experiences in Close Relationships, Attachment-Related
Anxiety. ECR-R Av = Experiences in Close Relationships, Attachment-Related Avoidance. PEB = ProEnvironmental Behavior.
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Clinical Case Studies
In order to more closely examine the potential relationship between pre-psychedelic
personality organization and post-psychedelic outcome measures, two subjects were selected for
closer qualitative analysis. More specifically, the subject with the most personality pathology
(11) and the subject with the least personality pathology (13) at baseline were selected for
clinical case studies. In order to maintain confidentiality, case studies do not include identifiable
demographic variables or direct quotes from subjects (with self-report and open-ended
qualitative responses summarized when necessary).
Subject 11: Subject 11 was selected for a case write-up because s/he evidenced the most
personality pathology in this study’s sample prior to psychedelic exposure, with the highest (least
healthy) score on four of five measures of personality organization (PNI Grandiosity, PNI
Vulnerability, IPO Reality Testing and IPO Primitive Defenses) and the second highest score on
the fifth measure of personality organization (IPO Identity Diffusion). Specifically, Subject 11
evidenced narcissistic grandiosity within one standard deviation above the normative average
(PNI-G = 2.98, normative average = 2.89 standard deviation = 0.66), narcissistic vulnerability
between two and three standard deviations above the normative average (PNI-V = 3.74,
normative average = 2.13, standard deviation = 0.74), identity diffusion within one standard
deviation above the normative average (IPO-ID = 63, normative average = 51.68, standard
deviation = 11.35), reality testing within one standard deviation above the normative average
(IPO-RT = 48, normative average = 38.46, standard deviation = 9.67) and primitive defenses
between one and two standard deviations above the normative average (IPO-PD = 47, normative
average = 36.24, standard deviation = 7.91).

i

With regard to reliable change indices, which indicate significant within-person change
over time, Subject 11 evidenced significantly improved reality testing (IPO-RT) by the onemonth follow-up, alongside significantly deteriorated overall symptomatology by the one-month
follow-up (GSI BSI) and significantly deteriorated attachment-related anxiety (ECR-R Ax) by
the one-month follow-up as well. Subject 11 also evidenced deteriorated attachment-related
avoidance (ECR-R Av) directly following psilocybin exposure, with a return to baseline by the
one-month follow-up. Subject 11 remained statistically unchanged on all other measures.
Overall, Subject 11 evidenced the least healthy personality organization in the sample
and also significantly deteriorated in numerous domains by the one-month follow-up. Subject 11
also evidenced improved reality testing, which may indicate that greater insight brought greater
destabilization. Based on this trajectory, future research should examine whether personality
pathology is a risk factor for psychological deterioration in the presence of psychedelic exposure,
and whether appropriate therapeutic interventions are able to capitalize on increased insight in
order to mitigate deterioration and, in turn, nurture psychological growth in its stead.
Subject 13: Subject 13 was selected for a case write-up because s/he evidenced the least
personality pathology in the study’s sample prior to psychedelic exposure, with the lowest
(healthiest) score on two measures of personality organization (IPO Reality Testing and PNI
Grandiosity), second lowest score on two measures of personality organization (IPO Identity
Diffusion and IPO Primitive Defenses) and fourth lowest score on the final measure of
personality organization (PNI Vulnerability). Specifically, Subject 13 evidenced reality testing
between one and two standard deviations below the normative average (IPO-RT = 24, normative
average = 38.46, standard deviation = 9.67), narcissistic grandiosity between two and three
standard deviations below the normative average (PNI-G = 1.19, normative average = 2.89,
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standard deviation = 0.66), identity diffusion between one and two standard deviations below the
normative average (IPO-ID = 36, normative average = 51.68, standard deviation = 11.35),
primitive defenses between one and two standard deviations below the normative average (IPOPD = 26, normative average = 36.24, standard deviation = 7.91) and narcissistic vulnerability
within one standard deviation below the normative average (PNI-V = 1.64, normative average =
2.13, standard deviation = 0.74). In line with this healthier profile, Subject 13 also evidenced the
sample’s healthiest attachment-related avoidance, placing within one standard deviation below
the normative average (ECR-R Av = 2.22, normative average = 2.92, standard deviation = 1.19)
and the sample’s second healthiest attachment-related anxiety, placing within one and two
standard deviations below the normative average (ECR-R Ax = 2.28, normative average = 3.56,
standard deviation = 1.19).
With regard to reliable change indices, which indicate significant within-person change
over time, Subject 13 evidenced significantly deteriorated reality testing (IPO-RT) by the onemonth follow-up and remained statistically unchanged on all other measures. Of note, Subject
13’s open-ended qualitative responses include a reflection that his/her view of reality shifted in
profound and positive ways following psychedelic exposure. This discrepancy between
deteriorated reality testing (based on the IPO-RT subscale) and improved reality testing (based
on subjective self-report) raises profound questions regarding the nature of consciousness and
reality itself. The IPO-RT subscale includes prompts such as “I know that I cannot tell others
certain things about the world that I understand but that to others would appear crazy,” and “I
have seen things which do not exist in reality.” From the perspective of clinical psychology,
endorsements of these prompts reflect the deteriorated reality testing of borderline and psychotic
organizations; conversely, from the perspective of transpersonal psychology (and related
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theoretical paradigms), endorsements of these prompts may at times reflect an expanded
understanding of the nature of reality and, in turn, improved reality testing. Here, Ken Wilber’s
theory of the pre/trans fallacy (initially explored in this study’s literature review) may prove
relevant (Wilber, 2000). According to Wilber’s theoretical model, there are three broad
developmental stages of consciousness: the pre-personal (pre-egoic, such as the infantile or
psychotic), the personal (egoic, such as that of the healthy adult) and the trans-personal (transegoic, such as that of the mystic). According to the pre/trans fallacy, non-rational stages of
consciousness (which include the pre and trans stages) share certain similarities (such as
egolessness) and are therefore often confused for one another. For example, trans-rational states
(e.g. mystical experiences) are often conflated with pre-rational states (e.g. psychotic breaks),
and vice versa. From this perspective, Subject 13 (who evidenced the healthiest personality
organization and attachment style in the sample prior to the Experience Retreat, and who also
met criteria for a mystical experience during psychedelic exposure) may be moving from a
personal to trans-personal state of consciousness as a function of psychedelic exposure. From
this theoretical perspective, the IPO-RT (and its a priori assumptions regarding the nature of
reality and consciousness) might be committing the pre/trans fallacy of conflating evolution with
devolution. From this theoretical vantage point, Subject 13’s dearth of significant reliable
change indices may suggest that self-reported growth is not occurring on the pre-personal or
personal/egoic levels of consciousness (which this study’s measures are designed to detect) but is
instead occurring on the transpersonal level of consciousness (which is not recognized by the
theoretical paradigms underlying this study’s measures and which, in turn, do not detect them).
In sum, Subject 11 evidenced the unhealthiest personality organization in the sample and
also significantly deteriorated in numerous domains by the one-month follow-up. Conversely,
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Subject 13 evidenced the healthiest personality organization in the sample and maintained the
status quo across post-psychedelic outcome measures (with self-reported improvement with
regard to awareness of consciousness and the nature of reality). Future research will be required
in order to determine whether this relationship between pre-psychedelic personality organization
and post-psychedelic outcome measures idiosyncratically reflects these two subjects, or whether
this relationship is maintained in a larger sample and, in turn, informs pre-psychedelic exclusion
criteria and/or post-psychedelic treatment recommendations.
Qualitative Data Analysis
Subjects provided responses to three open-ended questions over the course of data
collection: before the Experience Retreat (to explore reasons for pursuing psychedelic exposure),
directly after the Experience Retreat (to assess subjective changes following psychedelic
exposure) and at the one-month follow-up (to explore the maintenance of subjective changes
over time). Qualitative responses are summarized and explored below. See Appendix F for a
full compilation of all self-report responses.
Prior to psychedelic exposure, subjects responded to the following prompt: “In a few
sentences, please explain why you decided to participate in an Experience Retreat.” According
to self-report responses, the most common reason for pursuing psychedelic exposure (endorsed
by 13 subjects) was a desire to deepen or expand one’s relationship to (and awareness of) self,
consciousness and reality (e.g., “I’m hoping to get a better insight into my consciousness and
discover my true nature,” “I want to have a ‘peek to the other side’ and see what else is outside
of our material world,”). The second most frequent reason for pursuing psychedelic exposure
(endorsed by 7 subjects) was a desire to address mental health concerns, including treatmentresistant depression and sequelae following childhood trauma. Five subjects also voiced a desire
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to find purpose, meaning or direction in life (e.g., “I want to understand why I am here and what
I am doing with my life,” “I feel at a bit of a crossroads in my life and would like to find which
path to take,”). Four subjects also indicated a desire to shift problematic thought patterns (e.g.,
“I would like to get past some habitual ways of thinking,”). Lastly, four subjects hoped for a
novel or exciting experience (e.g., “Just to do something that seems very exciting,”) and two
subjects expressed a wish for overall self-improvement (e.g., “I’ve always had an interest in
personal development,”).
Following psychedelic exposure, subjects responded to the following prompt: “Do you
believe that taking psilocybin changed you? If so, how?” Of the eleven subjects who provided a
response at this timepoint, 8 subjects endorsed post-psychedelic change, 2 subjects denied postpsychedelic change and one subject was unsure. With regard to post-psychedelic change (and in
contrast to reliable change indices, which indicated improvement, as well as deterioration) only
positive changes were self-reported. The most commonly reported change (endorsed by 4
subjects) was a deepened or expanded relationship to (and awareness of) self, consciousness and
reality (e.g., “Opened me to the mysteries of an alternate realm,” “Ultimate reality is not timelinear, has no sense of good or bad, self or non-self, inside or outside. It just is, and is not. So in
that way it has given ‘me’ a new freedom. It is not that my self or ego has ceased to exist, but I
can find space around it, see it as the functional play of existence,”). Tied for the most
commonly reported change (also endorsed by 4 subjects) was improved psychological wellbeing
(e.g., “I was able to release emotional pain and childhood/adolescent trauma that I did not realize
I was still holding the weight of,”). Three subjects also endorsed greater acceptance, compassion
and gratitude, and another three subjects endorsed greater openness. Of note, two subjects
endorsed change that cannot be captured with words (e.g., “I feel like I have experienced a
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profound truth, beyond words…a wisdom beyond concepts,”). Additionally, one subject
endorsed shifted cognitions (“Showed me I could be free of self-limiting beliefs,”) and one
subject endorsed increased nature-relatedness (“Opened me to the wonders of nature,”).
At the one-month follow-up, subjects responded to the following prompt: “When you
look back on taking psilocybin, do you think it changed you? If so, how?” All nine subjects
who provided a response at this time point endorsed positive post-psychedelic change, although
two subjects acknowledged that the effects were starting to wear off. Here, the most commonly
reported change (endorsed by 5 subjects) was increased acceptance, compassion and gratitude
(e.g., “I have a greater reservoir of compassion, both for myself and for challenging dynamics I
may encounter,” “I feel more forgiving towards myself and others. I feel I’m able to let difficult
things be without having a compulsion to solve them or obsess about them; the good and the bad
can co-exist peacefully,”). The second most frequent change (endorsed by 3 subjects) was
improved psychological wellbeing (e.g., “I’m feeling less sad and lonely…I am less fearful of
the future,” “A lot less brain chatter – mind was generally calmer,”). Two subjects also endorsed
a deepened or expanded relationship to (or awareness of) self, consciousness and reality (e.g., “It
made me feel more definite about the other levels of existence,”). Increased nature-relatedness
was also endorsed by two subjects (e.g., “Much more aware and appreciative of plants (trees
especially),”), as was an improved capacity for meditation (e.g., “I find meditation much easier,
less irritated and can relax into it much more,”). Lastly, one participant identified shifts in
problematic thought patterns (“Some thought habits that often cause me distress have quieted
down a little, but they are still there, I just feel less frequently restricted by them,”).
Overall, this study’s self-reported post-psychedelic changes notably mirror those already
identified by the literature (and detailed in this study’s literature review). These changes include
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an altered relationship to (or awareness of) consciousness and reality (e.g. Ditman & Bailey,
1967; Doblin, 1991; Griffiths et al., 2008; Grof, 1970; Kurland et al., 1968; Lerner & Lyvers,
2006; Maclean et al., 2011; Pahnke et al., 1970; Unger, 1963), improved mental health and
psychological wellbeing (e.g. Barbosa et al., 2016; Dos Santos et al., 2016a; Griffiths et al.,
2011; Grof, 1970; Lyons et al., 2018; Mascher, 1967; Rucker et al., 2016; Savage et al., 1962;
Savage et al., 1964; Savage et al., 1968; Schmid & Liechti, 2018), greater acceptance,
compassion and gratitude (e.g. Carhart-Harris et al., 2016; Doblin, 1991; Griffiths et al., 2008;
Griffiths et al., 2011; Grof, 1970; Kavenská et al., 2015; Savage et al., 1964; Savage et al., 1968;
Schmid & Liechti, 2018; Watts et al., 2017), greater openness (Barbosa et al., 2016; CarhartHarris et al., 2016; Erritzoe et al., 2018; Maclean et al., 2011; Nour et al., 2017), and increased
nature-relatedness (Doblin, 1991; Forstmann & Sagioglou, 2017; Grof, 1970; Lyons & CarhartHarris, 2018; Nour et al., 2017). Of note, these findings also notably mirror the literature in that
these post-psychedelic changes are almost exclusively positive in nature (and, as a result, stand
in contrast to reliable change findings, which indicated significant improvement, as well as
significant deterioration). At this juncture, it’s currently unknown whether the positive nature of
self-report findings reflects the overwhelming benefit of psychedelic exposure, the healing nature
of the Experience Retreat’s set and setting, or a bias embedded within this study’s research
design (e.g., the self-selecting nature of this sample and, in turn, a potential bias toward reporting
only positive outcomes).
From a theoretical perspective, the diversity of self-reported changes lends support to
theorizers who have characterized the psychedelic encounter as a “catalyzer” (Grof, 1970, p. 73)
that “enlarges the psychic horizon” (Savage et al., 1964, p. 119), “broadens perception”
(Winkelman et al., 2007, p. 55), and “expands consciousness” (Sherwood et al., 1968, p. 96). In
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this sense, the psychedelic and therapeutic encounters may share a mechanism of action in
expanded consciousness (or increased awareness of relevant unconscious material), whereby
idiosyncratic healing reflects the needs of the individual and their unique healing process, as
opposed to a one-size-fits-all and predetermined outcome.
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CHAPTER FIVE
Discussion
Due to the Covid-19 global pandemic, and the premature end to data collection, the
sample in its current form includes 21 participants, many of whom did not complete the entire
protocol. Specifically, there were 8 subjects with completed measures at all three time points, 3
subjects with completed measures at two time points, 3 participants with completed measures at
one time point, and 7 participants with a partially completed data set at the first time point. With
such a small sample size, definitive conclusions would prove imprudent and even preliminary
trends are provisional at best. Nevertheless, a series of datapoints suggest that significant
findings may prove emergent, warranting future investigation once the circumstances allow.
Relevant datapoints are included below.
1) Five of twenty-two Hierarchical Linear Models were significant, indicating postpsychedelic improvement with regard to overall symptoms (BSI GSI), identity diffusion (IPOID), and reality testing (IPO-RT). Significant interactions were also found for primitive defenses
(IPO-PD) and narcissistic grandiosity (PNI-G), with the non-mystical experience group trending
toward improvement, and the mystical-experience group remaining largely unchanged over time.
Although constrained by low power across the board, the presence of multiple significant
findings (however nascent) within the context of so few participants suggests the possibility of
more robust findings in the context of a larger sample size.
2) While the vast majority of HLMs yielded insignificant findings, every HLM also
yielded large effect sizes when predicting the impact of psilocybin exposure on the degree and
shape of personality-related change over time (while controlling for social desirability). While
erratic outliers may explain this phenomenon, it’s also possible that large effect sizes
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paradoxically occurring alongside predominantly insignificant findings suggests the presence of
relationships that would emerge in the context of a larger sample size.
3) Although the majority of reliable change scores were insignificant, it’s nevertheless
notable that, for 12 of 21 measures, 2, 3 or 4 participants earned significant reliable change
scores, indicating either significant improvement, or significant deterioration. (In some cases,
it’s possible that HLMs didn’t yield significant findings, as significant effects in opposite
directions may have canceled each other out.) Following an intervention that lasted only a few
hours, it’s notable that even a few participants evidenced significant within-person change (at
times sustained at a one-month follow-up), as psychological constructs (such as personality
organization and attachment style, for example) are thought to be deeply entrenched and, in turn,
challenging to alter, even under the best of psychotherapeutic circumstances. These findings
suggest that psychedelic exposure may engender a potent psychological experience capable of
catalyzing improvement and deterioration, with further investigation necessary to clarify the
nature of this interaction.
4) With regard to qualitative clinical case studies, the subject with the unhealthiest prepsychedelic personality organization significantly deteriorated in numerous domains by the onemonth follow-up, while the subject with the healthiest pre-psychedelic personality organization
largely maintained the status quo across post-psychedelic outcome measures (with self-reported
improvement with regard to awareness of consciousness and the nature of reality). Future
research is warranted to determine whether this relationship between pre-psychedelic personality
organization and post-psychedelic outcome measures idiosyncratically reflects these two
subjects, or whether this relationship is maintained in a larger sample and, in turn, informs
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important pre-psychedelic exclusion criteria and/or post-psychedelic treatment
recommendations.
5) Qualitative analysis of self-report responses to open-ended questions indicates that the
majority of subjects experienced positive self-improvement directly following psychedelic
exposure, as well as at the one-month follow-up. According to self-report, improvement was
experienced in numerous domains, including improved mental health and psychological
wellbeing, greater acceptance, compassion, gratitude, and openness, increased nature-relatedness
and a deepened or expanded relationship to (or awareness of) consciousness and reality. Of note,
these findings mirror those already identified by the literature, both with regard to the type of
post-psychedelic changes reported, as well as the almost exclusively positive nature of these
subjective changes.
Of note, this study stands in contrast to both first- and second- wave research designs due
to the lack of psychotherapeutic supports offered before and after psychedelic exposure. With
regard to the first wave, research designs most frequently studied psycholytic psychotherapy,
whereby psychedelics were intermittently administered in the context of long-term treatment,
which often lasted months to years. While the second wave has shifted this paradigm, research
studies nevertheless commonly offer a handful of therapy sessions before and after psychedelic
exposure (with more if needed), in order to support pre-psychedelic preparation and postpsychedelic integration. In this study, however, participants attended the Psychedelic Society’s
Experience Retreats, where psilocybin truffles were administered legally in a ceremonial context,
but which does not provide individual therapy sessions with before and after the experience. As
a result, this study examines the potential implications of taking psychedelics outside of a
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clinical context. Three notable data points suggest the potential importance of psychotherapeutic
integration, all of which are explored below.
1) With regard to HLMs analyzing the main effect of Mystical Experiences, two out of
eleven relevant HLMs indicated that the mystical experience group evidenced significantly less
improvement than the non-mystical experience group. Though not statistically significant, this
trend was reflected in an additional seven of eleven HLMs. This finding is notable, as it stands
in contrast to the literature, which identifies mystical experiences as one of the most potent
predictors of positive post-psychedelic personality change (Doblin, 1991; Griffiths et al., 2008;
Grof, 1970; Kurland et al., 1968; Lebedev et al., 2016; Maclean et al., 2011; Maslow, 1959;
Pahnke, 1969; Pahnke et al., 1970; Savage et al., 1962; Unger, 1963). Without a therapeutic
space to integrate such profound insights, it’s possible that mystical experiences were akin to a
premature interpretation, destabilizing individuals in the face of such an overwhelming and
reality-shifting experience.
2) Reliable Change scores also indicate that, while certain participants evidenced
significant within-person change, other participants evidenced significant within-person
deterioration across numerous measures. From a theoretical perspective, it’s possible that
therapeutic intervention following psychedelic exposure could make the difference for those
individuals who deteriorated by providing a space to integrate painful insights into the selfstructure.
3) With regard to case studies, and while both individuals had mystical experiences, the
individual with the healthiest pre-psychedelic personality organization evidenced emotional
growth following psychedelic exposure, while the individual with the unhealthiest prepsychedelic personality organization evidenced significant deterioration. Once again, the data
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preliminarily suggests that some individuals may be more vulnerable in the face of
overwhelming psychedelic experiences, and would therefore benefit from therapeutic
intervention following psychedelic exposure.
With all of this in mind, future studies should seek to clarify whether post-psychedelic
outcomes differ based on the presence or absence of psychotherapeutic integration following
psychedelic exposure and, in turn, utilize relevant findings to inform best practices moving
forward.
When taken together, these findings indicate that future research is warranted in order to
further clarify the effect of psychedelic exposure on personality - as well as the effect of
personality on psychedelic exposure - and the potential mechanisms that explain these dynamic
relationships. Once implemented, this research will support the identification of relevant
exclusion criteria and appropriate treatment recommendations, as psychedelics are increasingly
legalized and, in turn, integrated into the psychotherapeutic frame.
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APPENDIX A
Rationale for Chosen Summary Measures
Brief Symptom Inventory (BSI). The Global Severity Index (GSI) was selected as a
summary measure for the BSI. Of note, the GSI is highly correlated at pre-test with the BSI’s
two other global indices, with Pearson’s coefficients of .92 with the Positive Symptom Total
subscale (PST) and .78 with the Positive Symptom Distress Severity subscale (PSDI). As a
result, the GSI is a strong summary score for the entire BSI scale.
Inventory of Personality Organization (IPO). The Inventory of Personality Organization
(IPO) yields three subscale scores: Identity Diffusion (IPO-ID), Primitive Defenses (IPO-PD)
and Impaired Reality Testing (IPO-RT). All three subscales will be analyzed, as they represent
distinct dimensions of personality organization and cannot be meaningfully combined into one
global score.
Pathological Narcissism Inventory (PNI). The Pathological Narcissism Inventory (PNI)
yields three global indices: Narcissistic Grandiosity (PNI-G) (an average of the Exploitativeness,
Self-Sacrificing Self-Enhancement and Grandiose Fantasy subscales), Narcissistic Vulnerability
(PNI-V) (an average of the Contingent Self-Esteem, Self-Sacrificing Self-Enhancement, Hiding
the Self, and Entitlement Rage subscales), and Pathological Narcissism Overall (PNI-O) (an
average of the PNI-G and PNI-V global indices). As study predictions sought to assess the
potential impact of psilocybin on narcissistic grandiosity in particular, the PNI-G and PNI-V will
be analyzed separately (in lieu of analyzing the PNI-O, which averages the PNI-G and PNI-V
global indices, and potentially blurs the distinction between these distinct dimensions of
grandiosity and vulnerability).
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Mentalization Scale (MentS). The Mentalization Scale (MentS) yields three subscale
scores and one overall composite score: Mentalization of Self (MentS-S), Mentalization of
Others (MentS-O), Motivation to Mentalize (MentS-M), and Mentalization Total (MentS-T). As
the scale’s summary measure, the MentS-T was selected for MentS analyses.
The Ryff Scale of Psychological Well-Being (Ryff). The Ryff Scale of Psychological
Well-Being (Ryff) yields subscale scores on six dimensions of wellbeing: autonomy,
environmental mastery, personal growth, positive relations with others, purpose in life and selfacceptance. As previously discussed, nearly a third of Ryff subscales rendered questionable to
unacceptable reliability scores (see Table 4). As further investigation indicated a problem with
subscale measures, as opposed to a problem with one single item, all subscales were averaged to
create an Overall Wellbeing score (Ryff-OW), which evidenced good to excellent reliability. As
a result, the Ryff-OW will be used as a summary score for the entire Ryff scale.
Experiences in Close Relationships-Revised (ECR-R). The Experiences in Close
Relationships-Revised (ECR-R) yields two subscale scores: attachment-related anxiety (Ax) and
attachment-related avoidance (Av). Both subscales will be analyzed, as they represent distinct
dimensions of attachment and cannot be meaningfully combined into one global score.
Pro-Environmental Behavior (PEB). The Pro-Environmental Behavior (PEB) measure
assesses the frequency with which individuals perform certain environmentally considerate
actions. This measure yields one overall score (PEB), which was used for the following
analyses.
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APPENDIX B
Sample Characteristics by Measure
BSI GSI Sample Characteristics: Over the course of data collection, the BSI was
completed by 21 participants prior to psilocybin exposure, 12 participants following psilocybin
exposure, and 9 participants at a one-month follow-up. In order to best understand sample
characteristics, only the 13 participants who completed the BSI at more than one time point are
included in the following analyses.
According to Derogatis and Melisaratos (1983), the non-patient (healthy) average on the
Global Severity Index (GSI) is .3 (with a standard deviation of .31) and the outpatient average is
1.32 (with a standard deviation of .72). As indicated by these norms, higher GSI scores reflect
worse symptom profiles and, conversely, lower GSI scores reflect healthier symptom profiles.
Prior to psilocybin exposure, 53.8% (n = 7) of subjects earned a GSI within one standard
deviation of the non-patient (healthy) average and 46.2% (n = 6) of subjects earned a GSI within
one standard deviation of the outpatient average. Following psilocybin exposure, 84.6% (n = 11)
of subjects earned a GSI within one standard deviation of the non-patient (healthy) average,
while 7.7% (n = 1) of subjects earned a GSI within one standard deviation of the outpatient
average. At the second time point, 7.7% (n = 1) of the sample did not participate in data
collection. At the one-month follow-up, 61.5% (n = 8) of participants remained within one
standard deviation of the non-patient average, while 7.7% (n = 1) of participants earned a GSI
within one standard deviation of the outpatient average. At the third time point, 30.8% (n = 4) of
the sample did not participate in data collection. In sum, the majority of the sample appeared to
be within the normal range at all time points, with only one subject approaching the outpatient
norm at follow-up (see Figure 1).
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Figure 1. BSI GSI scores over Time by subject.
Note: BSI = Brief Symptom Inventory. GSI = Global Severity Index.

IPO-ID Sample Characteristics: Over the course of data collection, the IPO was
completed by 20 participants prior to psilocybin exposure, 11 participants following psilocybin
exposure, and 9 participants at a one-month follow-up. In order to best understand sample
characteristics, only the 12 participants who completed the IPO at more than one time point are
included in the following analyses.
According to Lenzenweger et al. (2001), the normative average on the IPO-ID is 51.68
(with a standard deviation of 11.35), with higher IPO-ID scores indicating higher levels of
identity diffusion and lower scores indicating lower (healthier) levels of identity diffusion. With
regard to this study’s sample, virtually all participants fell within the normative range (or
healthier) at all three time points, with varying degrees of improvement and deterioration over
time (see Figure 2).
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Figure 2. IPO-ID scores over Time by subject.
Note: IPO-ID = Inventory of Personality Organization, Identity Diffusion subscale.
IPO-RT Sample Characteristics: According to Lenzenweger et al. (2001), the normative
average on the IPO-RT is 38.46 (with a standard deviation of 9.67), with higher IPO-RT scores
indicating worse reality testing and lower scores indicating better reality testing. With regard to
this study’s sample, the vast majority of participants fell within the normative range (or
healthier) at all three time points (with varying degrees of improvement and deterioration over
time), with one participant scoring between 1 and 2 standard deviations above the norm directly
following psilocybin exposure (see Figure 3).
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Figure 3. IPO-RT scores over Time by subject.
Note: IPO-RT = Inventory of Personality Organization, Reality Testing subscale.
IPO-PD Sample Characteristics: According to Lenzenweger et al. (2001), the normative
average on the IPO-PD is 36.25 (with a standard deviation of 7.91), with higher IPO-PD scores
indicating a higher reliance on primitive defenses and lower scores indicating a healthier
defensive structure. With regard to this study’s sample, the vast majority of participants fell
within the normative range (or healthier) at all three time points, with varying degrees of
improvement and deterioration over time (see Figure 4).
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Figure 4. IPO-PD scores over Time by subject.
Note: IPO-PD = Inventory of Personality Organization, Primitive Defenses subscale.
PNI-G Sample Characteristics: Over the course of data collection, the PNI was
completed by 15 participants prior to psilocybin exposure, 10 participants following psilocybin
exposure, and 9 participants at a one-month follow-up. In order to best understand sample
characteristics, only the 11 participants who completed the PNI at more than one time point are
included in the following analyses.
According to Pincus et al. (2009), the non-patient (healthy) average on the PNI-G is 2.89
(with a standard deviation of 0.66) and the outpatient average is 2.47 (with a standard deviation
of 0.87), with higher scores indicating higher levels of narcissistic grandiosity. With regard to
this study’s sample, all participants fell within the normative range (or healthier) at all three time
points, with varying degrees of improvement and deterioration over time (see Figure 5).

99

Figure 5. PNI-G scores over Time by subject.
Note: PNI-G = Pathological Narcissism Inventory, Grandiosity subscale.
PNI-V Sample Characteristics: According to Pincus et al. (2009), the non-patient
(healthy) average on the PNI-V is 2.13 (with a standard deviation of 0.74) and the outpatient
average is 2.42 (with a standard deviation of 0.83), with higher scores indicating higher levels of
narcissistic vulnerability. With regard to this study’s sample, the vast majority of participants
fell within the normative range (or healthier) at all three time points (with varying degrees of
improvement and deterioration over time), with one participant significantly higher than the
normative range at all three time points (see Figure 6).
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Figure 6. PNI-V scores over Time by subject.
Note: PNI-V = Pathological Narcissism Inventory, Vulnerability subscale.
MentS-T Sample Characteristics: Over the course of data collection, the MentS was
completed by 14 participants prior to psilocybin exposure, 10 participants following psilocybin
exposure and 9 participants at a one-month follow-up. In order to best understand sample
characteristics, only the 11 participants who completed the MentS at more than one time point
are included in the following analyses.
According to Dimitrijević et al. (2018), the non-patient (healthy) average on the MentS-T
is 106.29 (with a standard deviation of 11.37) and the clinical average is 100.26 (with a standard
deviation of 14.02). As indicated by these norms, higher MentS-T scores indicate stronger
mentalization capacities, while lower scores indicate relatively weaker mentalization capacities.
With regard to this study’s sample, virtually all participants fell within the normative range at all
three time points (with varying degrees of improvement and deterioration over time), with the
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exception of one participant who fell within the clinical range at time points 1 and 2 (with no
dataset for time point 3) (see Figure 7).

Figure 7. MentS-T scores over Time by subject.
Ryff Sample Characteristics: Over the course of data collection, the Ryff Scale of
Psychological Well-Being was completed by 15 participants prior to psilocybin exposure, 10
participants following psilocybin exposure and 9 participants at a one-month follow-up. In order
to best understand sample characteristics, only the 11 participants who completed the Ryff at
more than one time point are included in the following analyses.
Although Ryff (1989) provides normative data for the Ryff’s six subscales, the composite
Ryff-OW score is not traditionally employed by the literature, and normative data is therefore
not available for comparison purposes. Of note, higher Ryff-OW scores reflect higher levels of
well-being and, conversely, lower Ryff-OW scores indicate relatively lower levels of well-being
(see Figure 8).
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Figure 8. RYFF-OW scores over Time by subject.
ECR-R Ax Sample Characteristics: Over the course of data collection, the ECR-R was
completed by 14 participants prior to psilocybin exposure, 10 participants following psilocybin
exposure, and 9 participants at a one-month follow-up. In order to best understand sample
characteristics, only the 11 participants who completed the ECR-R at more than one time point
are included in the following analyses.
According to Fraley et al. (2000), the average norm on the ECR-R Ax is 3.56 (with a
standard deviation of 1.19), with higher scores indicating worse attachment-related anxiety and
lower scores indicating relatively healthier levels of attachment-related anxiety. With regard to
this study’s sample, virtually all participants fell within the normative range at all three time
points, with varying degrees of improvement and deterioration over time. At each time point,
one or two participants earned scores between 1 and 2 standard deviations above the norm,
indicating relatively higher levels of attachment-related anxiety (See Figure 9).
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Figure 9. ECR-R Ax scores over Time by subject.
Note: ECR-R = Experiences in Close Relationships-Revised.
ECR-R Av Sample Characteristics: According to Fraley et al. (2000), the average norm
on the ECR-R Av is 2.92 (with a standard deviation of 1.19), with higher scores indicating worse
attachment-related avoidance and lower scores indicating relatively healthier levels of
attachment-related avoidance. With regard to this study’s sample, virtually all participants fell
within the normative range at all three time points, with varying degrees of improvement and
deterioration over time, with the exception of one participant who earned notably elevated scores
at all three time points (see Figure 10).
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Figure 10. ECR-R Av scores over Time by subject.
Note: ECR-R = Experiences in Close Relationships-Revised.
PEB Sample Characteristics: Over the course of data collection, the PEB was completed
by 21 participants prior to psilocybin exposure and 9 participants at the one-month follow-up.
(As pro-environmental behavior cannot meaningfully change in the context of a retreat, this
measure was only collected twice: before psychedelic exposure and at the one-month follow-up,
once participants had re-entered their everyday life). In order to best understand sample
characteristics, only the 9 participants who completed the PEB at both time points are included in
the following analyses. Of note, normative data is not available for this measure (See Figure 11).
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Figure 11. Pro-Environmental Behavior (PEB) scores over Time by subject.
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APPENDIX C
Hierarchical Linear Model Analyses by Measure
GSI Mixed Model Analysis: A Hierarchical Linear Model analysis was conducted to
predict the degree and shape of GSI change over time, while controlling for SD. A first-order
autoregressive (AR1) covariance structure was the best fit for the data. The effect of linear Time
and quadratic Time2 were both significant predictors of GSI scores (see Table 11), indicating that
scores showed a significant curvilinear trend, with a slight upward curve in change over
time. This model predicted 64.8% of the variance in GSI scores (R2 = .648), reflecting a large
effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
interaction effect of Time x ME were significant, indicating that mystical experiences were not a
statistically significant moderator of the effect of GSI scores over time. With the inclusion of
predictors ME and ME x Time, the model explained an additional 7.7% of variance (a small to
medium effect size).
Figure 12 demonstrates the nature of the effect of the moderator variable. More
specifically, and on average, the non-mystical experience group showed greater improvement
between time points 1 and 2 than the mystical experience group. Of note, this finding is contrary
to the study’s original prediction (which projected the mystical-experience group to evidence
more improvement on the BSI than the non-mystical experience group) and, in fact, appears to
indicate that the opposite effect may have occurred. Though not statistically significant, the
effect size for this interaction is in the small to medium range.
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Table 11.
Fixed effects model: Tests of fixed effects predicting BSI GSI scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

12.772

4.897

.046

SD

1

12.671

.014

.908

1

10.346

10.300

.009*

1

9.072

7.850

.020*

1

11.950

.159

.697

Time
Time

2

ME

ME x Time
1
11.531
.922
.357
*Significant (<.05) change
Note: BSI = Brief Symptom Inventory. GSI = Global Severity Index. SD = Marlow-Crowne Social
Desirability scale. ME = Mystical Experience (0 = No, 1 = Yes).
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Figure 12. Interaction of ME and Time for BSI GSI scores controlling for SD.
Note: ME = Mystical Experience.

In sum, there was a significant and curvilinear pattern to change over time, with scores
decreasing at Time 2 (evidencing improved symptomology on the GSI directly following
psychedelic exposure) and increasing again at Time 3 (reflecting a return toward baseline after a
month follow-up period). Mystical experiences were not a significant moderator of the effect of
GSI scores over time, although the inclusion of predictors ME and ME x Time explained an
additional 7.7% of variance (a small to medium effect size).
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IPO-ID Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to
predict the degree and shape of IPO-ID change over time, while controlling for SD. A first-order
autoregressive (AR1) covariance structure was the best fit for the data. The effect of Time 2 was
a significant predictor of IPO-ID scores (see Table 12), indicating that scores showed a
significant curvilinear trend, with a slight downward curve (and reflecting improved identity
diffusion) in change over time. This model predicted 63.6% of the variance in IPO-ID scores (R2
= 0.636), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
interaction effect of Time x ME were significant, indicating that mystical experiences were not a
statistically significant moderator of the effect of IPO-ID scores over time. However, with the
inclusion of the predictors ME and ME x Time, the model explained an additional 24.5% of
variance (a large effect size).
Figure 13 demonstrates the nature of this effect. Specifically, the mystical experience
group averaged no change directly following psilocybin exposure (followed by improvement at
the one-month follow-up), whereas the non-mystical experience group averaged slight
improvement directly following psilocybin exposure (followed by further improvement at the
one-month follow-up). Additionally, and while both groups evidenced improved (lower levels
of) identity diffusion at follow-up, the non-mystical group averaged more improvement relative
to the mystical experience group. Of note, this finding is contrary to original study predictions,
which projected the mystical experience group to evidence greater improvement than the nonmystical experience group over time.
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Table 12.
Fixed effects model: Tests of fixed effects predicting IPO-ID scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

19.150

35.757

.000

SD

1

20.884

.693

.414

1

12.960

2.641

.128

1

11.018

8.194

.015*

1

11.990

.052

.824

Time
Time
ME

2

ME x Time
1
10.913
1.325
.274
*Significant (<.05) change
Note: IPO-ID = Inventory of Personality Organization, Identity Diffusion subscale. SD = MarlowCrowne Social Desirability scale. ME = Mystical Experience group (0 = No, 1 = Yes).

Figure 13. Interaction of ME and Time for IPO-ID scores controlling for SD.
Note: IPO-ID = Inventory of Personality Organization, Identity Diffusion subscale.
In sum, there was a significant and curvilinear pattern of change in IPO-ID over time,
with a slight downward curve (and improved identity diffusion) by the one-month follow-up.
Mystical experiences were not a significant moderator of the effect of IPO-ID over time,
although inclusion of predictors ME and ME x Time explained an additional 24.5% of variance
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(a large effect size). Here, the mystical experience group averaged no change directly following
psilocybin exposure (followed by improvement at the one-month follow-up), whereas the nonmystical experience group averaged slight improvement directly following psilocybin exposure
(followed by even greater improvement at the one-month follow-up relative to the mystical
experience group).
IPO-RT Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to
predict the degree and shape of IPO-RT change over time, while controlling for SD. An Identity
covariance structure was the best fit for the data. The effect of Time2 was a significant predictor
of IPO-RT scores (see Table 13), indicating that scores showed a significant curvilinear trend,
with a slight downward curve (and reflecting improved reality testing) in change over time. This
model predicted 77% of the variance in IPO-RT scores (R2 = 0.770), reflecting a large effect
size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
interaction effect of ME x Time were significant, indicating that mystical experiences were not a
statistically significant moderator of the effect of IPO-RT scores over time. Through the
inclusion of the predictors ME and ME x Time, the model explained an additional 1.5% of
variance (nearing a small effect size).
Figure 14 demonstrates the nature of this effect. More specifically, the non-mystical
experience group averaged more improvement relative to the mystical experience group by
follow-up. Of note, this finding is contrary to original study predictions, which projected the
mystical experience group to evidence greater improvement than the non-mystical experience
group over time.
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Table 13.
Fixed effects model: Tests of fixed effects predicting IPO-RT scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

15.776

57.046

.000

SD

1

15.288

1.388

.257

1

9.115

4.164

.071

1

10.642

6.052

.032*

1

14.392

.003

.957

Time
Time
ME

2

ME x Time
1
10.876
.966
.347
*Significant (<.05) change
Note: IPO-RT = Inventory of Personality Organization, Reality Testing subscale. SD = Marlow-Crowne
Social Desirability scale. ME = Mystical Experience group (0 = No, 1 = Yes).

Figure 14. Interaction of ME and Time for IPO-RT scores controlling for SD.
Note: IPO-RT = Inventory of Personality Organization, Reality Testing subscale.
In sum, there was a significant and curvilinear pattern of change in IPO-RT over time,
with a slight downward curve (and improved reality testing) by the one-month follow-up.
Mystical Experiences were not a significant moderator of the effect of IPO-RT over time, with
the inclusion of predictors ME and ME x Time explaining only an additional 1.5% of variance
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(nearing a small effect size). Though quite preliminary (in light of statistical insignificance, as
well as a negligible to small effect size), the non-mystical experience group averaged greater
improvement relative to the mystical experience group at the one-month follow-up (a trend that
is contrary to study predictions, which anticipated greater improvement by the mysticalexperience group).
IPO-PD Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to
predict the degree and shape of IPO-ID change over time, while controlling for SD. An Identity
covariance structure was the best fit for the data. Neither the effect of Time nor quadratic Time2
were significant (see Table 14). This model predicted 91.9% of variance in IPO-ID scores (R2 =
.919), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 – Yes) and the interaction of ME x Time. Although the main effect of ME was
insignificant, the interaction of ME x Time was a significant predictor of IPO-PD scores,
indicating mystical experiences were significant predictor of IPO-PD at certain time points.
With the inclusion of predictors ME and ME x Time, this model explained an additional 2.4% of
variance (R = .943), indicating a small effect size.
Figure 15 demonstrates the nature of this effect. More specifically, and on average, the
non-mystical experience group tended to evidence reduced levels of primitive defenses over
time, whereas the mystical-experience group tended to retain consistent levels across time points.
Of note, this finding is contrary to original study predictions (which projected the mystical
experience group to evidence greater improvement than the non-mystical experience group over
time) and, in fact, appears to indicate that the opposite effect has occurred.
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Table 14.
Fixed effects model: Tests of fixed effects predicting IPO-PD scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

20.556

40.187

.000

SD

1

22.562

.069

.795

1

11.910

.783

.394

1

11.098

.001

.973

1

11.805

.065

.802

Time
Time
ME

2

ME x Time
1
10.449
4.934
.049*
*Significant (<.05) change
Note: IPO-PD = Inventory of Personality Organization, Primitive Defenses subscale. SD = MarlowCrowne Social Desirability scale. ME = Mystical Experience group (0 = No, 1 = Yes).

Figure 15. Interaction of ME and Time for IPO-PD scores controlling for SD.
Note: IPO-PD = Inventory of Personality Organization, Primitive Defenses subscale.
In sum, the effects of linear Time, quadratic Time2 and ME were not significant
predictors of IPO-PD. However, the interaction of ME x Time was significant, indicating that
the non-mystical experience group evidenced improved (lower) levels of primitive defenses over
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time, whereas the mystical-experience group maintained similar levels of primitive defenses
across time points. Of note, these findings stand in contrast to study predictions, which projected
the mystical-experience group to demonstrate greater improvement than the non-mystical
experience group over time.
PNI-G Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to
predict the degree and shape of PNI-G scores over time, while controlling for SD. An Identity
covariance structure was the best fit for the data. Neither the effect of linear Time nor quadratic
Time2 were significant (see Table 15). Additionally, this model predicted 88.3% of variance (R
= .883), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Although the main effect of ME was
insignificant, the interaction of ME x Time was a significant predictor of PNI-G scores,
indicating mystical experiences were a significant predictor of PNI-G scores at certain time
points. With the inclusion of predictors ME and ME x Time, this model explained an additional
7% of variance (R = .883), indicating a small to medium effect size.
Figure 16 demonstrates the nature of this effect. More specifically, and on average, the
non-mystical experience group tended to evidence reduced levels of grandiosity over time,
whereas the mystical-experience group tended to retain consistent levels across time points. Of
note, this finding is contrary to original study predictions (which projected the mystical
experience group to evidence greater improvement than the non-mystical experience group over
time) and, in fact, appears to indicate that the opposite effect has occurred.
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Table 15.
Fixed effects model: Tests of fixed effects predicting PNI-G scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

17.148

16.015

.001

SD

1

18.226

.017

.898

1

16.620

.013

.910

1

17.077

.588

.454

1

12.255

.212

.653

Time
Time
ME

2

ME x Time
1
19.849
8.644
.008*
*Significant (<.05) change
Note: PNI-G = Pathological Narcissism Inventory, Grandiosity subscale. SD = Marlow-Crowne Social
Desirability scale. ME = Mystical Experience (0 = No, 1 = Yes).

Figure 16. Interaction of ME and Time for PNI-G scores controlling for SD.
Note: PNI-G = Pathological Narcissism Inventory, Grandiosity subscale. SD = Marlow-Crowne Social
Desirability scale.

In sum, the effects of linear Time, quadratic Time2 and ME were not significant
predictors of PNI-G. However, the interaction of ME x Time was significant, indicating that the
non-mystical experience group evidenced improved (lower) levels of grandiosity over time,
whereas the mystical-experience group maintained similar levels of grandiosity across time

116

points. Of note, these findings stand in contrast to study predictions, which projected the
mystical-experience group to demonstrate greater improvement than the non-mystical experience
group over time.
PNI-V Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to
predict the degree and shape of PNI-V change over time, while controlling for SD. A Toeplitz
(TP) covariance structure was the best fit for the data. Neither the effect of linear Time nor the
effect of quadratic Time2 were significant (see Table 16). Additionally, this model predicted
85.7% of variance in PNI-V scores (R2 = .857), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
interaction effect of Time x ME were significant, indicating that mystical experiences were not a
statistically significant moderator of PNI-V scores over time. With the inclusion of predictors
ME and ME x Time, the model explained an additional .4% of variance (R = .861), reflecting a
negligible effect size (see Figure 17).
Table 16.
Fixed effects model: Tests of fixed effects predicting PNI-V scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

18.169

17.047

.001

SD

1

19.181

1.368

.257

1

15.809

1.811

.197

1

11.299

.072

.794

1

13.334

.042

.840

Time
Time
ME

2

ME x Time
1
8.542
.796
.397
*Significant (<.05) change
Note: PNI-V = Pathological Narcissism Inventory, Vulnerability subscale. SD = Marlow-Crowne Social
Desirability scale. ME = Mystical Experience group (0 = No, 1 = Yes).
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Figure 17. Interaction of ME and Time for PNI-V scores controlling for SD.
Note: PNI-G = Pathological Narcissism Inventory, Vulnerability subscale. SD = Marlow-Crowne Social
Desirability scale.

In sum, none of the predictors were significantly associated with PNI-V. Of note, these
findings stand in contrast to study predictions, which projected reduced levels of narcissistic
grandiosity over time.
MentS-T Mixed Model Analysis: A Hierarchical Linear Model analysis was conducted to
predict the degree and shape of MentS-T change over time, while controlling for SD. A firstorder autoregressive (AR1) covariance structure was the best fit for the data. Neither the effect
of Time nor quadratic Time2 were significant (see Table 17), which likely reflects the limited
change over time in the sample overall (as reflected in reliable change indices). This model
predicted 83.6% of variance in MentS-T scores (R2 = .836), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
interaction effect of Time x ME were significant, indicating that mystical experiences were not a
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statistically significant moderator of the effect of MentS-T scores over time. However, with the
inclusion of predictors ME and ME x Time, this model explained an additional 2.8% of variance
(a small effect size). Figure 18 demonstrates the nature of the effect of the moderator variable,
which appears to reflect a regression to the mean.
Table 17.
Fixed effects model: Tests of fixed effects predicting MentS-T scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

16.397

119.166

.000

SD

1

17.377

.856

.368

1

10.693

.008

.931

1

9.922

.094

.765

1

11.551

.792

.392

Time
Time

2

ME

ME x Time
1
7.321
3.170
.116
Note: MentS-T = Mentalization Total. SD = Marlow-Crowne Social Desirability scale. ME = Mystical
Experience (0 = No, 1 = Yes).
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Figure 18. Interaction of ME and Time for MentS-T scores controlling for SD.
Note: MentS-T = Mentalization Total.
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In sum, and with limited change over time in the sample overall, none of the predictors
were significantly associated with MentS-T. Of note, these findings stand in contrast to study
predictions, which projected improved mentalization skills over time.
Ryff-OW Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to
predict the degree and shape of Ryff-OW change over time, while controlling for SD. An
Identity covariance structure was the best fit for the data. Neither the effect of Time nor
quadratic Time2 were significant (see Table 18), which likely reflects the limited change over
time in the sample overall (as reflected in reliable change indices). This model predicted 85.9%
of variance in Ryff-OW scores R2 = .859), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
interaction effect of ME x Time were significant, indicating that mystical experiences were not a
statistically significant moderator of the effect of Ryff-OW scores over time. However, with the
inclusion of predictors ME x and ME x Time, this model explained an additional 4.2% of
variance (a small to medium effect size). Figure 19 demonstrates the nature of the effect on the
moderator variable, with the non-mystical experience group evidencing relatively more
improvement over time in comparison to the mystical-experience group. Of note, this trend
stands in contrast to study predictions, which projected the mystical-experience group to
evidence more improvement over time.
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Table 18.
Fixed effects model: Tests of fixed effects predicting Ryff-OW score, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

17.613

117.303

.000

SD

1

18.825

.564

.462

1

12.736

2.887

.114

1

10.590

1.034

.332

1

12.639

.016

.902

Time
Time
ME

2

ME x Time
1
6.566
1.429
.273
*Significant (<.05) change
Note: Ryff-OW = The Ryff Scale of Psychological Wellbeing, Overall Wellbeing summary score.
SD = Marlow-Crowne Social Desirability scale. ME = Mystical Experience group (0 = No, 1 = Yes).

Figure 19. Interaction of ME and Time for Ryff-OW scores controlling for SD.
Note: Ryff-OW = The Ryff Scale of Psychological Wellbeing, Overall Wellbeing summary score.
In sum, and with limited change over time in the sample overall, none of the predictors
were significantly associated with Ryff-OW. Of note, these findings stand in contrast to study
predictions, which projected improved psychological wellbeing over time.
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ECR-R Ax Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted
to predict the degree and shape of Ax change over time, while controlling for SD. A first-order
autoregressive (AR1) covariance structure was the best fit for the data. Neither the effect of
Time nor quadratic Time2 were significant (see Table 19). In light of the significant
improvement and deterioration evidenced in this sample overall (as reflected by the
aforementioned reliable change indices), the insignificant effects of linear and quadratic time
likely indicate that the sample did not follow a uniform trajectory over time. This model
predicted 81.1% of variance in Ax scores (R2 = .811), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
interaction effect of Time x ME were significant, indicating that mystical experiences were not a
statistically significant moderator of the effect of Ax scores over time. With the inclusion of
predictors ME and ME x Time, this model explained an additional 2.9% of variance (a small
effect size). Figure 20 demonstrates the nature of the effect of the moderator variable. On
average, the mystical-experience group deteriorated slightly (higher levels of attachment-related
anxiety) over time points, while the non-mystical experience group improved slightly (reduced
levels of attachment-related anxiety) over time. Of note, this finding is contrary to the study’s
original prediction (which hypothesized that the mystical experience group would show greater
improvement than the non-mystical experience group) and in fact preliminarily indicates that the
opposite effect may have occurred.
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Table 19.
Fixed effects model: Tests of fixed effects predicting ECR-R Ax scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

13.857

14.375

.002

SD

1

14.337

.002

.965

1

11.279

1.431

.256

1

10.108

1.289

.282

1

11.173

.531

.481

Time
Time

2

ME

ME x Time
1
8.856
1.393
.269
Note: ECR-R = Experiences in Close Relationships-Revised. Ax = Anxiety subscale. SD = MarlowCrowne Social Desirability scale. MEG = Mystical Experience (0 = No, 1 = Yes).
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Figure 20. Interaction of ME and Time for ECR-R Ax scores controlling for SD.
Note: ECR-R = Experiences in Close Relationships-Revised.
In sum, none of the predictors were significantly associated with Ax. Of note, this may
be due in part to the data’s lack of a uniform trajectory: with some individuals improving, and
others deteriorating (as reflected by reliable change indices), these varied trajectories may be
canceling each other out. Nevertheless, the effects of linear and quadratic time explained 81.1%
of variance (a large effect size), with ME and Time x ME explaining an additional 2.9% of
variance (a small effect size). As a result, further investigation is warranted with a larger sample
size.
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ECR-R Av Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted
to predict the degree and shape of Av change over time, while controlling for SD. A Toeplitz
(TP) covariance structure was the best fit for the data. Neither the effect of linear Time nor
quadratic Time2 were significant (see Table 20). Additionally, this model predicted 85.6% of
variance in Av scores (R2 = .865), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 = Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
interaction effect of Time x ME were significant, indicating that mystical experiences were not a
statistically significant moderator of the effect of Av scores over time. In fact, with the inclusion
of predictors ME and ME x Time, this model predicted 7.1% less variance (R = .785) (See
Figure 21).
Table 20.
Fixed effects model: Tests of fixed effects predicting ECR-R Av scores, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

12.440

8.344

.013

SD

1

11.945

.865

.371

Time

1

17.751

.000

.994

Time2

1

5.678

.021

.891

ME

1

14.490

1.291

.274

ME x Time
1
1.695
.220
.692
Note: ECR-R = Experiences in Close Relationships-Revised. Av = Avoidance subscale. SD = MarlowCrowne Social Desirability scale. ME = Mystical Experience group (0 = No, 1 = Yes).
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Figure 21. Interaction of ME and Time for ECR-R Av scores controlling for SD.
Note: ECR-R = Experiences in Close Relationships-Revised. SD = Social Desirability.
In sum, none of the predictors were significantly associated with Av change over time
and the inclusion of ME and ME x Time in fact weakened the percentage of variance explained.
Of note, these findings stand in contrast to study predictions, which projected improved
(reduced) attachment-related avoidance over time, with the presence of mystical experiences
moderating this relationship.
PEB Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to
predict the degree of PEB change over time, while controlling for SD. (Of note, quadratic Time2
was not assessed, as PEB was only collected at two time points: before psychedelic exposure and
at the one-month follow-up). An Identity covariance structure was the best fit for the data. Of
note, the effect of Time was not significant (see Table 21), which likely reflects the limited
change over time in the sample overall (as reflected in reliable change indices). This model
predicted 95.4% of variance of PEB scores (R2 = .954), reflecting a large effect size.
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 =
No, 1 – Yes) and the interaction of ME x Time. Of note, neither the main effect of ME nor the
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interaction effect of ME x Time were significant, indicating that mystical experiences were not a
significant moderator of PEB scores over time. In fact, with the inclusion of predictors ME and
ME x Time, the model predicted .7% less variance (R2 = .947) (See Figure 22).
Table 21.
Fixed effects model: Tests of fixed effects predicting PEB score, controlling for SD.
Source

Numerator df

Denominator df

F

Sig.

Intercept

1

14.378

91.430

.000

SD

1

14.707

.049

.827

Time

1

6.558

.056

.821

ME

1

11.392

.476

.504

ME x Time
1
9.321
.257
.624
*Significant (<.05) change
Note: PEB = Pro-Environmental Behavior summary score.
SD = Marlow-Crowne Social Desirability scale. ME = Mystical Experience group (0 = No, 1 = Yes).

Figure 22. Interaction of ME and Time for PEB scores controlling for SD.
Note: PEB = Pro-Environmental Behavior summary score.
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In sum, none of the predictors were significantly associated with PEB change over time
and the inclusion of ME and ME x Time in fact weakened the percentage of variance explained.
Of note, these findings stand in contrast to study predictions, which projected improved
(increased) pro-environmental behavior over time, with the presence of mystical experiences
moderating this relationship.
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APPENDIX D
Reliable Change Score Analyses by Measure
GSI Reliable Change Scores: According to assessments of reliable change, 61.5% (n = 8)
of the sample did not evidence significant (>1.96) within-person improvement or deterioration
on the GSI between time points 1 and 2 (before and after the psychedelic retreat). In essence, the
symptom profiles for nearly two thirds of the sample were contrary to predictions and remained
unchanged directly following psilocybin exposure (see Table 22).
In contrast, and in alignment with predictions, 30.8% (n = 4) of the sample showed
reliable change between time points 1 and 2, with all four of these subjects evidencing improved
symptom profiles and reduced GSI scores by a factor of 3.65 (subject 10), 3.77 (subject 3), 4.03
(subject 4) and 6.29 (subject 2) standard deviations respectively. Of note, all four subjects
earned GSI scores within one standard deviation of the outpatient norm at baseline, and
subsequently earned GSI scores within one standard deviation of the non-patient norm directly
following psilocybin exposure.
Lastly, the trajectory for 7.7% (n = 1) of the sample is unknown, as Subject 7 did not
complete data entry at time point 2, directly following psilocybin exposure.
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 38.5% (n = 5)
of participants remained unchanged on the GSI; in other words, approximately one third of the
sample performed contrary to predictions and were unaffected by psilocybin exposure, earning
the same GSI score (and, by proxy, the same symptom profile) before and after psilocybin
exposure, as well as at the one-month follow-up.
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In contrast, and also contrary to study predictions, 15.4% (n = 2) of the sample
significantly deteriorated on the GSI at follow-up. Specifically, Subject 11 (who earned GSI
scores within one standard deviation of the outpatient norm at all three time points) did not
significantly change between time points 1 and 2, but significantly deteriorated between time
points 2 and 3, thus indicating a worsened symptom profile (and an increased GSI score by a
factor of 3.9 standard deviations when compared to baseline) one month following psilocybin
exposure. In comparison to baseline, Subject 7 also deteriorated at the one-month follow-up by a
factor of 2.01 standard deviations, although this subject earned GSI scores within one standard
deviation of the non-patient norm at both time points 1 and 3. (As this subject did not participate
in data collection at time point 2, it’s unknown whether this deterioration was evident directly
following psilocybin exposure, or whether it developed during the one-month follow-up period).
In contrast, and in alignment with study predictions (which anticipated sustained
improvement on the GSI through follow-up), 7.7% (n = 1) of the sample (subject 2), improved at
time point 2 (moving from a GSI score within one standard deviation of the outpatient norm at
baseline to a GSI score within one standard deviation of the non-patient norm in the immediate
wake of psychedelic exposure) and retained these gains at time point 3 (at the one-month followup). An additional 7.7% (n = 1) of the sample (subject 3) significantly improved at time point 2
(directly following psilocybin exposure) but lost these gains by time point 3 (when assessed at
one month). Though not indicative of a significant change at follow-up, subject 3 earned a GSI
score within one standard deviation of the outpatient norm at baseline and GSI scores within one
standard deviation of the non-patient norm at both time points 2 and 3.
Lastly, nearly a third of the sample did not participate in data collection at follow-up
(30.8%, n = 4), leaving their trajectories unknown. This includes Subject 1 and Subject 9, both
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of whom remained unchanged on the GSI between time points 1 and 2, as well as Subject 4 and
Subject 10, both of whom significantly improved between time points 1 and 2.
In sum, 61.5% (n = 8) of the sample did not evidence significant change (improvement or
deterioration) directly following psilocybin exposure. In contrast, 30.8% (n = 4) of the sample
evidenced significant improvement on the GSI directly following psilocybin exposure. One
participant did not complete data entry at time point 2, leaving the trajectory for 7.7% of the
sample unknown directly following psilocybin exposure. At the one-month follow-up, 46.2% (n
= 6) of the sample either continued to remain unaffected by psychedelic exposure or lost
significant gains seen at time point 2, evidencing a return to baseline by the one-month followup. In contrast, 23.1% (n = 3) of the sample evidenced significant change at follow-up, with
some evidencing significant improvement, and others evidencing significant deterioration.
Specifically, 15.4% (n = 2) of the sample evidenced significant deterioration (higher GSI scores)
by the one-month follow-up, while 7.7% (n = 1) of the sample maintained significant
improvement (lower GSI scores) at the one-month follow-up. Of note, nearly a third of the
sample (30.8%, n = 4) did not participate in data collection at follow-up, leaving their trajectories
unknown, with two of these subjects (15.4%, n = 2) having previously evidenced no significant
change directly following psilocybin exposure and the other two subjects (15.4%, n = 2) having
previously evidenced significant improvement directly following psilocybin exposure.
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Table 22.
Reliable change scores on BSI GSI by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
9
10
11
12
13

1.51
6.29*
3.77*
4.03*
-0.88
1.64
n/a
1.38
-1.26
3.65*
-0.01
0.88
0.63

n/a
-.75
-2.39*
n/a
1.38
-0.75
n/a
-1.38
n/a
n/a
-3.77*
-0.63
0.13

n/a
5.53*
1.38
n/a
0.50
0.88
-2.01*
0.00
n/a
n/a
-3.90*
0.25
0.75

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: BSI = Brief Symptom Inventory. GSI = Global Severity Index.

IPO-ID Reliable Change Scores: According to assessments of reliable change, 91.6% (n
= 11) of the sample did not evidence significant (>1.96) within-person improvement or
deterioration on the IPO-ID between time points 1 and 2 (before and after the psychedelic
retreat), while the trajectory for the final 8.3% (n = 1) of the sample is unknown, as Subject 7 did
not complete data entry at time point 2. In other words, essentially the entire sample performed
contrary to study predictions, as their identity diffusion remained unchanged directly following
psilocybin exposure (see Table 23).
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 46.2% (n = 6)
of participants remained unchanged on the IPO-ID; in other words, nearly one half of the sample
performed contrary to study predictions and were unaffected by psilocybin exposure, earning the
same IPO-ID score (and, by proxy, the same degree of identity diffusion) before and after
psilocybin exposure, as well as at the one-month follow-up.
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In contrast, and in alignment with study predictions, 23.1% (n = 3) of the sample
significantly improved on the IPO-ID at the one-month follow-up (evidencing lower levels of
identity diffusion). Of note, all three participants (Subject 2, Subject 5, and Subject 6) followed
the same trajectory, evidencing no change on the IPO-ID directly following psilocybin exposure,
followed by significant improvement during the one-month follow-up (by a factor of 2.67, 2.32
and 3.03 standard deviations respectively).
Lastly, 23.1% (n = 3) of the sample did not participate in data collection at follow-up,
leaving their trajectories unknown. This includes Subject 1, Subject 4 and Subject 10, none of
whom evidenced significant change directly following psilocybin exposure (although Subject 10
trended toward improvement with a reliable change score of 1.96 between time points 1 and 2,
which missed the significance cut-off by only .01).
In sum, 91.6% (n = 11) of the sample did not evidence significant change (improvement
or deterioration) directly following psilocybin exposure. One participant did not complete data
entry at time point 2, leaving the trajectory for 8.3% of the sample unknown. At the one-month
follow-up, 46.2% (n = 6) of the sample continued to remain unaffected by psychedelic exposure
and evidenced no change with regard to degree of identity diffusion. In contrast, and in
alignment with study predictions, which projected improved (lower) levels of identity diffusion
following psychedelic exposure, 23.1% (n = 3) of the sample significantly improved (earning
lower IPO-ID scores) by the one-month follow-up. Of note, 23.1% (n = 3) of the sample did not
participate in data collection at follow-up, leaving their trajectories unknown (none of these
subjects evidenced significant change directly following psilocybin exposure).
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Table 23.
Reliable change scores on IPO-ID by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
10
11
12
13

-0.89
-0.18
-1.60
0.71
0.53
1.07
n/a
-0.71
1.96
0.00
-1.07
-0.71

n/a
2.67*
1.60
n/a
2.32*
3.03*
n/a
0.89
n/a
-0.36
-0.71
-1.43

n/a
2.67*
1.60
n/a
2.32*
3.03*
1.96
0.89
n/a
-0.36
-0.71
-1.43

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: IPO-ID = Inventory of Personality Organization, Identity Diffusion subscale.

IPO-RT Reliable Change Scores: According to assessments of reliable change, 83.3% (n
= 10) of the sample did not evidence significant (>1.96) within-person improvement or
deterioration on the IPO-RT between time points 1 and 2 (before and after the psychedelic
retreat). In essence, the vast majority of the sample performed contrary to predictions, as their
reality testing remained unchanged directly following psilocybin exposure (see Table 24).
Additionally, and also contrary to study predictions (which anticipated improved reality
testing over time), 8.3% (n = 1) of the sample evidenced significantly worsened reality testing
directly following psilocybin exposure. Specifically, Subject 1 earned a higher IPO-RT score
(reflecting deteriorated reality testing) by a factor of -2.96 standard deviations following
psilocybin exposure.
Of note, the trajectory for the final 8.3% (n = 1) of the sample is unknown directly
following psilocybin exposure, as Subject 7 did not complete data entry at time point 2.
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According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 58.3% (n = 7)
of participants remained unchanged on the IPO-RT; in other words, over half of the sample
performed contrary to study predictions and were unaffected by psilocybin exposure, earning the
same IPO-RT score (and, by proxy, the same capacity for reality testing) before and after
psilocybin exposure, as well as at the one-month follow-up.
In contrast, and also contrary to study predictions, 8.3% (n = 1) of the sample
significantly deteriorated on the IPO-RT at the one-month follow-up. Specifically, Subject 13’s
reality testing remained unchanged directly following psilocybin exposure, and then significantly
deteriorated over the course of the follow-up period by a factor of -2.11 standard deviations.
Only 8.3% (n = 1) of the sample performed in alignment with study predictions and
evidenced significantly improved reality testing at the one-month follow-up. Specifically,
Subject 11, whose reality testing remained unchanged directly following psilocybin exposure,
evidenced significant improvement in this domain over the course of the follow-up period,
earning a lower (healthier) IPO-RT score by a factor of 2.33 standard deviations at one month.
Lastly, 25% (n = 3) of the sample did not participate in data collection at follow-up,
leaving their trajectories unknown. This includes Subject 4 and 10, neither of whom evidenced
significant change directly following psilocybin exposure, as well as Subject 1, whose reality
testing significantly deteriorated directly following psilocybin exposure by a factor of -2.96
standard deviations.
In sum, 83.3% (n = 10) of the sample did not evidence significant change (improvement
or deterioration) directly following psilocybin exposure. In contrast, 8.3% (n = 1) evidenced
significantly deteriorated reality testing directly following psilocybin exposure, while another
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8.3% (n = 1) of the sample did not complete data entry at time point 2, leaving their trajectory
unknown directly following psilocybin exposure. At the one-month follow-up, 58.3 (n = 7) of
the sample continued to remain unaffected by psychedelic exposure. In contrast, 16.6% (n = 2)
of the sample evidenced significant change at follow-up, with 8.3% (n = 1) evidencing a lower
IPO-RT score (improved reality testing) and 8.3% (n = 1) evidencing a higher IPO-RT score
(deteriorated reality testing) at the one-month follow-up. Of note, 25% (n = 3) of the sample did
not participate in data collection at the one-month follow-up, leaving their trajectories unknown
(with two of these subjects evidencing no significant change directly following psilocybin
exposure, and one of these subjects evidencing deteriorated reality testing directly following
psilocybin exposure).
Table 24.
Reliable change scores on IPO-RT by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
10
11
12
13

-2.96*
0.21
-0.63
0.21
0.85
0.42
n/a
-0.63
-0.63
-0.85
-1.06
-1.90

n/a
1.06
1.06
n/a
-0.85
1.27
n/a
0.85
n/a
3.17*
-0.21
-0.21

n/a
1.27
0.42
n/a
0.00
1.69
1.48
0.21
n/a
2.33*
-1.27
-2.11*

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: IPO-RT = Inventory of Personality Organization, Reality Testing subscale.

IPO-PD Reliable Change Scores: According to assessments of reliable change, 91.7% (n
= 11) of the sample did not evidence significant (>1.96) within-person improvement or
deterioration on the IPO-PD between time points 1 and 2 (before and after the psychedelic
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retreat), while the trajectory for the final 8.3% (n = 1) of the sample is unknown, as Subject 7 did
not complete data entry at time point 2. In other words, essentially the entire sample performed
contrary to study predictions and evidenced unchanged defensive structures directly following
psilocybin exposure (see Table 25).
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 66.7% (n = 8)
of participants remained unchanged on the IPO-PD; in other words, approximately two-thirds of
the sample performed contrary to study predictions and were unaffected by psilocybin exposure,
earning the same IPO-PD score (and, by proxy, evidencing the same defensive structure) before
and after psilocybin exposure, as well as at the one-month follow-up.
In contrast, and in alignment with study predictions, 8.3% (n = 1) of the sample
performed in alignment with study predictions and significantly improved on the IPO-PD at the
one-month follow-up (evidencing healthier defenses). Specifically, Subject 2 did not
significantly change directly following psilocybin exposure, but gradually improved across the
follow-up period, earning a significantly lower (healthier) IPO-PD score at the one-month
follow-up by a factor of 2.12 standard deviations.
Lastly, 23.1% (n = 3) of the sample did not participate in data collection at follow-up,
leaving their trajectories unknown. Of note, none of these subjects evidenced significant change
directly following psilocybin exposure.
In sum, 91.7% (n = 11) of the sample did not evidence significant change (improvement
or deterioration) directly following psilocybin exposure. One participant did not complete data
entry at time point 2, leaving the trajectory for 8.3% of the sample unknown. At the one-month
follow-up, 66.7% (n = 8) of the sample continued to remain unaffected by psychedelic exposure
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and evidenced no change with regard to defensive structure. In contrast, and in alignment with
study predictions, which projected improved defenses across time points, 8.3% (n = 1) of the
sample evidenced significant improvement at follow-up on the IPO-PD. Lastly, 21.3% (n = 3) of
the sample did not participate in data collection at follow-up, leaving their trajectories unknown.
Of note, none of these subjects evidenced significant change directly following psilocybin
exposure.
Table 25.
Reliable change scores on IPO-PD by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
10
11
12
13

-0.42
1.27
0.64
-0.64
-0.21
1.49
n/a
-0.42
0.42
1.27
-0.42
0.00

n/a
0.85
0.00
n/a
0.64
0.42
n/a
0.85
n/a
-0.64
0.42
-0.85

n/a
2.12*
0.64
n/a
0.42
1.91
0.42
0.42
n/a
0.64
0.00
-0.85

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: IPO-PD = Inventory of Personality Organization, Primitive Defenses subscale.

PNI-G Reliable Change Scores: According to assessments of reliable change, 81.8% (n =
9) of the sample did not evidence significant (>1.96) within-person improvement or deterioration
on the PNI-G subscale between time points 1 and 2 (before and after the psychedelic retreat). In
essence, the vast majority of the sample performed contrary to predictions, as their levels of
narcissistic grandiosity remained unchanged directly following psilocybin exposure (see Table
26).
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Only 9.1% of the sample (subject 6) performed in alignment with study predictions and
evidenced significantly reduced narcissistic grandiosity following psilocybin exposure (by a
factor of 3.62 standard deviations).
The trajectory for an additional 9.1% of the sample is unknown, as Subject 7 did not
complete data entry at time point 2, directly following psilocybin exposure. In sum, and contrary
to study predictions (which anticipated reduced levels of grandiosity directly following
psilocybin exposure), the vast majority of the sample remained unchanged directly following
psilocybin exposure.
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 63.6% (n = 7)
of participants remained unchanged on the PNI-G subscale; in other words, the vast majority of
participants performed contrary to predictions and remained unaffected by psilocybin exposure,
earning the same PNI-G score (and, by proxy, evidencing the same levels of narcissistic
grandiosity) before and after psilocybin exposure, as well as a one-month follow-up.
In contrast, only 18.2% (n = 2) of participants (Subject 2 and Subject 6) performed in
alignment with study predictions and evidenced improved (reduced) levels of narcissistic
grandiosity by the one-month follow-up. Specifically, subject 6 improved directly following
psilocybin exposure (by a factor of 3.62 standard deviations) and continued improving at the
one-month follow-up (by a factor of 5.33 standard deviations). Evidencing a slightly different
trajectory, Subject 2 did not evidence significant change directly following psilocybin exposure,
but improved more gradually across time points, ultimately evidencing significantly reduced
levels of grandiosity at one month (by a factor of 2.32 standard deviations).
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Lastly, 18.2% (n = 2) of participants did not participate in data collection at follow-up,
leaving their trajectories unknown. This includes Subject 1 and Subject 4, both of whom
remained unchanged on the PNI-G between time points 1 and 2.
In sum, 81.8% (n = 9) of the sample did not evidence significant change (improvement or
deterioration) directly following psilocybin exposure. In contrast, 9.1% of the sample (n = 1)
significantly improved (evidencing reduced grandiosity) directly following psilocybin exposure.
The trajectory for 9.1% of the sample is unknown directly following psilocybin exposure, as one
participant did not complete data entry at time point 2. At the one-month follow-up, 63.6% (n =
7) of the sample continued to remain unaffected by psilocybin exposure. In contrast, 18.2% (n =
2) evidenced significant change at follow-up, with both participants evidencing significant
improvement (lower levels of grandiosity). Of note, 18.2% (n = 2) of the sample did not
participate in data collection at follow-up, leaving their trajectories unknown (this includes two
subjects, neither of whom evidenced significant change directly following psilocybin exposure).
Table 26.
Reliable change scores on PNI-G by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
11
12
13

-1.95
1.27
0.34
0.16
0.37
3.62*
n/a
-0.73
-0.66
-0.73
-0.28

n/a
1.04
-0.70
n/a
0.51
1.71
n/a
1.13
1.34
0.61
-0.08

n/a
2.32*
-0.35
n/a
0.88
5.33*
-0.94
0.40
-0.01
-0.12
-0.36

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: PNI-G = Pathological Narcissism Inventor, Grandiosity subscale.
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PNI-V Reliable Change Scores: According to assessments of reliable change, 72.7% (n =
8) of the sample did not evidence significant (>1.96) within-person improvement or deterioration
on the PNI-V subscale between time points 1 and 2 (before and after the psychedelic retreat). In
essence, the vast majority of the sample performed contrary to predictions, as their levels of
narcissistic vulnerability remained unchanged directly following psilocybin exposure (see Table
27).
Only 18.2% (n = 2) of the sample (Subject 3 and Subject 6) performed in alignment with
study predictions and evidenced significantly improved (reduced) narcissistic vulnerability
following psilocybin exposure (by a factor of 3.70 and 6.44 standard deviations respectively).
Lastly, the trajectory of 7.7% (n = 1) of the sample is unknown, as Subject 7 did not
complete data entry at time point 2, directly following psilocybin exposure.
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and after the one-month follow-up), 54.5% (n = 6) of
participants remained unchanged on the PNI-V subscale at follow-up; in other words,
approximately half of participants performed contrary to predictions and remained unaffected by
psilocybin exposure, earning the same PNI-V score (and, by proxy, evidencing the same levels
of narcissistic vulnerability) before and after psilocybin exposure, as well as a one-month followup.
In contrast, 18.2% (n = 2) of participants (Subject 3 and Subject 6) performed in
alignment with study predictions and evidenced improved (reduced) levels of narcissistic
vulnerability by the one-month follow-up (by a factor of 3.33 and 7.83 standard deviations
respectively).
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Additionally, and contrary to study predictions, 9.1% (n = 1) of the sample (Subject 5)
evidenced significant deterioration (higher levels of vulnerability) over time by a factor of 2.54
standard deviations at the one-month follow-up.
Lastly, the trajectory of 18.2% (n = 2) of the sample is unknown, as Subject 1 and
Subject 4 did not participate in data collection at follow-up (neither subject evidenced significant
change directly following psilocybin exposure).
In sum, 72.7% (n = 8) of the sample did not evidence significant change (improvement or
deterioration) directly following psilocybin exposure. In contrast, 18.2% (n = 2) of the sample
evidenced significant improvement on the PNI-V directly following psilocybin exposure. One
participant did not complete data entry at time point 2, leaving the trajectory for 9.1% of the
sample unknown directly following psilocybin exposure. At the one-month follow-up, 54.5% (n
= 6) of the sample continued to remain unaffected by psychedelic exposure. In contrast, 27.3%
(n = 3) of the sample evidenced significant change at follow-up, with 18.2% (n = 2) evidencing
improved (lower) levels of grandiosity, and 9.1% (n = 1) evidencing deteriorated (higher) levels
of grandiosity at the one-month follow-up. Of note, 18.2% (n = 2) of the sample did not
participate in data collection at the one-month follow-up, leaving their trajectories unknown
(with neither participant evidencing significant change directly following psilocybin exposure).
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Table 27.
Reliable change scores on PNI-V by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
11
12
13

-0.47
0.19
3.70*
1.41
-1.64
6.44*
n/a
-0.60
-1.34
-0.73
1.16

n/a
0.89
-0.37
n/a
-0.90
1.39
n/a
2.17*
1.99*
-0.35
-0.25

n/a
1.08
3.33*
n/a
-2.54*
7.83*
1.71
1.57
1.32
0.70
0.91

_______________________________________________________
*Significant (>1.96) within-person change
Note: PNI-V = Pathological Narcissism Inventory – Narcissistic Vulnerability index.

MentS-T Reliable Change Scores: According to assessments of reliable change, 72.7% (n
= 8) of the sample did not evidence significant (>1.96) within-person change on the MentS-T
between time points 1 and 2 (before and after the psychedelic retreat), while 9.1% (n = 1) of the
sample (subject 6) evidenced significant improvement on the MentS-T by a factor of 2.72
standard deviations, and another 9.1% (n = 1) of the sample (subject 5) evidenced significant
deterioration on the MentS-T by a factor of -3.40 standard deviations (see Table 28). The
trajectory for an additional 9.1% (n = 1) of the sample is unknown, as Subject 7 did not complete
data entry at time point 2, directly following psilocybin exposure. In sum, and contrary to study
predictions (which anticipated improved mentalization skills following psilocybin exposure) the
vast majority of the sample’s mentalization capacities remained unchanged directly following
psilocybin exposure.
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 63.6% (n = 7)
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of the sample remained unchanged on the MentS-T; in other words, the majority of the sample
performed contrary to predictions and were unaffected by psilocybin exposure, earning the same
MentS-T score (overall capacity for mentalization) before and after psilocybin exposure, as well
as at a one-month follow-up. Also contrary to study predictions (which anticipated sustained
improvement on the MentS-T through follow-up), 9.1% (n = 1) of the sample (subject 5)
deteriorated at time point 2 (in the immediate wake of psychedelic exposure) but returned to
baseline at time point 3 (at a one-month follow-up). In contrast, and in alignment with study
predictions, 9.1% (n = 1) of the sample (subject 6) improved at time point 2 (in the immediate
wake of psychedelic exposure) and evidenced even further improvement by time point 3 (at the
one-month follow-up). Lastly, 18.2% (n = 2) of the sample did not participate in data collection
at follow-up, leaving their trajectories unknown. This includes Subject 1 and Subject 4, both of
whom remained unchanged on the MentS-T between time points 1 and 2.
In sum, 72.7% (n = 8) did not evidence significant change (improvement or deterioration)
directly following psilocybin exposure. In contrast, 18.2% (n = 2) of the sample evidenced
significant change, with one participant (Subject 6) evidencing a significantly higher MentS-T
score (improved mentalization skills) directly following psilocybin exposure and one participant
(Subject 5) evidencing a significantly lower MentS-T score (deteriorated mentalization skills)
directly following psilocybin exposure. One participant did not complete data entry at time point
2, leaving the trajectory of 9.1% of the sample unknown directly following psilocybin exposure.
At the one-month follow-up, 72.7% (n = 8) of the sample either continued to remain unaffected
by psilocybin exposure or returned to baseline following significant change at time point 2. In
contrast, 9.1% (n = 1) of the sample evidenced ongoing and significant improvement (higher
MentS-T score) at the one-month follow-up. Of note, 18.2% (n = 2) of the sample did not
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participate in data collection at follow-up, leaving their trajectories unknown (both of these
subjects remained unchanged on the MentS-T between time points 1 and 2).
Table 28.
Reliable change scores on MentS-T by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
11
12
13

1.36
0.34
-1.19
-0.17
-3.40*
2.72*
n/a
-0.34
-0.34
0.00
-0.34

n/a
-0.51
1.36
n/a
1.87
0.51
n/a
0.85
-0.85
-1.36
-0.68

n/a
-0.17
0.17
n/a
-1.53
3.23*
0.34
0.51
-1.19
-1.36
-1.02

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: MentS-T = Mentalization Total.

Ryff-OW Reliable Change Scores: According to assessments of reliable change, 83.3% (n
= 10) of the sample did not evidence significant (>1.96) within-person change on the Ryff-OW
between time points 1 and 2 (before and after the psychedelic retreat) (See Table 29). The
trajectory for the additional 16.6% (n = 2) of the sample is unknown, as Subject 7 and Subject 10
did not complete data collection at time point 2, directly following psilocybin exposure. Of note,
these findings are contrary to study predictions, which anticipated improved psychological
wellbeing following psilocybin exposure.
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 72.7% (n = 8)
of the sample remained unchanged on the Ryff-OW. The trajectory for the additional 27.3% (n =
3) of the sample is unknown, as Subject 1, Subject 4 and Subject 10 did not complete data
collection at the one-month follow-up. Of note, these findings are contrary to study predictions,
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which anticipated improved and sustained psychological wellbeing through the one-month
follow-up period.
In sum, 100% of the sample either evidenced no change on the Ryff-OW across time
points or didn’t earn a reliable change index due to missing data, indicating that psilocybin
exposure did not meaningfully predict within-person change on the Ryff-OW across time points.
Table 29.
Reliable change scores on Ryff-OW by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
10
11
12
13

0.36
0.29
0.80
0.65
-0.91
1.45
n/a
-0.36
n/a
-0.15
0.54
0.84

n/a
0.76
-0.18
n/a
0.04
-0.40
n/a
0.80
n/a
-0.33
-0.58
-0.11

n/a
1.05
0.62
n/a
-0.87
1.05
-0.04
0.44
n/a
-0.47
-0.04
0.73

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: Ryff-OW = The Ryff Scale of Psychological Wellbeing, Overall Wellbeing summary score.

ECR-R Ax Reliable Change Scores: According to assessments of reliable change, 54.5%
(n = 6) of the sample did not evidence significant (>1.96) within-person improvement or
deterioration on the Ax subscale between time points 1 and 2 (before and after the psychedelic
retreat). In essence, approximately half of the sample performed contrary to predictions, as their
attachment-related anxiety remained unchanged directly following psilocybin exposure (see
Table 30).
Furthermore, and evidencing the opposite effect of what was hypothesized, 18.2% (n = 2)
of the sample (subjects 5 and 8) deteriorated following psychedelic exposure, earning
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significantly increased scores on the Ax subscale (by a factor of -2.43 and -2.54 standard
deviations respectively).
Only 18.2% of the sample (subjects 4 and 6) performed in alignment with study
predictions and evidenced significantly reduced attachment-related anxiety directly following
psilocybin exposure (by a factor of 2.54 and 4.96 standard deviations respectively). The
trajectory of 9.1% (n = 1) of the sample is unknown, as Subject 7 did not complete data entry at
time point 2, directly following psilocybin exposure.
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and the one-month follow-up period), 36.4% (n = 4) of
participants remained unchanged on the Ax subscale; in other words, approximately one-third of
the sample performed contrary to predictions and remained unaffected by psilocybin exposure,
earning the same Ax score (and, by proxy, evidencing the same levels of attachment-related
anxiety) before and after psilocybin exposure, as well as at the one-month follow-up.
Furthermore, and evidencing the opposite effect of what was hypothesized, 18.2% (n = 2)
of participants evidenced significantly worsened attachment-related anxiety by follow-up.
Specifically, Subject 8 significantly deteriorated between time points 1 and 2 and maintained this
deterioration at time point 3 (by a factor of -2.43 standard deviations), while Subject 11
evidenced no change on the Ax subscale between time points 1 and 2 but deteriorated between
time points 2 and 3 (by a factor of -4.22 standard deviations). An additional 9.1% (n = 1) of the
sample significantly deteriorated between time points 1 and 2 but returned to baseline by
timepoint 3 (Subject 5).
In contrast, only 18.2% (n = 2) of participants performed in alignment with study
predictions and evidenced improved (reduced) attachment-related anxiety by the one-month
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follow-up. Specifically, Subject 6 significantly improved directly following psilocybin exposure
and maintained these gains at follow-up (by a factor of 3.5 standard deviations), while Subject 2
evidenced no change directly following psilocybin exposure but evidenced significant
improvement at follow-up (by a factor of 2.54 standard deviations).
Of note, an additional 18.2% (n = 2) of the sample did not participate in data collection at
follow-up, leaving their trajectories unknown. This includes Subject 1 (who did not evidence
significant Ax change directly following psilocybin exposure) and Subject 4 (who evidenced
significantly improved attachment-related anxiety directly following psilocybin exposure by a
factor of 2.54 standard deviations).
In sum, 54.5% (n = 6) did not evidence significant change (improvement or deterioration)
directly following psilocybin exposure. In contrast, 36.4% (n = 4) of the sample evidenced
significant change, with two participants (Subject 5 and Subject 8) evidencing deteriorated
(higher) levels of attachment-related anxiety and two participants (Subject 4 and Subject 6)
evidencing improved (lower) levels of attachment-related anxiety directly following psilocybin
exposure. One participant did not complete data entry at time point 2, leaving the trajectory of
9.1% of the sample unknown directly following psilocybin exposure. At a one-month follow-up,
45.5% (n = 5) of the sample either continued to remain unaffected by psilocybin exposure or
returned to baseline following significant change at time point 2. In contrast, 36.4% (n = 4) of
the sample evidenced significant change at follow-up, with two participants (Subject 8 and
Subject 11) evidencing deteriorated (higher) levels of attachment-related anxiety and two
participants (Subject 6 and Subject 2) evidencing improved (lower) levels of attachment-related
anxiety at the one-month follow-up. Of note, 18.2% (n = 2) of the sample did not participate in
data collection at follow-up, leaving their trajectories unknown (with one of these subjects
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having evidenced no significant change directly following psilocybin exposure, and the other of
these subjects having evidenced significant improvement directly following psilocybin
exposure).
Table 30.
Reliable change scores on ECR-R Ax by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
11
12
13

0.85
1.09
0.61
2.54*
-2.43*
4.96*
n/a
-2.54*
0.48
0.24
-0.61

n/a
1.46
-0.85
n/a
1.09
-1.46
n/a
0.11
-4.22*
-1.70
0.98

n/a
2.54*
-0.24
n/a
-1.35
3.50*
0.72
-2.43*
-3.74*
-1.46
0.37

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: ECR-R Ax = Experiences in Close Relationships-Revised Anxiety subscale.

ECR-R Av Reliable Change Scores: According to assessments of reliable change, 63.6%
(n = 7) of the sample did not evidence significant (>1.96) within-person improvement or
deterioration on the Av subscale between time points 1 and 2 (before and after the psychedelic
retreat). In essence, approximately two-thirds of the sample performed contrary to predictions,
as their attachment-related avoidance remained unchanged directly following psilocybin
exposure (see Table 31).
Furthermore, and evidencing the opposite effect of what was hypothesized, 18.2% (n = 2)
of the sample (subjects 8 and 11) deteriorated following psychedelic exposure, earning
significantly increased scores on the Av subscale (by a factor of -3.31 and -2.79 respectively).
Only 9.1% (n = 1) of the sample (subject 6) performed in alignment with study
predictions and evidenced significantly reduced attachment-related avoidance directly following
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psilocybin exposure (by a factor of 3.71 standard deviations). The trajectory of 9.1% (n = 1) of
the sample is unknown, as Subject 7 did not complete data entry at time point 2, directly
following psilocybin exposure.
According to reliable change indices assessing within-person change between time points
1 and 3 (before psychedelic exposure and the one-month follow-up period), 54.5% (n = 6) of
participants remained unchanged on the Av subscale; in other words, approximately one half of
the sample performed contrary to predictions and were unaffected by psilocybin exposure,
earning the same Av score (and, by proxy, evidencing the same level of attachment-related
avoidance) before and after psilocybin exposure, as well as at a one-month follow-up.
Furthermore, and evidencing the opposite effect of what was hypothesized, 9.1% (n = 1)
of the sample (Subject 8) significantly deteriorated (evidencing higher levels of attachmentrelated avoidance) between time points 1 and 2 (by a factor of -3.31 standard deviations) and
maintained this deterioration at time point 3.
An additional 9.1% (n = 1) of the sample (Subject 11) significantly deteriorated between
time points 1 and 2 (by a factor of -2.79 standard deviations) but returned to baseline levels of
attachment-related avoidance by follow-up.
Of note, only 9.1% (n = 1) of participants performed in alignment with study predictions
and evidenced improved (reduced) attachment-related avoidance by the one-month follow-up.
Specifically, Subject 6 significantly improved directly following psilocybin exposure and
maintained these gains at follow-up (by a factor of 3.98 standard deviations).
Of note, an additional 18.2% (n = 2) of the sample did not participate in data collection at
follow-up, leaving their trajectories unknown. This includes Subject 1 and Subject 4, neither of
whom evidenced significant change directly following psilocybin exposure.
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In sum, 63.6% (n = 7) of the sample did not evidence significant change (improvement or
deterioration) directly following psilocybin exposure. In contrast, 27.3% (n = 3) of the sample
evidenced significant change, with two participants (Subject 8 and Subject 11) evidencing
deteriorated (higher) levels of attachment-related avoidance directly following psilocybin
exposure and one participant (Subject 6) evidencing significantly improved (lower) attachmentrelated avoidance directly following psilocybin exposure. One participant did not complete data
entry at time point 2, leaving the trajectory of 9.1% of the sample unknown directly following
psilocybin exposure. At a one-month follow-up, 63.6% (n = 7) of the sample either continued to
remain unaffected by psilocybin exposure or returned to baseline following significant change at
time point 2. In contrast, 18.2% (n = 2) of the sample evidenced significant change at follow-up,
with one participant (Subject 8) evidencing deteriorated (higher) levels of attachment-related
avoidance and one participant (Subject 6) evidencing improved (lower) levels of attachmentrelated avoidance at the one-month follow-up. Of note, 18.2% (n = 2) of the sample did not
participate in data collection at follow-up, leaving their trajectories unknown (neither of these
subjects evidenced significant change directly following psilocybin exposure).
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Table 31.
Reliable change scores on ECR-R Av by subject.
______________________________________________________________________________
Subject ID

Btwn Timepoints 1 & 2

Btwn Timepoints 2 & 3

Btwn Timepoints 1 & 3

______________________________________________________________________________
1
2
3
4
5
6
7
8
11
12
13

0.52
-0.26
0.67
1.86
-1.57
3.71*
n/a
-3.31*
-2.79*
0.52
0.52

n/a
-1.19
0.26
n/a
0.26
0.26
n/a
1.07
2.79*
-0.79
-0.26

n/a
0.64
-0.52
n/a
-1.31
3.98*
0.29
-2.24*
0.00
-0.26
0.26

______________________________________________________________________________
*Significant (>1.96) within-person change
Note: ECR-R Av = Experiences in Close Relationships-Revised Avoidance subscale.

PEB Reliable Change Scores: According to assessments of reliable change, 100% (n = 9)
of the sample did not evidence significant (>1.96) within-person change on the PEB between
time points 1 and 3 (before psychedelic exposure and after the one-month follow-up period) (See
Table 32). In sum, psilocybin exposure did not meaningfully predict within-person change on
the PEB over time. Of note, these findings stand in contrast to study predictions, which
anticipated improved pro-environmental behavior at the one-month follow-up.
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Table 32.
Reliable change scores on PEB by subject.
___________________________________
Subject ID

Btwn Timepoints 1 & 3

___________________________________
2
3
5
6
7
8
11
12
13

0.45
1.13
0.23
-0.68
0.45
-0.45
-0.90
0.23
-0.23

___________________________________
*Significant (>1.96) within-person change
Note: PEB = Pro-Environmental Behavior summary score.
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APPENDIX E
Summary of Statistical Analyses by Measure
BSI Summary: The Global Severity Index (GSI) was selected as a summary measure for
the Brief Symptom Inventory (BSI). A Hierarchical Linear Model was conducted using GSI
score as the outcome variable and SD as a control. Additionally, reliable change indices were
also calculated in order to assess within-person change between time points. As predicted, both
types of analyses preliminarily suggest that participants evidence significant improvement on the
GSI directly following psilocybin exposure.
Contrary to study predictions, however, which anticipated sustained improvement over
time, mixed model analyses indicate that the sample, on average, trended back toward baseline at
follow-up. With that said, reliable change indices indicate that two separate trajectories may
have emerged during the follow-up period, which could be cancelling each other out within the
mixed model analyses. Specifically, while 23.1% (n = 3) of the sample evidenced significant
change at follow-up, these participants did not follow a uniform trajectory, with 15.4% (n = 2)
evidencing significant deterioration (higher GSI scores) and 7.7% (n = 1) evidencing significant
improvement (lower GSI scores). It’s possible (though speculative at this juncture) that these
divergent pathways may be explained by whether or not a given subject had a mystical
experience: of the four subjects with reliable change at follow-up, the two participants who had a
mystical experience (Subject 11 and Subject 3) either remained unchanged at time point 2 and
then deteriorated significantly at time point 3, or improved at time point 2, but then lost these
gains at time point 3. In contrast, the participant with no mystical experience (Subject 2)
sustained significant improvement across time points 2 and 3. The fourth subject with
significant change at follow-up has an unknown ME status.
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A second Hierarchical Linear Model, which included the main effect of ME, as well as
the interaction effect of Time x ME, provides further preliminary support for this potential
interaction. Although neither effect was significant, this model explained an additional 7.7% of
variance (a small to medium effect size), with the non-mystical experience group showing
greater improvement between time points 1 and 2 than the mystical experience group (the
opposite of study predictions, which projected the mystical experience group to evidence greater
improvement over time). Overall, these preliminary trends warrant further investigation with a
larger sample size.
IPO-ID Summary: A Hierarchical Linear Model was conducted using IPO-ID score as
the outcome variable and SD as a control. Additionally, reliable change indices were also
calculated in order to assess within-person change between time points. Of note, both types of
analyses preliminarily suggest that participants remain unchanged directly following psilocybin
exposure and then evidence significantly improved (lower) levels of identity diffusion at the onemonth follow-up.
A second Hierarchical Linear Model, which included the main effect of ME, as well as
the interaction of ME x Time, was not significant, but notably explained an additional 24.5% of
variance (a large effect size). On average, the non-mystical experience group evidenced greater
improvement (less identity diffusion) relative to the mystical-experience group directly following
psilocybin exposure, as well as at the one-month follow-up (the opposite of study predictions,
which anticipated the mystical-experience group to improve more over time). Overall, these
preliminary trends warrant further investigation with a larger sample size.
IPO-RT Summary: A Hierarchical Linear Model was conducted using IPO-RT score as
the outcome variable and SD as a control. The effect of Time2 was a significant predictor,
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indicating that IPO-RT scores showed a significant curvilinear trend, with a slight downward
curve (and reflecting improved reality testing) in change over time. Reliable change indices,
which were calculated in order to assess within-person change between time points, indicate less
significant change overall (with 10 of 11 subjects evidencing insignificant within-person change
directly following psilocybin exposure and 7 of 9 subjects evidencing insignificant within-person
change at the one-month follow-up). As a result, and while Hierarchical Linear Models indicate
that significant change occurred over time, Reliable Change Indices indicate that this change was
not clinically significant.
A second Hierarchical Linear Model, which included the main effect of ME, as well as
the interaction of ME x Time, was not significant. It is perhaps relevant to note that both
subjects who evidenced significant within-person change at the one-month follow-up also met
criteria for having had a mystical experience, though their pathways diverged, with Subject 11
evidencing significantly improved reality testing and Subject 13 evidencing significantly
deteriorated reality testing by the one-month follow-up.
IPO-PD Summary: Mixed model analyses were conducted using IPO-PD as the outcome
variable and SD as a control. Additionally, reliable change indices were also calculated to in
order to assess within-person change between time points. The effect of linear Time, quadratic
Time2 and ME were not significant predictors of IPO-PD. However, the interaction of ME x
Time was significant, indicating that the non-mystical experience group evidenced improved
(lower) levels of primitive defenses over time, whereas the mystical-experience group
maintained similar levels of primitive defenses across time points. Reliable change indices
reflect similar findings. Although the sample was characterized by minimal change overall, the
participant who earned a significant reliable change score at follow-up did not have a mystical
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experience during psilocybin exposure and, in turn, evidenced improved (reduced) levels of
primitive defenses over time. Of note, these findings stand in contrast to study predictions,
which projected the mystical-experience group to demonstrate greater improvement than the
non-mystical experience group over time.
PNI-G Summary: Mixed model analyses were conducted using PNI-G as the outcome
variable and SD as a control. The effects of linear Time, quadratic Time2 and ME were not
significant predictors of PNI-G. However, the interaction of ME x Time was significant,
indicating that the non-mystical experience group evidenced improved (lower) levels of
grandiosity over time, whereas the mystical-experience group maintained similar levels of
grandiosity across time points. Reliable change indices further reflect this finding. Although the
sample was characterized by minimal change overall, both participants who earned significant
reliable change scores at follow-up did not have a mystical experience during psilocybin
exposure and, in turn, evidenced improved (reduced) levels of grandiosity over time. Of note,
these findings stand in contrast to study predictions, which projected the mystical-experience
group to demonstrate greater improvement than the non-mystical experience group over time.
PNI-V Summary: A Hierarchical Linear Model analysis was conducted using PNI-V as
the outcome variable and SD as a control, with predictors including linear Time and quadratic
Time2, as well as ME and ME x Time. Contrary to study predictions (which anticipated reduced
levels of narcissistic vulnerability over time, moderated by mystical experiences) mixed model
analyses did not meaningfully predict PNI-V. According to reliable change indices, 18.2% (n =
2) of the sample evidenced significant within-person change at time point 2 and 27.3% (n = 3) of
the sample evidenced significant within-person change by time point 3. As a result, and in the
context of such a small sample, it is currently unknown whether the absence of significant mixed
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model findings is due to limited change in the sample overall, or whether divergent pathways
canceled each other out. Specifically, of those who evidenced significant within-person change,
two participants improved directly following psilocybin exposure and maintained these gains at
the one-month follow-up (evidencing reduced levels of narcissistic vulnerability over time),
while the third participant did not reliably change between time points 1 and 2, but significantly
deteriorated by time point 3 (evidencing higher levels of narcissistic vulnerability at one month).
Overall, further investigation will be required in order to clarify these findings.
MentS Summary: The Mentalization Total score (MentS-T) was selected as a summary
measure for the Mentalization Scale (MentS). Mixed model analyses were conducted using
MentS-T as the outcome variable and SD as a control, with predictors including linear Time and
quadratic Time2, as well as ME and ME x Time. Additionally, reliable change indices were also
calculated in order to assess within-person change between time points. Contrary to study
predictions (which anticipated improved mentalization skills over time), mixed model analyses
did not meaningfully predict MentS-T. Reliable change indices support the conclusion that this
is due to minimal change in the sample overall, as the vast majority of participants remained
unchanged on the MentS-T (and therefore earned insignificant reliable change scores) across
time points. Overall, this data preliminarily supports the conclusion that psilocybin exposure
does not affect an individual’s capacity for mentalization.
Ryff-OW Summary: The Ryff’s Overall Wellbeing summary score (Ryff-OW) was
selected as a summary measure for the entire Ryff Scale of Psychological Wellbeing (the Ryff).
Mixed model analyses were conducted using Ryff-OW as the outcome variable and SD as a
control, with predictors including linear Time and quadratic Time2, as well as ME and ME x
Time. Additionally, reliable change indices were also calculated in order to assess within-person
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change between time points. Contrary to study predictions (which anticipated improved
psychological wellbeing over time), mixed model analyses did not meaningfully predict RyffOW. Reliable change indices support the conclusion that this is due to minimal change in the
sample overall, as the vast majority of participants remained unchanged on the Ryff-OW (and
therefore earned insignificant reliable change scores) across time points. Overall, this data
preliminarily supports the conclusion that psilocybin exposure does not affect an individual’s
overall psychological wellbeing.
ECR-R Ax Summary: A Hierarchical Linear Model was conducted using Ax as the
outcome variable and SD as a control, with predictors including linear Time and quadratic
Time2. Although neither of these effects significantly predicted Ax change over time, reliable
change indices indicate that this may be due to the sample’s lack of a uniform trajectory: with
some participants significantly improving, and others significantly deteriorating, divergent
trajectories may be canceling each other out within mixed model analyses. Specifically, by the
one-month follow-up, 36.4% (n = 4) of the sample evidenced significant change, with two
participants evidencing deteriorated (higher) levels of attachment-related anxiety and two
participants evidencing improved (lower) levels of attachment related-anxiety. It’s possible
(though speculative at this juncture) that these divergent pathways may be explained by whether
or not a given subject had a mystical experience: of the four subjects with reliable change at
follow-up, the two participants who improved did not have a mystical experience (Subject 6 and
Subject 2), while the two participants who deteriorated diverged on this variable (Subject 11 had
a mystical experience, while Subject 8 did not).
A second Hierarchical Linear Model, which included the main effect of ME, as well as
the interaction effect of Time x ME, provides further preliminary support for this potential
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interaction. Although neither effect was significant, this model explained an additional 2.9% of
variance (a small effect size), with the mystical-experience group deteriorating slightly, and the
non-mystical experience group improving slightly (the opposite of study predictions, which
projected the mystical experience group to evidence stronger improvement over time). Overall,
these preliminary trends warrant further investigation with a larger sample size.
ECR-R Av Summary: Mixed model analyses were conducted using Av as the outcome
variable and SD as a control, with predictors including linear Time and quadratic Time2, as well
as ME and ME x Time. Contrary to study predictions (which anticipated reduced levels of
attachment-related avoidance over time, moderated by mystical experience) mixed model
analyses did not meaningfully predict Av (and, in fact, the inclusion of ME and ME x Time
weakened the percentage of variance explained). According to reliable change indices, 27.3% (n
= 3) of the sample evidenced significant within-person change at time point 2 and 18.2% (n = 2)
of the sample maintained significant within-person change at time point 3. As a result, and in the
context of such a small sample, it is currently unknown whether the absence of significant mixed
model findings is due to limited change in the sample overall, or whether divergent pathways
canceled each other out. Specifically, of those who evidenced significant change, two
participants significantly deteriorated directly following psilocybin exposure (evidencing
amplified attachment-related avoidance), with one subject maintaining this deterioration at
follow-up, and another returning to baseline. In contrast, a third participant significantly
improved following psilocybin exposure (evidencing reduced levels of attachment-related
avoidance) and maintained these gains at follow-up. Overall, further investigation will be
required in order to clarify these findings.
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PEB Summary: The Pro-Environmental Behavior (PEB) measure assesses the frequency
with which individuals perform certain environmentally considerate actions. This measure
yields one overall score (PEB), which was used for all analyses. Mixed model analyses were
conducted using PEB as the outcome variable and SD as a control, with predictors including
Time, ME and ME x Time. (Of note, quadratic Time2 was not assessed, as PEB was only
collected at two time points: before psychedelic exposure and at the one-month follow-up).
Additionally, reliable change indices were also calculated in order to assess within-person
change between time points. Contrary to study predictions (which anticipated improved PEB
over time), mixed model analyses did not meaningfully predict PEB. Reliable change indices
support the conclusion that this is due to minimal change in the sample overall, as 100% of
participants remained unchanged on the PEB (and therefore earned insignificant reliable change
indices) between time points. Overall, this data preliminarily supports the conclusion that
psilocybin exposure does not affect an individual’s engagement with pro-environmental
behavior.
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APPENDIX F
Self-Report Responses to Open-Ended Questions
Question 1 (administered before psychedelic exposure): “In a few sentences, please explain
why you decided to participate in an Experience Retreat?”
Response Type 1: To deepen or expand relationship to (and awareness of) self, consciousness
and reality (13 Subjects):
1. I want to have a 'peek to the other side' and see what else there is outside of our material
world.
2. Curiosity about exploring consciousness.
3. I'm hoping to get a better insight into my consciousness and discover my true nature.
4. To aim to reach a state of deep connection with the world around me
5. I would like to deepen my connection with my subconscious, my internal wiring, "bios".
6. I want to gain new insights into myself and the world.
7. Understand what is there, at the subconscious level.
8. I want to explore my subconscious and see what messages and information I will receive
from it (myself?).
9. I feel like there is something hidden, that I can almost grab but not quite yet.
10. I understand it can help with digging deeper into the psyche and becoming more aware in
general.
11. I'd imagine the psychedelic-experience could give me a new perspective on some things
and I hope to learn a few things about myself.
12. I wanted to understand better myself.
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13. To explore consciousness in a different way. To explore past unpleasant events that
negatively affect my life today
14. I would like to have a bigger perspective on my life. And from what I've been reading, it
helps with basic existential angst.
Response Type 2: To address mental health concerns and improve psychological wellbeing (7
Subjects)
1. I have been dealing with a trauma from childhood. I want to understand how this
resonates in my everyday life. I am in a healing process. This method, alternative to other
that do not seem to fit me, seems to be the best to advance in my life.
2. Mainly to help improve my mental health.
3. I have been suffering from depression for many years, and I have been treatment
resistant. I have been following the recent research about psychedelics and its effect on
depression, and I want to try it for myself.
4. I've experienced a depressive episode which prompted me to start psychotherapy. My
therapist nudged me towards a retreat because she felt it might facilitate the process. I'd
also independently been thinking about taking psilocybin, just not in a group setting.
5. Understand what is preventing me from being connected to my emotions and the people
around me.
6. To understand why I am constantly wearing armor in an effort to be in control and
successful. To experience a different way of being that I can strive towards consciously
following the retreat.
7. I decided to experience the effects on myself and see if I can overcome some problems I
have been struggling with.
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Response Type 3: To find purpose, meaning or direction in life (5 Subjects)
1. In order to create a more intentional and meaningful life.
2. I wonder if having this experience will help me to find my way and to understand my
purpose in life as I am rather disoriented, jumping from one thing to another every few
months.
3. I want to understand why I am here and what I am doing with my life.
4. I want to be guided to find a new personal or professional direction. I feel at a bit of a
crossroads in my life and would like to find which path to take.
5. Quite a pivotal time in my life with ending a long-term relationship and leaving my
business. Intrigued about psychedelics and in the reading what they can offer.
Response Type 4: Shift problematic thought patterns (4 Subjects)
1. I also have some limiting beliefs/things that have held me back in my life, that hopefully
the experience will help me learn from and move past.
2. I would like to get past some habitual ways of thinking.
3. I want to break old thinking patterns that I sometimes feel stuck to.
4. To free myself from some stuck mental patterns.
Response Type 5: Excitement, novelty, and exploration (4 Subjects)
1. I want to have a new experience.
2. Just to do something that seems very exciting.
3. My constant curiosity to explore my physical as well as psychological boundaries.
4. I am and always have been a very curious person. Psychedelic substances I think are
really interesting. I read a lot of publications, watched documentaries, listened to peoples
reports etc. So for a long time I wanted to try it for myself.
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Response Type 6: Self-improvement (2 Subjects)
1. I've always had an interest in personal development, meditation and the human condition.
Having read about the science behind psychedelic use as a therapy, I decided to explore
this avenue.
2. After hearing and reading a lot about psychedelics and the positive impact it could have
on your life…I decided to come to the retreat.
Question 2 (administered directly after psychedelic exposure): “Do you believe that taking
psilocybin changed you? If so, how?”
Response Type 1: Deepened or expanded relationship to (or awareness of) self,
consciousness and reality (4 Subjects)
1. Opened me to the mysteries of an alternate realm.
2. I think it put me into clear connection with the universe as a source of love, which is
unforgettable and can be tapped into as and when I need it.
3. Some of the immediate benefits seem to be understanding self as construct, as merely a
play of the universe expressing itself through 'me' and translated through the brain as it
has evolved to constrain 'reality' into workable constructs, to try to create a coherent
narrative, of a consistent 'self', flowing in time. And the experience allowed me to see /
experience that all those things are merely the construct of mind. Ultimate reality is not
time-linear, has no sense of good or bad, self or non-self, inside or outside. It just is, and
is not. So in that way it has given 'me' a new freedom. It is not that my self or ego has
ceased to exist, but I can find space around it, see it as the functional play of existence.
And, currently at least, I can still drop into the non-space where any construct of self, or
any construct at all ceases to exist as a separate notion.
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4. I also met several higher entities and had quite long interactions. Those messages are
firmly in me to guide, drive and inspire me
Response Type 2: Improved psychological wellbeing (4 Subjects)
1. Have been more attentive, slower and calmer.
2. I feel less threatened by the outside world and other people.
3. I was able to release emotional pain and childhood/adolescent trauma that I did not
realize I was still holding the weight of. It was immensely cathartic and in being able to
release this emotional pain of the past as myself in the present, I feel I have been able to
integrate and internalize my resilience as it relates to my trauma recovery much more
fully than I had prior.
4. I still feel very much myself but in a way so much more myself than before.
Response Type 3: Greater acceptance, compassion and gratitude (3 Subjects)
1. I am finding it easier to accept my self and others just as they are.
2. I feel self-pride and greater compassion to myself as well as greater radical acceptance
and peace towards my family trauma.
3. I feel deep gratitude for my parents who loved me and have given me a good start in life I
feel touched by all the people who've ever loved me I feel I have a permission to fully
love myself I have an inexplicable feeling that "I've got it"; nothing in me or my life
needs changing, and I can handle the challenges life throws in my way - and also accept
that things aren't perfect and let that go and fade into the background and focus on the
good I want to say "YESSS!" to life.
Response Type 4: Greater openness (3 Subjects)
1. I feel more open.
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2. More open, aware, trusting.
3. I feel more open (to experiences, to people).
Response Type 5: Change that’s beyond words or outside the intellectualized realm (2
Subjects)
1. I feel something very deep inside me has been shifted. I haven't quite been able to make
sense of it intellectually.
2. I feel like I have experienced a profound truth, beyond words. And it feels to hold so
much value beyond merely being an 'experience'. There was access to a wisdom beyond
concepts.
Response Type 6: Shifted problematic thoughts (1 Subject)
1. Showed me I could be free of self-limiting beliefs.
Response Type 7: Improved nature-relatedness (1 Subject)
1. Opened me to the wonders of nature.
Question 3 (administered one-month after psychedelic exposure): “When you look back on
taking psilocybin, do you think it changed you? If so, how?”
Response Type 1: Greater acceptance, compassion and gratitude (5 Subjects)
1. I feel like I have a greater reservoir of compassion, both for myself and for challenging
dynamics I may encounter. Greater ability to radically accept challenging circumstances.
2. I have a very great feeling of gratitude and have continued to do a gratitude journal.
3. More grateful of what I have.
4. I'd say as a whole I feel more at ease with the way things are in my life right know and
also more comfortable with myself - I feel like everything is fine, whatever will be, will
be.
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5. I feel more forgiving towards myself and others. I feel I'm able to let difficult things be
without having a compulsion to solve them or obsess about them; the good and the bad
can co-exist peacefully. I'm more thankful for all the good that I have experienced, and
all the love that I've received.
Response Type 2: Improved psychological wellbeing (3 Subjects)
1. After the retreat I had a lot less brain chatter - mind was generally calmer. This is less so
now, but still a difference from before.
2. I'm feeling less sad and lonely. I feel more connected with everything around me. I am
less fearful of the future.
3. I felt calmer and more present, though I feel the effects are wearing off.
Response Type 3: Deepened or expanded relationship to (or awareness of) self,
consciousness and reality (2 Subjects)
1. It has changed my view on reality and myself, in profound ways that I can't really
explain.
2. It made me feel more definite about the other levels of existence.
Response Type 4: Improved nature-relatedness (2 Subjects)
1. Can easily tap into peace and comfort in being surrounded by nature, much more aware
and appreciative of plants (trees especially).
2. Yes, the connection between me, people and nature.
Response Type 5: Improved meditation (2 Subjects)
1. Feel like I have a more defined headspace to work towards when meditating.
2. I find meditation much easier, less irritated and can relax into it much more.
Response Type 6: Shifted problematic thoughts (1 Subject)
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1. Some thought habits that often cause me distress have quieted down a little, but they are
still there, I just feel less frequently restricted by them.
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